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“I	have	not	failed.	I've	just	found	10,000	ways	that	won't	work.”	
-Thomas	A.	Edison	
	
	
	
“The	greatest	danger	for	most	of	us	is	not	that	our	aim	is	too	
high	and	we	miss	it,	but	that	it	is	too	low	and	we	reach	it.”	
-Michaelangelo	
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Wound	healing:	a	general	outline	
Non-healing	wounds	are	a	major	problem	in	diseases	like	venous	
insufficiency,	post-thrombotic	syndrome	and	diabetes	mellitus	(DM).	
Especially	with	an	increase	in	DM	in	the	Western	modern	population,	research	
in	wound	healing	is	getting	more	and	more	important.	In	normal	wound	
healing,	after	tissue	damage,	three	overlapping	healing	phases	can	be	
distinguished:	the	inflammatory,	proliferation	and	remodeling	phase	(1).		
	
Wound	healing	phase	one:	inflammation	
Clot	formation	
The	inflammatory	phase	usually	takes	4-6	days	in	normal	wound	healing.	
Directly	after	tissue	damage,	a	thrombus,	is	formed	as	a	result	of	activation	of	
the	coagulation	cascade.	The	coagulation	cascade	is	activated	by	the	release	of	
Tissue	Factor	(TF),	which	is	a	part	of	the	extrinsic	pathway	(2,	3).	Tissue	
Factor	activates	thrombin	(FII)	formation	via	activation	of	several	factors,	
including	FIXa	and	FVIIIa	(Fig.	1).	In	addition,	in	vivo,	the	pathway	intrinsic	
pathway	plays	a	role,	which	results	in	more	thrombin	formation,	which	is	
necessary	in	hemorrhage	of	large	wounds.		
	
	
Figure	1:	The	coagulation	cascade.	Vanderbroucke	et	al.,	2001.	N	Engl	J	Med.	
Thrombin	cleaves	the	fibrinopeptides	A	and	B	of	fibrinogen,	which	converts	
fibrinogen	into	fibrin.	Multiple	cleaved	fibrin	monomers	bind	together,	
forming	a	fibrin	network,	which	is	stabilized	by	cross-linking	by	Factor	FXIIIa	
(Fig.	2).	This	thrombus,	also	containing	platelets,	stops	the	wound	from	
	
11	
bleeding	and	provides	a	temporary	scaffold	for	invading	cells,	such	as	
endothelial	cells	and	inflammatory	cells	(2,	4,	5).	Platelet	coagulation	in	the	
thrombus	is	facilitated	by	Von	Willebrand	Factor	(VWF),	a	glycoprotein	which	
is	released	by	the	endothelium	when	damaged.	Furthermore,	VWF	stimulates	
the	clotting	cascade	by	binding	to	FVIII	and	collagen.	VWF	is	then	cleaved	by	a	
disintegrin	and	metalloproteinase	with	a	thrombospondin	type	1	motif,	
member	13	(ADAMTS13).	Lack	of	VWF	leads	to	bleeding	disorders,	whilst	
non-clearance	of	vWF	leads	to	a	high	risk	of	thrombosis.		
A	few	hours	after	thrombus	formation,	neutrophils	are	the	first	inflammatory	
cells	to	invade	the	wound	area.	These	short-lived	cells	are	a	part	of	the	innate	
immune	system	and	clear	the	debris	by	phagocytosis.	Additionally,	they	are	
also	able	to	phagocytose	and	kill	bacteria	by	producing	toxic	components	such	
as	reactive	oxygen	species	(ROS),	reactive	nitrogen	species	(RNS)	and	
myeloperoxidase	(MPO)	(6).		Recently,	it	has	been	found	that	neutrophils	are	
able	to	excrete	their	own	DNA	and	form	so-called	neutrophil	extracellular	
traps	(NETs)	(7).	NETs	will	be	discussed	in	detail	later.	Several	hours	after	
neutrophil	invasion,	monocytes	arrive	at	the	wound	site,	where	they	convert	
into	macrophages.	Both	the	attraction	and	conversion	of	macrophages	are	
modulated	by	the	fibrin	matrix	(2),	which	makes	it	important	in	the	transition	
from	a	pro-inflammatory	environment	into	an	anti-inflammatory,	or	wound	
healing,	environment.	In	the	early	phase	wound	healing,	macrophages	are	pro-
inflammatory	(M1),	but	soon	switch	to	an	anti-inflammatory	(M2)	phenotype.	
M2	macrophages	secrete	growth	factors	like	TGF-β	by	phagocytosis	of	
apoptotic	neutrophils	(8),	which	promote	the	transition	to	an	anti-
inflammatory	state	and	the	next	phase	of	wound	healing.		
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Figure	2:	The	conversion	of	fibrinogen	to	a	fibrin	network.	Adapted	image	from	Côté	et	
al.,	1998.	Blood.	
Wound	healing	phase	two:	proliferation	
Around	4	days	after	wounding,	when	the	inflammatory	cells	in	the	tissue	start	
producing	anti-inflammatory	growth	factors	and	cytokines,	endothelial	cells	
(EC)	infiltrate	the	wound	bed.	The	formation	of	new	vessels,	or	angiogenesis,	
predominantly	takes	place	when	these	ECs	bind	to	fibrinogen	(2,	9).	The	
ingrowth	rate	of	these	ECs	depends	on	the	fibrin	structure,	which	will	be	
described	in	more	detail	later.	Fibroblasts	are	also	attracted	to	the	wound	bed	
and	contribute	to	collagen	deposition.	After	approximately	5	days	these	
fibroblast	proliferate	into	myofibroblasts,	which	causes	wound	contraction	
and	closure.	Furthermore,	they	synthesize	Extracellular	Matrix	(ECM)	
components,	mainly	collagen,	that	gradually	replace	the	fibrin	matrix.	The	
proliferation	phase	can	take	around	20	days	in	normal	wound	healing.		
	
13	
	
Wound	healing	phase	three:	remodeling	
After	approximately	21	days	in	normal	wounds,	the	remodeling	phase	of	
wound	healing	is	initiated.		
This	last	phase	of	wound	healing	is	characterized	by	the	replacement	of	
myofibroblasts	by	collagen	and	other	extracellular	matrix	(ECM)	proteins.	
Maturation	of	the	collagen,	which	in	skin	occurs	in	different	types	(I,	III	and	
IV),	can	take	three	weeks	and	may	even	take	a	year	in	the	case	of	a	large	
wound.		
A	close-up	of	the	coagulation	cascade:	fibrin(ogen)	
As	previously	mentioned,	fibrin	is	one	of	the	most	important	ECM	proteins	in	
early	wound	healing,	as	it	provides	a	scaffold	for	migrating	cells	and	
angiogenesis	(10).	Fibrin	is	formed	after	the	cleavage	of	fibrinopeptide	A	and	
B	from	fibrinogen.	Fibrinogen	is	a	soluble	glycoprotein	produced	mainly	by	
hepatocytes.	It	consists	of	three	chains:	Aα,	Bβ	and	ƴ.	All	three	components,	
are	produced	separately	in	the	hepatocytes,	encoded	by	three	different	genes.	
Two	chains	of	each	component	are	connected	by	disulfide	bridges	to	form	
fibrinogen.	All	of	the	chains	form	a	coiled	coil	(Fig.	3).	The	molecule	has	three	
major	domains:	one	E-domain	(middle)	and	two	D-domains	(containing	
carboxy-terminals	of	Bβ	and	ƴ	chains	and	part	of	the	Aα	chain)	(2,	11,	12).	The	
two	αC	regions	(carboxy-terminals)	of	the	Aα	chains	are	important	in	fibrin	
assembly,	activation	of	factor	XIII,	cell	adhesion	and	modulation	of	fibrinolysis	
(4).		
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Figure	3:	The	fibrinogen	molecule.	Source:	Köhler	et	al.,	2015	(13)	
	
In	the	presence	of	thrombin,	cleavage	of	fibrinopeptide	A	and	B	occurs,	
exposing	two	polymerization	sites	at	the	N-termini	of	the	α	and	β	chains	(14).	
These	sites	are	able	to	bind	to	the	αC-termini	of	other	fibrinogen	molecules	
cleaved	by	thrombin,	and	are	important	in	mediation	of	the	fibrin	matrix	
assembly	and	interaction	with	a	large	spectrum	of	cells,	including	heparin,	
endothelial	cells,	fibroblasts	and	platelets.	The	fibrin	matrix	is	stabilized	by	
factor	XIIIa,	formed	by	thrombin	from	factor	XIII	in	the	presence	of	calcium,	
which	cross-links	the	C-termini	of	ƴ	chains	of	the	fibrinogen	molecules	(15).	
The	structure	of	the	fibrin	matrix	depends	on	many	factors	such	as	fibrinogen	
levels,	platelet,	thrombin	and	calcium	concentrations,	clotting	rate,	pH,	glucose	
levels	and	modifications	in	the	fibrinogen	molecule	(16,	17).	These	factors	can	
be	stimulated	by	events	such	as	smoking,	myocardial	infarctions,	coronary	
artery	disease,	strokes	and	diabetes.	Thrombosis	is	also	associated	with	
inflammatory	diseases	like	rheumatoid	arthritis,	inflammatory	bowel	disease	
and	chronic	obstructive	pulmonary	disease.	Clot	structure	is	important	for	
processes	like	fibrinolysis	and	EC	ingrowth.	For	example,	if	a	clot	is	dense,	EC	
ingrowth	is	delayed,	leading	to	inhibited	angiogenesis	(18).	Also,	fibrinolysis	is	
inhibited,	leading	to	a	persisting	fibrin	clot	which	delays	the	transition	from	
the	proliferation	phase	to	the	remodeling	phase	in	wound	healing.	
Fibrinolysis	
Regulation	of	the	clotting	cascade	is	a	crucial	process.	Absence	of	clot	
formation	can	cause	extensive	bleeding	after	damage	to	the	vessel	wall,	and	a	
persisting	clot	can	be	the	cause	of	thrombosis.	Thrombi	may	have	an	altered	
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structure,	resulting	in	resistance	to	fibrinolysis.	Fibrin	can	be	cleaved	by	
plasmin.	Plasminogen	is	a	zymogen	that	is	activated	to	plasmin	by	
plasminogen	activators,	such	as	tissue-type	plasminogen	activator	(tPA).	tPA	
is	produced	by	endothelial	cells	and	is	able	to	bind	to	fibrin,	which	activates	a	
positive	feedback	loop	(14).	Thrombin,	on	the	other	hand,	is	able	to	activate	
thrombin-activatable	fibrinolysis	inhibitor	(TAFI),	which	is	a	plasma	protein	
that	can	inhibit	fibrinolysis	(15,	19).When	bleeding	is	controlled,	the	pro-
inflammatory	response	weakens	and	the	wounded	site	is	more	at	equilibrium.	
Only	then,	fibrinolysis	occurs	and	the	fibrin	matrix	can	be	replaced	by	
myofibroblasts	and	collagen	tissue.			
A	specific	process	in	the	inflammatory	phase:	neutrophils	and	
NETs	formation	
Neutrophils	are	short-lived	inflammatory	cells.	Immediately	after	wounding,	
they	are	recruited	to	the	wound	site.	Neutrophils	can	be	linked	to	three	
different	antimicrobial	mechanisms:	(1)	Phagocytosis:	pathogens	are	engulfed	
into	a	phagosome	and	destroyed	by	NADPH-dependent	mechanisms	or	by	
antimicrobial	proteins.	(2)	Degranulation:	pathogens	are	killed	by	
antimicrobial	proteins,	that	are	released	into	the	ECM	by	neutrophils	and	(3)	
NETosis,	a	process	in	which	neutrophils	excrete	their	DNA,	histones	and	other	
antimicrobial	components	into	the	ECM	by	degrading	their	own	membranes	
(20).					
	
NET	formation	
NETosis,	the	process	of	neutrophil	extracellular	traps	(NETs)	formation,	is	the	
most	recently	described	antimicrobial	mechanism	of	neutrophils.	During	
NETosis,	NETs	are	released.	They	consist	of	extracellular	fibers	of	
decondensed	chromatin	and	granule	proteins,	such	as	antimicrobial	factor	
myeloperoxidase	(MPO)	and	neutrophil	elastase	(NE).	NETs	trap	and	kill	
microbes	efficiently	(7).		
It	is	generally	believed	that	MPO	plays	a	very	important	role	in	the	breakdown	
of	the	nuclear	envelope.	Perforation	of	the	outer	membrane	of	the	neutrophil	
follows	after	the	components	are	mixed	(21).	This	makes	NETosis	very	
different	from	apoptosis	and	necrosis,	as	in	these	processes	the	nuclear	
envelope	and	granules	remain	intact	(22).	However,	the	full	mechanism	
behind	NETosis	remains	unclear.	
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During	infection,	NETosis	is	activated	by	the	presence	of	pathogens.	Bacteria	
and	fungi	are	very	strong	inducers	of	NETosis	(23,	24).	One	of	the	strongest	
inducers	of	NETosis	is	Staphylococcus	aureus	(S.	aureus)(24).	S.	aureus	can	
cause	major	problems	and	infections	by	Methicillin-resistant	Staphylococcus	
aureus	(MRSA)	are	very	hard	to	treat	and	worldwide	of	medical	concern.	NETs	
might	be	an	effective	way	to	limit	bacterial	spreading	and	to	improve	bacterial	
clearance.	However,	S.	aureus	has	defense	mechanisms	that	conquer	NETs.	By	
producing	nuclease,	they	are	able	to	break	down	NETs	(25)	and	escape,	whilst	
the	number	of	neutrophils	decreases,	as	they	die	after	NETosis.				
In	addition	to	pathogens,	a	variety	of	other	inducers	of	NETosis	has	been	
described.	These	include	PMA	(7,	22,	26),	LPS	(7,	27,	28)	and	calcium	
ionophores	(29,	30).	In	vivo,	NETs	play	a	role	in	pathophysiological	conditions	
such	as	tuberculosis,	pneumonia,	lung	fibrosis,	sepsis	and	thrombosis	(31-34).	
Thrombi	have	been	shown	to	be	more	persistent	when	NETs	are	present	(35),	
and	patients	with	sepsis	that	have	higher	NETs	levels	in	plasma	are	
considered	to	have	a	worse	outcome	due	to	their	inflammatory	status	(36)	
and	contribution	to	the	formation	of	microthrombi	(37).		
NETs	are	able	to	interact	with	several	factors	of	the	coagulation	cascade.	
Platelets	are	known	to	bind	neutrophils,	which	stimulate	both	neutrophil	and	
platelet	activation	and	platelet	aggregation,	by	the	release	of	multiple	
inflammatory	cytokines	and	other	molecules	(35,	38).	Also,	NETs	are	able	to	
stimulate	fibroblasts	to	differentiate	into	myofibroblasts	(34)	and	stimulate	
fibrin	formation	and	deposition	in	thrombi	by	triggering	FXII	and	TF	(32,	39).	
Fibrin	clots	were	shown	to	have	thicker	fibrin	fibers	in	the	presence	of	
histones,	which	are	abundantly	present	in	NETs	(40).	This	effect	can	be	
enlarged	in	the	presence	of	DNA;	as	the	diameter	of	the	fibers	increases,	the	
network	itself	becomes	stiffer,	making	it	harder	to	lyse.	In	wound	healing,	this	
could	be	problematic,	as	clot	lysis	is	necessary	for	the	transition	from	fibrin	to	
collagen.	Also,	persisting	NETs	cause	a	persisting	inflammatory	response,	as	
they	contain	anti-microbial	factors	such	as	MPO	and	NE.	Therefore,	it	we	
hypothesized	that	NETs	play	a	role	in	non-healing	wounds.		
Disturbed	wound	healing	in	diabetes	
Patients	with	diabetes,	especially	type	2,	often	suffer	from	chronic	wounds	or	
ulcers,	due	to	their	thin	skin,	vascular	insufficiency	and	neuropathy.	The	fibrin	
network	of	diabetic	wounds	is	denser	and	less	porous	(41),	due	to	slower	
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coagulation	and	higher	fibrinogen	levels.	A	denser	fibrin	matrix	could	lead	to	
disturbed	EC	and	fibroblast	ingrowth,	causing	inhibition	of	angiogenesis	and	
collagen	deposition	(2,	18).	Furthermore,	diabetic	chronic	wounds	are	
considered	to	be	arrested	in	the	pro-inflammatory	phase	of	wound	healing.	
Insulin	resistance	in	type	2	DM	has	been	linked	to	increased	pro-inflammatory	
factors	such	as	TNF-α,	IFN-ƴ	and	IL-1β	(42).	This	pro-inflammatory	state	of	
the	immune	cells	causes	insensitivity	to	actual	stimuli,	such	as	bacterial	
infections.	Instead,	neutrophils	from	diabetic	patients	are	more	prone	to	form	
spontaneous	NETs	(43).	As	NETs	contain	cytotoxic	histones	and	MPO,	they	
have	a	negative	effect	wound	the	progression	of	wound	healing,	as	their	
compounds	inhibit	processes	like	re-epithelization	(44,	45)	and	angiogenesis	
(46).	Normally,	NETs	are	cleared	by	macrophages,	but	in	chronic	wounds	it	
could	be	expected	that	this	function	is	also	compromised.	If	true,	NETs	could	
play	an	important	role	in	the	persisting	pro-inflammatory	phase	in	diabetic	
chronic	wounds,	disturbing	the	healing	process.		
	
Aim	and	outline	of	this	theses	
In	this	thesis,	we	studied	the	induction	and	the	effect	of	NETs	in	fibrin	in	
different	diseases,	with	a	focus	on	diabetic	wound	healing.	The	aim	of	this	
thesis	is	to	obtain	more	insight	in	the	effect	of	NETs	and	the	induction	of	
NETosis	in	chronic	wounds.		
In	the	first	part	we	focus	on	the	induction	of	NETs.	In	chapters	2-4	we	
investigate	different	stimuli	that	cause	NETosis.	Because	many	different	
stimuli	of	NETosis	have	been	described	in	literature,	we	made	an	overview	of	
different	stimuli	and	we	test	several	inducers	in	a	standardized	setting	in	
chapter	2.	Bacteria	are	very	potent	inducers	of	NETosis,	so	in	chapter	3,	we	
investigate	the	role	of	Protein	A,	a	well-known	immunomodulator	produced	
by	S.	aureus,	on	NETosis.	Bacterial	biofilms	also	have	been	described	to	
influence	neutrophil	function.	Therefore,	in	chapter	4	we	investigate	S.	aureus	
formation	of	biofilm	and	its	association	with	neutrophils.	NETs	play	a	role	in	
different	diseases,	such	as	sepsis	and	thrombosis.	In	chapters	5	and	6	we	
look	at	the	effect	of	NETs	and	nucleosomes	(extracellular	DNA)	on	children	
with	sepsis	and	patients	with	arterial	thrombosis	at	a	young	age.	In	chapter	5,	
we	study	NETs	(MPO-DNA)	levels	in	serum	from	children	with	Meningococcal	
sepsis	and	correlate	these	levels	to	patient	outcome	and	inflammatory	
markers	that	can	cause	NETosis.	VWF	cleavage	is	stimulated	when	VWF	and	
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ADAMTS13	are	bound	to	NETs	and	eDNA.	This	process	is	hypothesized	to	be	
further	affected	by	FH.	Therefore,	in	chapter	6,	we	studied	the	effect	of	Factor	
H	on	the	cleavage	of	von	Willebrand	factor	(VWF)	by	disintegrin	and	
metralloproteinase	with	a	thrombospondin	type	1	motif,	member	13	
(ADAMTS13)	in	young	patients	with	arterial	thrombosis	(‘Arterial	Thrombosis	
at	a	young	age:	the	role	of	TAFI	and	other	Coagulation	factors	(ATTAC)’	study).	
Fibrinogen	levels	in	diabetic	patients	are	higher	and	form	clots	in	diabetic	
wounds	that	are	inadequate	for	achieving	optimal	angiogenesis.	Therefore,	in	
chapter	7	we	study	the	effect	of	healthy	fibrin	applied	to	a	diabetic	wounds	
wound	in	rats.		
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Abstract 
Multiple	inducers	of	in	vitro	Neutrophil	Extracellular	Trap	(NET)	formation	
(NETosis)	have	been	described.	Since	there	is	much	variation	in	study	design	
and	results,	our	aim	was	to	create	a	systematic	review	of	NETosis	inducers	
and	perform	a	standardized	in	vitro	study	of	NETosis	inducers	important	in	
(cardiac)	wound	healing.	In	vitro	NETosis	was	studied	by	incubating	
neutrophils	with	PMA,	living	and	dead	bacteria	(S.	aureus	and	E.	coli),	LPS,	
(activated)	platelets	(supernatant),	glucose	and	calcium	ionophore	Ionomycin	
using	3-hour	periods	of	time-lapse	confocal	imaging.	 
PMA	is	a	consistent	and	potent	inducer	of	NETosis.	Ionomycin	also	
consistently	resulted	in	extrusion	of	DNA,	albeit	with	a	process	that	differs	
from	the	NETosis	process	induced	by	PMA.	In	our	standardized	experiments,	
living	bacteria	were	also	potent	inducers	of	NETosis,	but	dead	bacteria,	LPS,	
(activated)	platelets	(supernatant)	and	glucose	did	not	induce	NETosis.		
Our	systematic	review	confirms	that	there	is	much	variation	in	study	design	
and	results	of	NETosis	induction.	Our	experimental	results	confirm	that	under	
standardized	conditions,	PMA,	living	bacteria	and	Ionomycin	all	strongly	
induce	NETosis,	but	real-time	confocal	imaging	reveal	different	courses	of	
events.	
Introduction	
Neutrophil	extracellular	traps	(NETs)	formation,	also	called	NETosis,	is	
considered	one	of	the	defense	mechanisms	against	pathogens	1.	During	
NETosis,	the	nucleus	of	a	neutrophil	decondenses	and	the	nuclear	envelope	
breaks,	mixing	chromatin,	cytoplasmic	and	granular	components.	Also,	the	cell	
membrane	breaks,	followed	by	an	extrusion	of	the	neutrophil’s	DNA,	histones	
and	antimicrobial	proteins	into	the	extracellular	space	1.	Subsequently,	
pathogens	are	trapped	in	the	NETs	and	either	killed	by	the	toxicity	of	the	
antimicrobial	substances	of	the	NETs,	or	immobilized	to	facilitate	
phagocytosis	by	other	neutrophils	or	macrophages	2.	NETs	have	been	shown	
to	play	a	role	in	multiple	diseases,	such	as	thrombosis	3-6,	fibrotic	diseases	7,	
cardiovascular	diseases	8	and	sepsis	9-11.	Therefore,	elucidation	of	the	
mechanism	behind	NETosis	has	become	an	increasingly	important	topic.	
Many	stimuli	have	been	reported	to	induce	NETosis	12.	Gram	positive	1,13,14	and	
negative	bacteria	1,14	and	fungi	15	induce	NETosis	and	subsequently	are	
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trapped	in	the	NETs.	Many	other	inducers	have	also	been	described,	but	their	
NETosis	inducing	capabilities	are	not	consistent.		These	include	
lipopolysaccharides	(LPS)	1,10,16-18,	inflammatory	cytokines	such	as	IL-6	19	and	
IL-8	1,16,18,20	and	the	calcium	(Ca2+)	ionophore	A23187	and	Ionomycin	21,22.	A	
difference	in	experimental	methods	and	definitions	of	NETosis	might	
contribute	to	these	conflicting	results.	
	
For	in	vitro	studies,	phorbol	12-myristate	13-acetate	(PMA),	a	plant	derived	
organic	compound	and	well-known	activator	of	the	ubiquitous	signal	
transduction	enzyme	protein	kinase	C	(PKC),	is	often	used	as	an	inducer	of	
NETosis	1,3,12,18.	So	even	though	PMA	is	consistently	reported	as	NETosis	
inducer,	it	is	not	physiologically	relevant,	since	it	does	not	activate	
physiological	processes	in	vivo.	Therefore,	it	is	important	to	study	the	effects	
of	other,	physiological,	NETosis	inducers.	This	is	especially	relevant	in	studies	
on	human	diseases,	such	as	cardiovascular	wound	healing,	in	which	NETs	also	
play	a	role.	Results	from	published	studies	often	cannot	be	compared	because	
they	are	derived	from	a	multitude	of	experimental	settings.	Therefore,	we	first	
made	a	comprehensive	systematic	review	to	make	an	overview	of	inducers	of	
interest	in	cardiovascular	wound	healing.	Subsequently,	we	selected	the	most	
relevant	inducers	and	tested	their	effect	on	NETosis	induction	in	a	
standardized	experimental	setup	using	static	conditions	and	imaged	using	
time-lapse	confocal	imaging. 
Material	and	methods	
Systematic	Literature	Review	
A	systematic	literature	review	of	the	Medline-Ovid,	Embase,	Web	of	Science	
and	Cochrane	databases	was	conducted,	using	search	and	selection	criteria	
according	to	the	PRISMA-2015	criteria	for	writing	a	systematic	literature	
review	23.	MeSH-terms	for	“neutrophil	extracellular	traps”	were	not	available.	
We	therefore	used	the	search	terms	“neutrophil	extracellular	traps”	and/or	
“NET(osis)”.	Moreover,	we	included	only	journal	articles	about	in	vitro	NET	
induction,	and	only	inducers	that	were	described	as	inducer	of	NETosis	by	at	
least	two	papers.	Only	journal	articles	of	which	the	full-text	was	available	to	us	
were	included.	Reviews	were	excluded.	MEDLINE-OVID:	(neutrophil	
extracellular	trap*	[TIAB]	OR	NETosis	[TIAB])	NOT	Review	NOT	patient*	[TI]	
Select	“journal	article”.	Articles	were	included	up	to	January	2017.	This	review	
was	executed	independently	by	two	researchers	to	prevent	bias.	Outcomes	of	
	
24	
this	review	were	used	for	creating	an	overview	to	perform	comparison	
experiments	only.		
Neutrophil	isolation	
Neutrophils	were	isolated	from	blood	from	healthy	donors	using	density	
gradient	medium	LymphoprepTM	(Stem	cell	Technologies,	Grenoble,	France).	
All	experiments	were	approved	by	the	Medical	Ethics	Committee	of	the	
Erasmus	MC.	Blood	was	diluted	1:1	with	PBS	(Phosphate	Buffered	Saline	
without	Ca2+/Mg,	17-516F,	Lonza,	Walkersville	USA),	loaded	onto	the	
LymphoprepTM	and	centrifuged	at	830	x	g	for	15	minutes	at	room	
temperature.	Erythrocytes	were	lysed	by	incubation	with	erythrolysis	buffer	
(3.1M	NH4Cl,	0.2M	KHCO3,	0.02M	EDTA,	pH	7.4)	for	10	minutes	at	room	
temperature	followed	by	centrifugation	at	690	x	g	for	8	minutes	at	room	
temperature.	Cells	were	washed	two	times	(690	x	g	for	8	minutes	and	560	x	g	
for	5	minutes)	with	HEPES	buffer	(0.115M	NaCl,	0.012mM	CaCl2,	1.51mM	
MgCl2,	4mM	KCl,	0.01M	HEPES,	pH	7.4)	and	the	concentration	of	cells	was	
determined	using	a	ABX	Micros	80	cell	counter	(Horiba,	Irvine,	California).	
	
Neutrophils	were	transferred	to	DMEM	culture	medium	containing	10%	FCS,	
L-glutamine	and	Penicillin/Streptomycin	(all	from	Biowhittaker,	Lonza,	
Walkersville,	USA)	or	DMEM	culture	medium	without	any	additions	for	
bacterial	experiments.	Hoechst	34580	(1:10	000,	Life	Technologies,	
Landsmeer,	The	Netherlands)	for	staining	DNA	and	Propidium	Iodide	(PI,	
1:400,	Sigma	Aldrich,	Zwijndrecht,	The	Netherlands)	for	staining	extracellular	
DNA	were	added	and	cells	were	incubated	for	at	least	1	hour	at	37⁰C	on	
gelatin-coated	(Sigma	Aldrich,	Zwijndrecht,	The	Netherlands)	24	wells	glass-
bottom	plates.	
Selection	of	NETosis	inducers	for	in	vitro	experiments	
From	the	inducers	we	documented	in	our	search	we	selected	inducers	that	
were	well	described	and	play	a	role	in	(cardiovascular)	wound	healing.	We	
then	selected	the	best	described	inducers	as	well	as	the	inducers	with	the	
most	variation	in	reported	effect	to	test	in	our	own	standardized	experimental	
setup.	As	a	source	for	cytokines,	we	used	activated	platelets	supernatant,	
containing	cytokines	such	as	IL-8,	PDGF	and	VEGF	24,25.	
Bacterial	strains	and	culture	
Gram-positive	(S.	aureus	Newman)	and	gram-negative	(E.	coli	ATCC	25922	
(O6:B1))	bacteria	were	cultured	in	100	ml	Iscove’s	Modified	Dulbecco’s	Media	
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(Gibco®	IMDM	medium,	Life	Technologies,	Landsmeer,	The	Netherlands)	at	
37⁰C	overnight.	The	next	day	the	bacteria	were	diluted	to	a	final	concentration	
of	108	bacteria	per	ml	as	determined	by	OD600	measurements	.	For	
experiments	with	dead	bacteria,	the	bacteria	were	either	killed	by	incubation	
at	90⁰C	for	10	minutes	or	by	exposure	to	UV	light	with	6000	µWs/cm2	for	66	
seconds.	
NETosis	induction	and	time-lapse	imaging	
Isolated	neutrophils	(107	cells/well)	were	added	to	a	24	wells	plate	in	a	final	
volume	of	500	µl.	Stock	solutions	of	PMA	and	Ionomycin	were	prepared	in	
dimethyl	sulfoxide	(DMSO,	Sigma	Aldrich).	Platelets	(platelet	rich	plasma)	
were	isolated	from	EDTA	blood	by	centrifugation	for	7	minutes	at	260	x	g	
without	brake,	and	activated	for	10	minutes	by	adding	thrombin	(1	U/ml).	
Activated	platelets	supernatant	was	collected	by	centrifuging	the	activated	
platelets	at	2000	x	g	for	10	minutes.	
To	induce	NETosis,	non-bacterial	inducers	were	individually	added	to	each	
well.	Before	addition	(t=0),	an	image	was	taken	and	starting	directly	after	
addition	of	the	inducers,	cells	in	a	random	field	were	imaged	every	15	minutes	
for	3	hours	with	a	20x	0.7	n.a.	lens	by	using	confocal	microscopy	(Leica	SP5	
AOBS,	Leica	Microsystems,	Wetzlar,	Germany).	Excitation	with	a	405	laser	and	
a	BP	420-500	emission	filter	for	Hoechst	and	a	561	excitation	and	BP	580-620	
emission	filter	for	PI.	In	this	setting,	the	dish	was	mechanically	moved	
between	fields.	We	stopped	imaging	after	three	hours,	since	after	three	hours	
spontaneous	cell	death	was	observed	in	control	neutrophils.	In	experiments	
containing	bacteria,	we	imaged	continuously	for	one	hour	since	all	neutrophils	
underwent	NETosis	within	one	hour	in	all	bacterial	conditions.	We	defined	
NETosis	as	a	host	defense	mechanism	in	which	neutrophils	release	their	
nuclear	and	granular	contents	to	contain	and	kill	pathogens21.	The	NETs	that	
are	released	form	extensive	webs	of	DNA	coated	with	cytotoxic	histones	and	
microbicidal	proteases.		In	cells	that	stained	only	positive	for	Hoechst,	the	cell	
membrane	was	still	intact.	After	breakdown	of	the	cell	membrane,	the	DNA	
became	PI	positive.	Unstimulated	cells	(in	experiments	without	platelets)	and	
resting	platelets	were	used	as	negative	control	and	PMA	stimulated	cells	were	
used	as	positive	control.		
Immunofluorescence		
To	confirm	in	vitro	NETosis	in	the	bacteria	experiments,	we	added	an	
immunofluorescent	staining	with	a	MPO-Dylight488	complex	(1:250)	to	the	
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neutrophils	immediately	before	induction.	Then,	we	quantified	the	positive	
NETs	by	using	confocal	microscopy	(Leica	SP5	AOBS).	
As	another	measurement	for	NETosis,	cells	were	stimulated	by	the	described	
inducers	for	3	hours,	fixed	and	stained	for	myeloperoxidase	(MPO,	Dako).	
Briefly,	after	antigen	retrieval	with	Proteinase	K,	the	slides	were	blocked	with	
skim	milk	powder	(5%)	in	PBS	Tween	0.1%	pH7.4	and	incubated	overnight	
with	polyclonal	rabbit	anti-human	MPO	(1:300)	at	4°C.	After	washing	with	
PBS	Tween	0.1%	pH7.4	slides	were	incubated	with	secondary	antibody	
Dylight	goat	anti	rabbit	488	(1:200)	for	30	minutes.	Slides	were	mounted	with	
Prolong	Diamond	antifade	with	DAPI	(Thermofischer).	Images	were	made	by	
using	confocal	microscopy	(Leica	SP5	AOBS)	and	Structured	Illumination	
Microscopy	(Zeiss	Elyra	PS1	LSM	780	structured	illumination	microscope,	Carl	
Zeiss,	Jena,	Germany).	
Image	Analysis	
All	images	were	analyzed	using	ImageJ	(Version	1.49,	National	Institutes	of	
Health,	USA).	We	quantified	the	number,	area	and	mean	intensity	of	Hoechst	
positive	and	PI	positive	cells	using	a	macro	that	includes	a	segmentation	of	the	
nuclei	on	a	Gaussian	blurred	image	(sigma=2px)	with	a	threshold	and	a	
watershed	segmentation	(supplemental	file	2).	A	minimal	and	maximal	size	of	
Hoechst	positive	and	PI	positive	cells	was	included	in	the	macro.	The	Hoechst	
and	PI	threshold	was	kept	constant	within	one	experiment.	We	determined	
the	ratio	of	PI	positive	cells	and	corrected	at	t=0	for	dead	cells	in	the	start	
mixture.	To	correct	for	regular	cell	death	during	the	experiment,	conditions	
were	compared	to	the	negative	controls:	no	additions	or	resting	platelets,	in	
which	no	NETosis	was	observed.			
Statistics	
All	data	are	presented	as	mean±SEM.	A	repeated	measurements	ANOVA	was	
used	to	detect	differences	in	NET	ratio	with	time	and	inducer	as	independent	
parameters.	Results	were	considered	statistically	significant	when	p<0.05.	
Data	were	analyzed	using	SPSS	v22	(IBM,	USA).		
Results		
Systematic	Literature	Review		
Our	systematic	search	strategy	resulted	in	870	scientific	articles,	of	which	655	
were	excluded	following	selection	according	to	the	described	criteria	(Fig.	1).	
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In	the	215	remaining	articles	we	identified	25	different	NETosis	inducers.	
These	inducers	are	presented	in	Table	1.		
	
Figure	1:	PRISM	chart	of	the	systematic	literature	review.		
Table	1:	Overview	of	in-literature	described	in	vitro	NETs	inducers.	MOI:	Multiplicity	Of	
Infection	(number	of	bacteria	to	number	of	cells).	CFU:	Colony	Forming	Units.	
Inducer	 Concentration	 Induction	time	 NETosis	 Reference	
PMA	 4-50	nM	(3-30.8	ng/ml)	 10	min-16h	 Yes	 1-3,12,16,19,20,26-112	
	 60-100	nM	(37-62	ng/ml)	 30	min-16h	 Yes	 7,18,21,113-146	
	 120-1620	nM	(74-1000	
ng/ml)	
10	min-4h	 Yes	 147-166	
	 100000	nM	(6168	ng/ml)	 10	min-24h	 Yes	 14,167,168	
H2O2	 0.1	µM	 3h	 No	 116	
	 100-1000	µM	 4h	 Yes	 61,114	
	 4000	µM		 200	min	 Apoptosis	 18	
	 10000	µM		 200	min	 Necrosis	 18	
	 10000	µM	 4-5h	 Yes	 54	
	 0.03%		 3h	 Yes	 169	
Growth	factors/platelets	
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IL-8	 1-250	ng/ml	 10	min-5h		 Yes	 1,12,27,29,42,64,161,1
70-172	
	 10	ng/ml	 3h	 Little	 16	
	 100-800	ng/ml	 4-18h	 No	 18,76,82	
IL-1β	 10	ng/ml	 6h	 Little	 62	
	 50	ng/ml	 2h	 Yes	 27	
TNF-α	 1	ng/ml	 6h	 Little	 62	
	 7-20	ng/ml	 30	min-5h	 Yes	 19,20,54	
	 100	ng/ml	
100	ng/ml	
2h	
4h	
Yes	
No	
27	
76	
Platelets	 5x107	/ml	 	 No	 10	
	 2x105	–	5x105	 1h	 No	 44	
Activated	
platelets	
2x105	–	5x105	(+	50	µM	
TRAP)	
1h	 Yes	 44	
	 5x105	(+	1.3	µg/mL	
collagen)	
2h	 Yes	 173	
	 1:400	(+	0.01	U/mL	
Thrombin)	
	4h	 Yes	 174	
	 25-100	ml	(+	5	μmol/L	
PGE1)	
20	min	 Yes	 175	
	 25-100	ml	(+	25	μmol/l	
TRAP-6)	
20	min	 Yes	 175	
	 25-100	ml	(+	5	μmol/l	
ADP)		
20	min	 Yes	 175	
	 25-100	ml	(+	1	μg/ml	
collagen)	
20	min	 Yes	 175	
	 25-100	ml	(+	0.05	IU/ml	
recombinant	thrombin)	
(+CoCr)	
20	min	
	
	
Yes	
	
Yes	
175	
	
176	
Calcium	
A23187	 0.2-25	µM	 20	min-4h	 Yes	 22,130,151,177-179	
	 1	µM	 1h	 No	 180	
	 100	µM	 1-4h	 Little	 167	
Ionomycin	 0.9-7	µM		 30	min-4h	 Yes	 21,29,34,130,132	
	 100	µM	 1-4h	 Little	 167	
MSU	
crystals	
100-200	µg/ml	 3-5h	 Yes	 71,118,181	
	 1000	µg/ml	
	
20	pg/cell	
2h	
	
2h	
Yes	
Yes	
Yes	
182	
134	
80	
Glucose	
Glucose	
Oxidase		
100	mU/ml	 1-4h	 Yes	 12,172	
Glucose	 5.5-10	nM	 2h	 No	 183	
	 20-30	nM		 2h	 Yes	 183	
	 5000000	nM		 3h	 No	 58	
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	 25000000	nM		 3h	 Yes	 58	
Bacterial/fungal	products	
LPS	 0.1	ng/ml	
0.1-10	µg/ml	
1h	
15	min-18h	
Yes	
Yes	
184	
1,19,28,54,61,64,71,76,
82,83,147,158,161,185
-194	
	 0.1-25	µg/ml	 2,5-3h	 Little	 16,21	
	 0.3-5	µg/ml	 15	min	 No	 10,17	
	 50	µg/ml	 30-90	min	 Yes	 155,195	
	 	
10	mg/L	
	
30	min	
No	
Yes	
18	
190	
	 	 30	min	 Yes	 196	
LPS	+	
Glucose	
2	µg/ml	+	30000000	nM	 3h	 Little	 19	
	 2.5-25	µg/ml	 2,5h	 Yes	 21	
LPS	+	
Platelets		
1-5	µg/ml	+	5x107-2.4x108	
/ml	
30	min	+		 Yes	 10,197	
	 25-100	ml	+		 20	min	 Yes	 175	
β-glucan	 200	µg/ml	 15-240	min	 Yes	 198,199	
	 1000	µg/ml		 1h	 Yes	 129	
Bacteria/fungi	
S.	aureus		 0.03-50	MOI		 30	min-24h	 Yes	 12,14,34,40,71,116,16
9,200-202	
	 6x106/ml	
25	µl	OD	0.5	
1h	
3h	
Yes	
Yes	
180	
86	
S.	pneumonia	 10	MOI	 10	min-24h	 Yes	 14	
S.	pneumonia	
(dead)	
2x107/ml	 4h	 Yes	 118	
E.	coli		 	 4h	 No	 15	
	 3-50	MOI	 10	min-24h	 Yes	 14,34,79,124,202	
	 100	MOI	 1-4h	 Yes	 51,184	
	 106	-107	CFU	 5min-1h	 Yes	 189,203	
	 2000	CFU	 1-8h	 Yes	 189	
P.	aeruginosa	 1-50	MOI	 5h	 Some	 204	
	 10-100	MOI	 10	min-24h	
8h	
Yes	
Yes	
14,34,168,205-207	
208	
	 6x106/ml	 1h	 Yes	 180	
A.	fumigatus	
(hyphae)	
750	CFU	/	50	µl	 2h	 Yes	 209	
	 0.2-2000	MOI	
106	conidia	
40-180	min	
3h	
Yes	
Yes	
64,77	
191	
C.	albicans	
(yeast)	
0.5	MOI	
2	MOI	
2	MOI	
90	min	
15	min	
4h	
Little	
Yes	
No	
125	
210	
210	
	 5	MOI	 3h	 No	 148	
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PMA	is	the	most	frequently	used	stimulus	with	a	100%	success	rate	for	
inducing	NETosis.	In	literature	different	concentrations	are	used	ranging	from	
5	nM	to	100	µM.	NETosis	was	observed	within	a	time	frame	ranging	from	10	
minutes	to	24	hours	1-3,7,12,14,16,18-21,26-69,71-158,160-168,192.		
S.	aureus	has	consistently	been	described	to	be	a	potent	inducer	of	
NETosis12,14,34,40,71,75,104,131-133.	In	literature	search	a	variety	of	other	bacteria	
were	reported,	that	also	induced	NETosis,	although	most	species	are	weak	
NETosis	inducers	compared	to	S.	aureus	14.	E.	coli	P.	aeruginosa,	C.	albicans	
yeast	and	M.	bovis	have	also	been	described	as	potent	NETosis	inducers	in	
most	papers,	but	discrepancies	occur	15,148,159,207,210.		
The	NETosis	inducing	properties	of	LPS	have	been	investigated	in	many	
papers,	but	the	results	are	contradicting.	For	example,	in	LPS-activated	
neutrophils	multiple	papers	state	to	have	observed	NETosis	after	30	min	with	
100	ng/ml	76,83,158,161,187,	whereas	other	authors	did	not	observe	NETosis	using	
a	concentration	of	10	µg/ml	18.		
Results	for	glucose	as	an	inducer	for	NETosis	indicate	that	higher	
concentrations	(20-30	mM)	of	glucose	appear	to	induce	NETosis	whilst	low	
concentrations	(5-10	mM)	do	not	58,187.	Higher	concentrations	of	glucose	are	
thought	to	resemble	a	hyperglycemic	environment	for	neutrophils	and	may	
mimic	the	situation	in	patients	with	badly	regulated	Diabetes	Mellitus.	
NETosis	induced	by	glucose	therefore	seems	concentration	dependent.	
Studies	with	A23187	report	conflicting	results.	Six	studies	reported	induction	
of	NETosis	after	stimulation	with	5µg/mL	and	0.2-25	µM	for	20	minutes	to	4	
hours	22,130,151,179,181,183.	Two	other	studies	reported	little	to	no	NETosis	after	
induction	with	1	and	100	µM	of	A23187for	1-4	hours	167,182.	Ionomycin	is	also	
reported	to	induce	NETosis	after	30-180	min	21,29,34,130,132,167,195.	
	 10	MOI	 3h	 Little	 120	
	 10	MOI	 2h	 Yes	 123	
C.	albicans	
(hyphae)	
	
M.	bovis	
0.2-4.2	MOI	
	
10	MOI	
10-1000	MOI	
5-min–4h	
30	min	
4h	
1-4h	
Yes	
Yes	
Yes	
No	
125,126,210-212	
213	
177	
159	
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Experiments	with	IL-8	as	an	inducer	of	NETosis	gave	various	results.	In	one	
study,	NETosis	was	induced	between	30-240	min	after	administration	of	10-
100ng/ml	IL-8	12.	However,	in	other	studies,	after	stimulation	with	200-
800ng/ml	IL-8	for	4-18h	NETosis	was	not	observed	18,76,82.	TNF-α	is	reported	
as	an	inducer	of	NETosis	in	five	studies,	while	two	papers	report	little	or	no	
NETosis.	NETosis	was	observed	30	minutes	to	6	hours	after	administration	of	
7-100ng/ml	TNF-α	19,20,27,54,62.	One	study	used	a	concentration	of	1ng/mL	and	
reported	little	effect	of	TNF-α	as	an	inducer,	and	one	study	did	not	observe	
NETosis	at	all	after	4h	with	100ng/ml76.		
Another	investigated	inducer	was	H2O2.	Some	experiments	including	H2O2	did	
not	show	clear	NETosis	but	showed	other	forms	of	cell	death	such	as	
apoptosis	and	necrosis	18,116.	However,	H2O2	also	was	reported,	by	other	
studies,	to	be	a	good	inducer	of	NETosis	54,61,114,169.	
In	summary,	the	data	in	literature	show	that	PMA	is	a	well-defined	inducer	of	
NETosis	with	a	100%	success	rate.	Bacterial	inducers	of	NETosis	such	as	S.	
aureus	(10:1	-	20:1	bacteria	to	neutrophils)	also	seem	consistent	inducers,	but	
in	some	strains	discrepancies	occur	and	the	process	is	less	well	described	than	
PMA.	Other	inducers,	such	as	cytokines	IL-8	and	activated	platelets,	different	
glucose	concentrations	and	especially	LPS,	display	a	variable	outcome.		
Our	literature	search	revealed	the	observation	that	numerous	experiments	
have	been	performed	in	which	it	became	clear	that	all	inducers,	with	the	
exception	of	PMA,	have	been	studied	with	experimental	conditions	that	
differed	between	studies,	such	as	time	frame,	concentration	and	NETs	imaging	
procedure.	This	could	partly	explain	the	observed	differences	in	NETosis	
induction.	
Hence,	there	is	a	need	for	a	well-controlled	evaluation	of	NETosis	inducers.	
We	therefore	performed	a	standardized	study	in	which	we	tested	the	NETosis	
capability	of	different	NETs	inducers	(as	defined	in	Table	2).	Bacterial	
infections,	diabetes	and	calcium	influx	all	influence	cardiovascular	wound	
healing	differently.	Therefore,	we	selected	S.	aureus,	E.	coli,	LPS,	Ionomycin,	
glucose	and	combinations	with	(activated)	platelets	and	LPS	for	our	panel.	
PMA	will	be	taken	as	a	positive	control,	whilst	unstimulated	cells	are	a	
negative	control	in	experiments	without	platelets,	and	resting	platelets	are	a	
negative	control	in	experiments	with	platelets.	In	this	study,	we	use	a	well-
defined	experimental	setup	to	test	multiple	conditions	at	the	same	time	on	the	
same	neutrophils.		
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Table	2:	Concentrations	of	the	potential	NETosis	inducers	in	the	experiments.	
NETosis	inducer	and	final	concentrations	
PMA	(Sigma	Aldrich,	Saint	Louis,	Missouri,	USA)	
• 50	ng/ml	
• 250	ng/ml	
Platelets	(isolated	from	EDTA	blood)	
• 5x107	/ml	
Supernatant	of	activated	platelets	(isolated	from	EDTA	blood)	
• 5x107	/ml	
D-Glucose	(Amresco)	
• 25	µM	
• 25	mM	
Ionomycin	(Sigma	Aldrich)	
• 3	µg/ml	
• 5	µg/ml	
LPS	(Sigma	Aldrich):	source	
E.	coli	O55:B5	
• 10	ng/ml	
• 100	ng/ml	
• 1000	ng/ml	
• 5	µg/ml	
E.	coli	O111:B4	
• 10	ng/ml	
• 100	ng/ml	
• 1000	ng/ml	
• 5	µg/ml	
P.	aeruginosa	
• 10	ng/ml	
• 100	ng/ml	
• 1000	ng/ml	
• 5	µg/ml	
Platelets	+	LPS	(E.	coli	O111:B4)	
• 5x107	/ml	+	5	µg/ml	
Activated	platelets	supernatant	+	LPS	(E.	coli	O111:B4)	
• 5x107	/ml	+	5	µg/ml	
Living	bacteria	
S.	aureus	(Newman)	
• 108/ml	(±10:1)	
E.	coli	ATCC	25922	(O6:B1)	
• 108/ml	(±10:1)	
Dead	bacteria	
S.	aureus	(Newman)	
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• 1010/ml	(±1000:1)	
E.	coli	ATCC	25922	(O6:B1)	
• 1010/ml	(±1000:1)	
 
NETosis	experiments	
PMA	
In	our	experiments	PMA	(n=7)	consistently	and	strongly	induced	NETosis	
(61.5	±	9.3	%	of	PMA	stimulated	neutrophils	vs	4.1	±	1.3	%	of	unstimulated	
neutrophils,	p<0.001)	(Table	3,	Fig.	2	and	supplemental	Fig.	1).	NETosis	was	
observed	about	1.5	hours	after	administration	of	PMA	and	observed	for	both	
concentrations	(50	ng/ml	and	250	ng/ml).		
Table	3:	Percentage	of	neutrophils	that	underwent	NETosis.	%	NETosis	per	time	point	
(hr)	is	given	as	mean	(SEM).	P-value	of	repeated	measures	ANOVA	with	Bonferroni	post-
hoc	test	results	per	NETosis	inducer	versus	unstimulated	neutrophils.	
		 n	 Time	(hr)	 p-value	
	 	 0	 1	 2	 3	 	
None	 5	 1.94	(0.43)	 3.8	(1.35)	 3.68	(1.08)	 4.10	(1.34)	 n.s.	
PMA	(250	ng/ml)	 7	 3.89	(0.91)	 7.81(1.64)	 31.94	(6.17)	 61.52	(9.34)	 <0.001	
LPS	(5	µg/ml)	 7	 2.98	(1.58)	 2.62	(1.26)	 2.90	(1.08)	 3.98	(1.69)	 n.s.	
Glucose	(25	mM)	 3	 4.71(1.06)	 4.92	(1.90)	 6.40	(1.98)	 6.58	(1.96)	 n.s.	
Platelets	(5x107)	 5	 2.53	(0.71)	 2.80	(1.12)	 1.12	(0.89)	 1.16	(0.92)	 n.s.	
Activated	Platelets	
(5x107)	
7	 2.00	(0.60)	 3.24	(1.15)	 1.45	(0.61)	 1.27	(0.47)	 n.s.	
Activated	Platelets	
Supernatant	(5x107)	
7	 2.84	(1.12)	 4.48	(1.19)	 5.68	(2.31)	 5.94	(2.45)	 n.s.	
Platelets	and	LPS	
(5x107	+	5	µg/ml)	
7	 2.60	(0.79)	 3.57	(0.72)	 2.43	(1.09)	 3.09	(0.98)	 n.s.	
Activated	Platelets	and	
LPS	(5x107	+	5	µg/ml)	
7	 2.35	(0.77)	 2.75	(1.34)	 2.65	(0.93)	 3.77	(1.09)	 n.s.	
Activated	Platelets	
Supernatant	and	LPS	
(5x107	+	5	µg/ml)	
7	 2.87	(1.10)	 6.86	(1.84)	 7.01	(2.88)	 7.88	(3.56)	 n.s.	
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Figure	2:	NETosis	induction	for	the	different	inducers.	NETosis	was	defined	as	the	ratio	
between	the	number	of	Hoechst	and	PI	positive	cells.	PMA	induced	NETosis	when	
compared	to	unstimulated	neutrophils,	p<0.001	repeated	measures	ANOVA	post-hoc	
Bonferroni	(*)	(none	n=5,	PMA	n=7,	LPS	n=7,	glucose	n=5).	Error	Bars	+/-	SEM.	 
Living	bacteria	
In	our	experiments	both	gram	positive	and	gram	negative	bacteria	strongly	
induced	NETosis.	In	S.	aureus	stimulated	samples	(n=3),	NETs	were	observed	
after	10-20	minutes	and	in	E.	coli	stimulated	samples	(n=3),	NETs	were	
observed	within	one	hour	(Fig.	3),	as	confirmed	by	live	MPO	staining	
(Supplemental	Fig.	2).	NETs	induction	by	both	bacteria	strains	differed	in	the	
amount	of	viable	(Hoechst	positive)	neutrophils.	After	the	addition	of	S.	
aureus,	no	Hoechst	positive	neutrophils	were	observed	after	40	minutes.	After	
the	addition	of	E.	coli,	neutrophils	remained	viable	during	the	total	
experiment.	After	the	addition	of	dead	S.	aureus	and	E.	coli	(n=3),	phagocytosis	
of	the	bacteria	by	the	neutrophils	and	no	NETosis	was	observed	
(Supplemental	Fig.	3).	
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Figure	3:	NETs	formed	by	S.	aureus	and	E.	coli	20	minutes	after	stimulation	for	one	hour.	
DNA	(Hoechst,	blue,	405)	and	Extracelullar	DNA	(PI,	red,	561)	were	stained.		
LPS	and	glucose	
No	NETosis	was	observed	when	neutrophils	were	incubated	with	LPS	(n=7)	or	
glucose	(n=5).	For	LPS,	multiple	concentrations	and	variants	(Table	2)	were	
tested,	but	none	induced	NETosis.	Also,	combinations	of	LPS	with	platelets,	
activated	platelets	and	activated	platelets	supernatant	were	unsuccessful	in	
inducing	NETosis	(Fig.	4)	(n=7	for	all).	
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Figure	4:	NETosis	per	inducer	comparing	the	effect	of	platelets	and	the	effect	of	activated	
platelets	supernatant	(n=5,	n=7	respectively).	NETosis	was	defined	as	the	ratio	between	
Hoechst	and	PI	positive	cells.	Neutrophils	stimulated	by	platelets	were	compared	against	
neutrophils	stimulated	by	LPS,	platelets	+	LPS,	activated	platelets,	activated	platelets	+	
LPS,	activated	platelets	supernatant,	activated	platelets	supernatant	+	LPS	using	
repeated	measures	ANOVA	post-hoc	Bonferroni	(*).	No	significant	differences	were	found	
(p>0.05	all).	Error	Bars	+/-	SEM.	
Ionomycin	
When	neutrophils	were	incubated	with	Ionomycin	(n=3),	the	sequence	of	
events	leading	to	DNA	extrusion	was	different	from	the	process	we	observed	
after	the	addition	of	PMA.	Within	15	minutes	after	the	addition	of	Ionomycin,	
the	membranes	of	the	neutrophils	became	porous,	as	shown	by	staining	the	
nuclei	for	PI	(Fig.	5,	supplemental	video	1and	2).	In	our	three	hour	imaging	
timeframe,	DNA	was	seen	to	slowly	leak	out	of	the	cells.	This	process	was	not	
observed	in	cells	that	died	as	a	result	of	necrosis	or	apoptosis,	where	the	DNA	
remains	within	the	cells	12.	At	the	end	of	the	experiment,	the	neutrophils	
treated	with	Ionomycin	and	the	neutrophils	that	were	incubated	with	PMA	
looked	similar,	and,	therefore,	this	difference	in	the	DNA	extrusion	process	
may	be	missed	in	studies	that	did	not	study	early	time	points.	
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Figure	5:	The	effect	of	Ionomycin	compared	to	PMA.	(A)	Time	lapse	images	of	PMA	and	
Ionomycin	at	different	time	frames.	The	arrows	indicate	the	decondensation	of	the	nuclei	
before	(Hoechst,	405)	and	after	(PI,	561)	DNA	extrusion.	(B)	The	amount	of	Hoechst	and	
PI	positive	cells	in	PMA	and	Ionomycin	stimulated	cells	and	unstimulated	cells,	show	the	
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difference	in	the	process	of	NETosis.	In	the	PMA	stimulated	cells,	the	number	of	Hoechst	
positive	cells	go	down	as	the	PI	positive	cells	(NETosis)	go	up.	In	the	Ionomycin	
stimulated	cells,	the	number	of	PI	positive	cells	go	up	very	rapidly,	but	the	Hoechst	
positive	cells	remain	similar.	In	unstimulated	cells,	the	intensity	of	Hoechst	staining	
remains	high	and	no	PI	staining	was	detected.	
Activated	platelets	
We	did	not	observe	NETosis	after	incubating	the	neutrophils	with	thrombin	
activated	platelets,	activated	platelets	supernatant,	platelets	and	LPS	and	
activated	platelets	plus	LPS	(all	n.s.	n=7).	However,	in	two	experiments,	
NETosis	was	observed	after	incubating	the	neutrophils	with	LPS	and	activated	
platelets	supernatant,	while	in	the	other	experiments	(n=7)	no	NETosis	was	
induced.	A	possible	explanation	for	this	variation	could	be	the	variance	
between	donors,	though	blood	samples	were	taken	from	healthy	donors,	and	
none	of	the	observed	results	could	be	linked	to	either	sex	or	age.		
	
Discussion 
Our	in	vitro	study,	performed	in	a	well-defined	and	well-controlled	time-lapse	
setting,	revealed	that	PMA,	bacteria	and	Ionomycin	were	robust	inducers	of	
NETosis.	The	other	reported	NETosis	inducers	were	less	potent.		
First,	we	performed	a	systematic	literature	review	of	NETosis	inducers.	This	is	
the	first	systematic	review	to	address	NETosis	inducers.	NETosis	is	currently	
intensively	investigated	and	therefore	a	systematic	review	on	this	topic	is	very	
needed.	Our	literature	search	revealed	that	PMA	and	bacteria	were	consistent	
inducers	of	NETosis.	Both	are	being	used	in	a	more	routine	way	in	research	
now.	PMA	is	used	to	mainly	investigate	the	effect	of	other	inducers	and	the	
ROS-pathway.		
Studies	on	other	inducers	presented	conflicting	results.	The	difference	in	
experimental	setting,	timing	and	dosing	might	contribute	to	the	variation	in	
results.	Therefore,	we	performed	in	vitro	experiments	in	a	standardized		
laboratory	setting.	In	these	experiments,	we	used	concentrations	based	on	
literature	and	a	time	frame	of	3	hours,	PMA	was	also	used	as	a	positive	control
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in	our	experiments,	as	it	was	a	consistent	inducer	throughout	the	literature.	In	
the	imaging	of	NETosis	by	Ionomycin,	we	observed	a	different	sequence	of	
events,	but	according	to	the	definition	of	NETosis	that	we	use	in	this	paper,	
Ionomycin	is	also	a	qualified	inducer.	NETosis	was	not	observed	with	other	
tested	inducers.		
Bacteria	and	bacterial	products	
In	our	standardized	experiments,	living	gram	negative	as	well	as	living	gram	
positive	bacteria	were	strong	and	consistent	NETosis	inducers.	Several	
studies,	using	a	variation	of	experimental	conditions,	support	our	findings	12-
15,214.	
Our	study	also	showed	that	different	species	gave	a	different	time	of	onset	of	
NETosis	and	a	different	percentage	of	the	neutrophils	that	underwent	
NETosis.	This	is	in	line	with	Pilsczek	et	al	14.	We	saw	more	NETosis	after	the	
induction	with	S.	aureus	compared	to	E.	coli.		
Dead	bacteria	did	not	induce	NETosis	in	our	experiments.	Isolated	LTA	
(derived	from	gram-positive	bacteria)	and	LPS	(derived	from	gram-negative	
bacteria),	both	bacterial-wall	proteins,	have	been	described	to	induce	NETosis.	
We	hypothesized	that	dead	bacteria	also	expose	these	proteins	and,	therefore,	
were	expected	to	be	potent	NETosis	inducers.	We	killed	the	bacteria	with	two	
methods	(heat	and	UV),	however,	did	not	observe	NETosis	in	either	situation.		
When	we	added	LPS,	no	NETosis	was	induced.	In	literature,	contradictory	
reports	are	found	regarding	LPS	as	a	NETosis	inducer.	To	test	whether	the	
type	of	LPS	explains	this	contradiction,	we	used	three	different	types	of	LPS	
(derived	from	E.	coli	O55:B5,	E.	coli	O111:B4	and	P.	aeruginosa),	which	also	
were	used	in	literature.	Data	are	shown	in	Figure	2.	Post	Hoc	testing	showed	
no	difference	between	LPS	and	unstimulated	neutrophils.	These	results	are	in	
line	with	our	experiment	where	dead	gram-negative	bacteria,	with	LPS	on	the	
surface,	also	failed	to	induce	NETosis.	Therefore,	the	ability	of	LPS	to	induce	
NETosis	should	be	studied	further.	
Glucose	
In	literature,	glucose	is	described	as	NETosis	inducer58,183.	In	our	experiments,	
glucose	did	not	induce	NETosis.	One	study	suggested	that	high	levels	of	
glucose	make	neutrophils	more	sensitive	to	NETosis	inducers	such	as	
cytokines	or	LPS58.	In	contrast,	other	literature	that	claims	that	neutrophils	
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become	insensitive	to	stimuli	when	maintained	in	high	glucose	concentrations	
19.		
Calcium	ionophore	
Incubation	of	the	neutrophils	with	the	Ionomycin	resulted	in	an	extrusion	of	
DNA,	however,	this	process	differed	from	the	PMA	induced	NETosis.	
Ionomycin	opens	the	calcium	channels	of	cells,	thus	causing	high	intracellular	
Ca2+	levels.	This	resulted	in	pore	formation	in	the	cellular	membranes	and	
positive	staining	for	PI	in	the	cells,	followed	by	leakage	of	PI-positive	material	
out	of	the	cells.	In	the	NETosis	induced	by	PMA,	nuclear	swelling	is	seen	as	the	
first	step.	Still,	we	considered	the	process	after	Ionomycin	induction	NETosis,	
since	in	other	forms	of	cell	death,	i.e.	necrosis	and	apoptosis,	the	nuclear	
envelope	remains	intact,	which	prevents	DNA	excretion	from	the	dead	cell	12.		
We	emphasize	that	it	is	important	to	visualize	the	whole	NETosis	process	and	
not	only	rely	on	end	stage	measurements.	We	have	shown	that	there	is	
variation	in	the	process	of	DNA	extrusion	with	Ionomycin.	Since	other	studies	
on	Ionomycin	only	measured	at	the	end	of	the	NETosis	process,	they	may	have	
missed	these	variations.		
Platelets	
In	our	experiments,	resting	platelets	did	not	induce	NETosis.	This	results	is	in	
contrast	with	literature	10,44.	We	also	did	not	see	NETosis	induction	when	we	
incubated	neutrophils	with	activated	platelets	or	activated	platelets	plus	LPS,	
as	described	by	one	other	study	175.	The	majority	of	the	studies,	however,	
described	that	the	excretion	of	growth	factors	by	activated	platelets	
(stimulated	by	for	example	LPS	or	PAF)	will	activate	neutrophils	and	stimulate	
NETosis	10,44,173,174.		
	
Difference	in	neutrophil	function		
Interestingly,	we	observed	that	NETosis	induction	with	activated	platelets	was	
variable	amongst	healthy	individuals,	since	strong	NETosis	was	observed	in	
two	samples	while	absent	in	five	other	samples.	Our	donors	were	healthy	
individuals.	Individual	variation	in	neutrophil	response	might	be	an	
explanation	for	variable	results.	Therefore,	all	experiments	with	neutrophils	
should	include	blood	samples	from	multiple	healthy	donors	and	should	be	
repeated	multiple	times	to	obviate	as	much	variation	as	possible.		
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Study	limitations	and	recommendations	
To	our	knowledge	this	is	the	first	in	vitro	study	that	compares	a	
comprehensive	panel	of	NETosis	inducers	under	standardized	experimental	
conditions	using	time-lapse	imaging,	allowing	a	direct	quantification	of	the	
NETosis	strength	using	image	analysis	to	quantify	the	data.	We	consider	it	a	
strong	point	of	our	study	that	time-lapse	images	allow	visualization	of	the	
actual	NETosis	process.	Therefore,	NETosis	can	be	identified	with	higher	
certainty	than	when	using	single	images.	Our	approach	was,	for	example,	very	
helpful	in	interpreting	the	experiments	with	Ionomycin.	In	our	study	our	
medium	contained	10%	FCS.	While	this	is	widely	used	for	cell	culture	
purposes,	in	NETosis	experiments	this	could	affect	NETosis,	since	FCS	
contains	nucleases,	which	have	been	described	to	break	down	NETs	in	vitro	
215.	However,	nucleases	break	down	the	NETs	after	they	have	formed,	and	we	
did	not	observe	this	in	our	time-lapse	analysis.	Also,	it	is	unlikely	that	either	
the	use	of	DMEM	or	FCS	would	have	an	effect	on	any	of	the	tested	inducers.	
For	example,	the	most	used	medium	for	NETosis	experiments	is	RPMI-1640,	
but	studies	have	also	reported	LPS,	one	of	the	most	contradictive	inducers	in	
our	panel,	not	to	have	much	effect	in	their	studies	16,18,21.	We	are	aware	that	
Ca2+	in	buffers	can	have	an	effect	on	NETosis.	Therefore,	we	used	PBS	free	
from	Ca2+,	and	our	HEPES	buffer	only	contained	a	minimal	concentration	of	12	
µM	Ca2+.		
A	drawback	of	any	in	vitro	setting	obviously	is	that	an	in	vitro	setup	cannot	
completely	reflect	the	in	vivo	situation.	Inducers	like	LPS	also	are	expected	to	
trigger	an	immune	response	in	vivo,	which	could	trigger	alternate	pathways	
that	induce	NETosis.		
NETosis	can	be	found	in	many	pathological	conditions	such	as	thrombosis	and	
sepsis,	which	leads	to	a	rising	interest	in	exploration	of	its	pathways.	These	
pathways	could	be	further	explored	in	vitro	in	a	setup	similar	to	ours.		
Conclusion 
Our	literature	research	showed	that	living	gram	positive	and	negative	
bacteria,	PMA	and	Ionomycin	are	strong	NETs	inducers.	Other	inducers	are	
less	potent.	Our	additional	experiments,	which	were	performed	under	one	
experimental	condition	confirmed	these	our	results	found	during	our	
literature	research.  
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Abstract	
Staphylococcus	aureus	(S.	aureus)	are	strong	inducers	of	Neutrophil	
Extracellular	Traps	(NETs),	a	defense	mechanism	of	neutrophils	against	
pathogens.		
	
Our	aim	was	to	explore	the	role	of	Protein	A	in	S.	aureus-induced	NETosis.	We	
determined	the	Protein	A	production	of	four	different	S.	aureus	strains	and	
found	a	direct	relationship	between	the	strength	of	NETosis	induction	and	
Protein	A	production:	strains	producing	higher	concentrations	of	Protein	A	
evoke	significantly	more	NETs.		A	S.	aureus	strain	in	which	Protein	A	as	well	as	
a	second	binding	protein	for	immunoglobulins	(Sbi)	have	been	knocked-out	
(ΔSpA	ΔSbi)	induced	significantly	less	NETosis	than	the	wild	type	strain.	
NETosis	induction	by	this	knockout	strain	can	be	rescued	by	the	addition	of	
purified	Protein	A.	Dead	S.	aureus	did	not	induce	NETosis.	
In	conclusion,	Protein	A	is	a	determinant	for	NETosis	induction	by	S.	aureus.		
	
Introduction	
Upon	encountering	bacteria,	neutrophils	can	form	neutrophil	extracellular	
traps	(NET)	as	part	of	their	antimicrobial	defense	mechanism.	During	NETosis,	
neutrophils	excrete	their	DNA	into	the	extracellular	space,	along	with	histones	
and	other	antimicrobial	factors.	These	NETs	trap	bacteria	and	thereby	limit	
bacterial	spreading	1,2.	NETs	have	been	shown	to	play	an	important	role	in	the	
seriousness	of	several	pathological	conditions,	such	as	chronic	wounds	3,	
thrombosis	4-6	and	sepsis	7-9.			
	
The	bacterial	potency	of	NETosis	is	different	between	bacterial	species	10.	A	
very	potent	inducer	of	NETosis	is	Staphylococcus	aureus	(S.	aureus)	11,12.	S.	
aureus	is	a	gram	positive	bacterium	that	can	cause	many	different	infections	
and,	particularly	when	dealing	with	Methicillin	Resistant	S.	aureus	(MRSA),	
can	cause	critical	problems	in	hospitals.	S.	aureus	possesses	multiple	evasion	
strategies	against	the	human	immune	system,	such	as	the	production	of	
immune-modulators	13-17	and	the	secretion	of	nucleases,	which	enables	them	
to	escape	NETs	16.		
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S.	aureus	also	can	evade	phagocytosing	neutrophils	by	blocking	neutrophil	
rolling	on	activated	endothelial	cells	and	by	targeting	both	antibodies	and	
opsonins,	necessary	for	pathogen	recognition	by	neutrophils	18.	One	of	the	
main	bacterial	proteins	involved	in	phagocytosis	evasion	is	Protein	A.	
Staphylococcal	Protein	A	(SpA)	is	a	42	kD	large	protein	which	is	covalently	
linked	to	the	staphylococcal	surface	and	can	be	secreted	into	the	extra-
bacterial	environment	17,19,20.		
	
Staphylococcal	Protein	A	is	known	to	be	able	to	manipulate	or	to	avoid	early	
host	adaptive	immune	responses.	It	can	bind	to	the	Fcγ	domain	of	IgG	and,	
therefore	inhibit	opsonization	that	precedes	phagocytosis	17,19-22.	Furthermore,	
it	can	induce	apoptosis	in	B-cells	by	binding	to	the	Fab	regions	of	the	B-cell	
receptor	and	act	as	a	B-cell	superartigen	23.	However,	little	is	known	about	its	
direct	effect	on	innate	immune	cells,	particularly	neutrophils.	Because	
neutrophils	are	one	of	the	earliest	effector	host	immune	cell	against	S.	aureus	
invasion	and	because	of	their	ability	to	form	NETs,	we	were	interested	to	
study	whether	Protein	A	is	also	involved	in	NETosis.	To	achieve	this,	we	
determined	the	Protein	A	production	in	different	S.	aureus	strains	and	its	
relationship	with	NETosis	inducing	capacity.	Next,	we	obtained	more	insight	
in	the	role	of	Protein	A	in	NETosis	by	studying	the	rescue	of	NETosis	with	
Protein	A	in	a	S.	aureus	Protein	A	knockout	strain.	
	
Material	and	methods	
Bacterial	strains		
Bacterial	strains	used	in	this	study	are	listed	in	Table	1.	Strains	were	obtained	
from	the	bacterial	collection	of	Department	of	Medical	Microbiology	and	
Infectious	Diseases,	Erasmus	MC	Rotterdam.		
	
Table	1:	Overview	of	the	S.	aureus	strains	used	in	this	study.	
Strain	
Genetic	
background	
Description	 Source	
Newman		
ST8	
Wild	type,	Laboratory	strain	
Hansenova	et	
al	
USA300		 ST8	 Clinical	Strain	 Sultan	et	al	
M116		 ST238,	ST8	 Clinical	Strain	 Sultan	et	al	
RN6390	
ST8	 Laboratory	strain,	derivative	of	
8325-4	
Hansenova	et	
al	
Newman	ΔSpA	
ΔSbi	
ST8	 Laboratory	Strain,	derivate	from	
Newman	strain	
van	den	Berg	et	
al	
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Bacterial	growth	condition		
All	strains	were	cultured	on	TrypticaseTM	Soy	Agar	(TSA)(Becton	Dickinson,	
Breda,	The	Netherlands)	with	5%	sheep	blood	overnight	at	37	°C.		Protein	A	
and	the	second	binding	protein	for	immunoglobulins	(Sbi)	double	knockout	
Newman	strain	(ΔSpA	ΔSbi)	was	cultured	on	TSA	containing	5	µg/ml	
gentamycin	and	5	µg/ml	tetracycline	to	maintain	its	knockout	status.	After	an	
overnight	incubation	at	37	°C	bacteria	were	suspended	in	NaCl	0.9%	solution	
(OD	0.5	at	OD600nm)	and	200	µL	was	added	to	a	sterile	Erlenmeyer	flask	
containing	100	ml	Iscove's	Modified	Dulbecco's	Medium	(IMDM)	(Gibco,	
Bleiswijk,	The	Netherlands).		
	
The	flask	was	then	incubated	for	24	hours	at	37	°C	at	150	rpm.	The	next	day,	
based	on	OD600nm	measurements,	the	individual	strains	were	concentrated	to		
reach	a	final	concentration	of	2x1010	bacteria/ml.	Heat	killed	bacteria	were	
generated	by	incubating	the	bacteria	at	96	°C	for	10	minutes.	Bacteria	were	
then	harvested	and	transferred	to	new	IMDM	medium.	To	control	for	the	
effectiveness	of	the	heat	treatment,	the	heat-killed	bacteria	were	stained	with	
Propidium	Iodide	(PI,	diluted	1:400,	Sigma	Aldrich,	Zwijndrecht,	The	
Netherlands)	and	a	sample	was	cultured	to	check	for	growth	by	plating.	
	
Secreted	Protein	A	measurement	
The	concentrations	of	released	Protein	A	by	S.	aureus	strains	were	measured	
using	a	sandwich	ELISA	type	assay	specific	for	Protein	A	(Enzo,	Bruxelles,	
Belgium)	according	to	the	manufacturer’s	protocol.	The	detection	range	of	the	
kit	was	15.6-1000	pg	Protein	A/ml.	S.	aureus	strains	Newman,	USA300,	
RN6390,	M116	and	Newman	ΔSpA	ΔSbi	were	cultured	as	described	above	and	
after	overnight	culturing,	20	µL	of	the	supernatant	was	collected,	centrifuged	
at	4000	rpm	and	then	filtered.	Supernatant	from	Newman	ΔSpA	ΔSbi	bacteria	
was	included	as	a	negative	control.	The	optical	density	at	450nm	was	
measured	using	a	Biotek	plate	reader	(Biotek)	with	Gen5	software	and	used	to	
calculate	the	protein	A	concentration.		
	
FACS	analysis	of	surface	associated	Protein	A	
Four	milliliter	of	IMDM	was	inoculated	with	an	overnight	culture	of	S.	aureus	
(Newman,	USA300,	RN6390	and	M116)	to	obtain	OD600nm	of	0.05.	The	
individual	cultures	were	incubated	for	24	hours	at	37	°C	with	continuous	
shaking	at	230	rpm.	The	OD600nm	of	the	bacteria	culture	was	normalized	to	
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0.300	and	the	bacteria	were	washed	3	times	with	PBS,	followed	by	
centrifugation	for	5	minutes	at	4000g.	The	individual	bacterial	pellets	were	
suspended	in	100	µl	PBS.	Ten	microliters	of	each	bacterial	suspension	was	
mixed	with	either	10	µl	of	1:50	dilution	of	anti-protein	A	IgY-FITC	(FITC-
labeled	Chicken	anti-Protein	A,	(Gallus	Immunotech	Inc.,	Fergus,	Canada)	or	
with	10	µl	PBS,	used	as	negative	control,	in	a	U	shape	96-well	microplate	
(Greiner	Bio-One,	Oberösterreich,	Germany).	The	plate	was	then	
incubated	at	10	°C	for	45	minutes	at	800	rpm	in	the	dark.	After	washing	3	
times	with	200	µl	PBS,	bacteria	were	centrifuged	for	5	minutes	at	3500g.	
Bacteria	were	suspended	in	50	µL	of	PBS	and	their	fluorescence	(emission	
488-522	nm)	was	quantified	with	Accuri	C6	Flow	Cytometer	and	analyzed	
using	Accuri	C6	Software	(version	1.0.264.21)	(both	BD	Bioscience,	Breda,	The	
Netherlands).	Values	are	expressed	in	Mean	Fluorescence	Intensity	(MFI).		
	
Neutrophil	isolation	
Neutrophils	were	isolated	as	described	previously	24.	Briefly,	medium	
LymphoprepTM	(Stemcell	Technologies)	was	used	to	isolate	neutrophils	from	
donor	blood.	Red	blood	cells	were	lysed	using	Erythrolysis	buffer	(155	mM	
NH4Cl,	10	mM	KHCO3,	1	mM	EDTA,	pH	7.4)	and	then	neutrophils	were	washed	
two	times	with	HEPES	buffer.	A	final	neutrophil	concentration	of	2x107	
cells/ml	was	used.	All	experiments	were	approved	by	the	Medical	Ethics	
Committee	of	the	Erasmus	MC.	
	
NETosis	induction	and	imaging	
Neutrophils	were	stained	for	DNA	with	Hoechst	34580	(diluted	1:10	000,	Life	
Technologies)	and	for	extracellular	DNA	with	Propidium	Iodide	(PI,	diluted	
1:400,	Sigma	Aldrich)	in	500	µl	DMEM	culture	medium	(Biowhittaker,	Lonza).	
The	cells	were	allowed	to	attach	to	gelatin-coated	coverslips	at	37	°C	for	at	
least	1	hour.			
	
To	induce	NETosis,	500	µl	2x1010	bacteria/ml	were	added	to	500µl	2x107	
neutrophils/ml	in	a	Attofluor	Cell	Chamber	(Thermo	Fisher	Scientific,	
Bleiswijk,	The	Netherlands).	The	chamber	was	sealed	and	the	neutrophils	
were	continuously	imaged	with	a	confocal	microscope	(Leica	SP5	AOBS).	
Hoechst	and	PI	were	excited	by	405	nm	(emission	BP	450-550	nm)	and	561	
nm	(emission	570-620	nm)	lasers,	respectively.	NETs	were	visible	as	PI	
positive	elongated	structures	and	were	quantified	(see	quantification).	
	
	
60	
In	order	to	study	the	effect	of	Protein	A	on	NETosis	induction	by	S.	aureus	
Newman	ΔSpA	ΔSbi	strain,	100	µl	of	either	0.01,	0.1	or	1	mg/ml	of	purified	
Protein	A	(Sigma	Aldrich,	Zwijndrecht,	The	Netherlands)	was	added	to	the	
Newman	ΔSpA	ΔSbi	strain	prior	to	co-incubation	with	neutrophils	(final	
concentration	range	0.9-90	µg/ml	Protein	A). 
	
NETs	quantification	
Z-stack	images	were	taken	from	randomly	distributed	fields	of	view	within	the	
cell	chamber	every	3-5	minutes,	in	a	time	frame	of	5-40	minutes.	Every	image	
had	the	same	X,	Y	and	Z	dimensions.	In	each	image,	NETs	were	manually	
traced	in	every	z-stack	by	using	ImageJ	(Version	1.49,	National	Institutes	of	
Health,	USA).	The	total	volume	(µm3)	of	NETs	was	calculated	from	10-15	
images	per	strain.	The	average	percentage	of	NETs	coverage	was	then	
calculated:	total	volume	of	NETs/total	volume.		
	
Statistical	analyses	
Data	are	presented	as	mean	±	standard	error	of	the	mean	(SEM).	A	statistical	
t-test	with	Statistical	Package	for	the	Social	Sciences	(SPSS,	IBM,	version	21)	
was	used	to	analyze	differences	between	groups.	Results	were	considered	
significant	if	p<0.05.	
	
Results	
The	secretion	of	Protein	A	in	the	supernatant	of	the	overnight	grown	S.	aureus	
strains	Newman	and	USA300	(ST8)	(0.44	µg/ml	and	0.42	µg/ml,	respectively)	
was	almost	8	times	higher	than	that	of	M116	and	RN6390	(0.08	µg/ml	and	
0.06	µg/ml,	respectively)(Figure	1A).	No	Protein	A	was	measured	in	the	
Protein	A	knockout	Newman	ΔSpA	ΔSbi.		
The	amount	of	Protein	A	associated	to	the	bacterial	surface	was	higher	in	
Newman	and	USA300	(3703	±	404	MFI	and	3767	±	163	Mean	Fluorescence	
Intensity	(MFI),	respectively)	compared	to	M116	and	RN6390	(2336	±	288	
MFI	and	1649	±	254	MFI,	respectively)	(Figure	1B).		In	literature	it	was	
described	that	Protein	A	is	in	particular	expressed	in	classical	bacterial	growth	
media	during	the	exponential	growth	phase.	To	determine	if	this	is	the	case	in	
IMDM,	we	as	well	made	a	growth	curve	and	determined	at	3	time	points	the	
amount	of	surface	associated	Protein	A.	Interestingly,	the	level	of	the	surface	
associated	Protein	A	during	stationary	phase	(2.5	and	3.5	hours)	is	higher	
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compared	to	its	exponential	phase	(24	hours,	Figure	1C),	except	for	strain	
RN6390.			
	
Figure	1:	Protein	A	produced	by	S.	aureus.	A:	Protein	A	secretion	is	higher	in	S.	aureus	
strains	Newman	and	USA300	compared	to	S.	aureus	strains	M116	and	RN6390,	as	
determined	by	an	ELISA	assay	(n=1).	B:	A	higher	amount	of	Protein	A	is	bound	to	the	
surface	of	S.	aureus	strains	Newman	and	USA300	compared	to	S.	aureus	strains	M116	and	
RN6390,	as	determined	by	FACS	(n=3).	C:	Amount	of	Protein	A	bound	to	the	surface	of	S.	
aureus	measured	on	2.5,	3.5	and	24	hours	as	determined	by	FACS.	Except	for	strain	
RN6390,	the	amount	of	surface	bound	Protein	A	is	increasing	over	time	(n=3).	
	
When	we	tested	these	S.	aureus	strains	to	see	whether	the	amount	of	Protein	A	
plays	a	role	in	NETosis,	we	observed	a	positive	correlation	between	Protein	A	
levels	and	NETosis.	High	Protein	A	producing	strains	Newman	and	USA300	
induced	significantly	more	NETosis	(Newman	10.7	±	1.9	%	and	USA300	13.5	±	
3.8	%	of	the	total	volume)	compared	to	the	low	Protein	A	producing	strains	
M116	(0.7	±	0.2	%,	p<0.001	and	p=0.003,	respectively)	and	RN6390	(3.4	±	1.4	
%,	p=0.005	and	p=0.02,	respectively)	(Figure	2).	Corresponding	NETs	
volumes	are	3750	±	675	µm3	(Newman),	4738	±	1347	µm3	(USA300),	245	±	72	
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µm3	(M116)	and	1208	±	482	µm3	(RN6390).	NETosis	in	all	strains	started	
within	5	minutes	and	within	40	minutes	all	neutrophils	had	formed	NETs.	
	
Figure	2:	NETs	induction	by	different	S.	aureus	strains	Newman,	USA300,	M116	and	
RN6390.	A:	in	vitro	NETs	formation	as	indicated	by	PI	(red).	B:	Strains	Newman	and	
USA300	induce	significantly	more	NETs	than	M116	and	RN6390.   
*					p<	0.05	
**			p<	0.01	
***	p<0.001 
	
To	further	determine	the	contribution	of	Protein	A	to	NETosis	induction,	we	
used	a	SpA	Sbi	double	knockout	strain	of	S.	aureus	Newman	(ΔSpA	ΔSbi)	to	
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induce	NETosis.	Only	very	modest	NETosis	was	observed	(2.3	±	0.9	%),	which	
was	significantly	lower	than	of	the	WT	Newman	strain	(p<0.001).	We	could	
recover	NETosis	by	the	knockout	strain	by	adding	purified	Protein	A.	Addition	
of	0.9,	9	or	90	µg/ml	of	purified	Protein	A	to	the	knockout	strain,	prior	to	
NETosis	induction,	rescued	NETosis	induction	(8.1	±	1.9	%,	p=0.01;	7.4	±	1.2	
%,	p=0.005;	7.2	±	1.7	%,	p=0.02,	respectively)(Figure	3)	to	comparable	levels	
that	were	observed	for	WT	Newman	strain	(p=0.36,	p=0.26	and	p=0.19,	
respectively).	
Additionally,	we	also	were	able	to	rescue	NETosis	formation	to	the	level	
induced	by	WT	Newman	when	Protein	A	was	added	to	the	modestly	NETosis	
inducing	strain	M116	(0.7	±	0.2	%	in	M116	vs	9.1	±	2.0	%	in	M116	plus	Protein	
A,	p<0.001),	giving	it	the	same	NETosis	induction	rate	compared	to	WT	
Newman	(p=0.63,	Figure	4).		
 
Figure	3:	Reversed	effect	of	significantly	reduced	NETosis	by	S.	aureus	knockout	strain	
after	the	addition	of	purified	Protein	A.	Except	for	S.	aureus	Newman	ΔSpAΔSbi,	all	
conditions	induce	more	NETosis	than	Protein	A	only.	*	indicates	significant	difference	
from	S.	aureus	Newman	ΔSpAΔSbi.	#	indicates	significant	difference	when	compared	to	
neutrophils	stimulated	with	0.9	µg/ml	Protein	A.		
*	/	#				 p<	0.05	
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**	/	##		p<	0.01	
***	/	###	p<0.001	
	
Additionally,	we	also	were	able	to	rescue	NETosis	formation	to	the	level	
induced	by	WT	Newman	when	Protein	A	was	added	to	the	modestly	NETosis	
inducing	strain	M116	(0.7	±	0.2	%	in	M116	vs	9.1	±	2.0	%	in	M116	plus	Protein	
A,	p<0.001),	giving	it	the	same	NETosis	induction	rate	compared	to	Newman	
(p=0.63,	Figure	4).		
	
Figure	4:	The	effect	of	living	and	dead	S.	aureus	and	the	presence	of	Protein	A	(both	
produced	by	S.	aureus	and	added)	on	NETosis	in	different	rescue	experiments.	 
	
No	NETosis	was	observed	when	0.9,	9	or	90	µg/ml	of	purified	Protein	A	was	
added	to	the	neutrophils	without	bacteria	(0.0	±	0.0,	Figure	3).	To	explore	the	
effect	of	bacterial	viability	on	NETosis	induction,	0.9	and	9	µg/ml	Protein	A	
were	added	to	dead	bacteria	(WT	Newman).	No	NETosis	was	observed	(Figure	
4)	which	indicates	that	living	bacteria	are	needed	in	order	to	induce	NETosis.	
We	observed	that	dead	bacteria	were	phagocytosed	by	neutrophils,	however,	
when	0.9-90	µg/ml	Protein	A	was	added,	bacteria	were	not	cleared	by	the	
neutrophils	(Figure	5).			
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Figure	5:	The	effect	of	Protein	A	on	dead	bacteria	in	the	presence	of	neutrophils	after	40	
minutes	of	incubation.	A:	Dead	S.	aureus	Newman	incubated	with	neutrophils.	Arrows	
indicate	phagocytosis.	B:	Dead	S.	aureus	Newman	incubated	with	0.9	µg/ml	Protein	A	and	
neutrophils.	Blue:	DNA.	Red:	Dead	bacteria.				
	
Discussion	
In	this	study	we	demonstrated	that	Protein	A	secretion	is	positively	correlated	
to	NETosis	induction	by	S.	aureus.	Previously,	it	has	been	described	that	
different	bacterial	species	induce	different	NETosis	responses	10,12,24.	We	
showed	that	between	different	S.	aureus	strains,	differences	in	NETosis	
response	are	seen,	which	is	correlated	to	the	amount	of	Protein	A	present.	
Furthermore,	NETosis	induction	by	S.	aureus	with	little	to	no	Protein	A	
present	can	be	rescued	by	adding	Protein	A.		
	
In	our	study,	the	bacterial	cell	wall-associated	protein	A	level	is	higher	during	
the	stationary	phase	than	during	the	exponential	phase.	In	a	previous	study	by	
Gao	et	al.,	using	trypticase	soy	broth	(TSB)	medium,	the	spa	gene,	that	encodes	
Protein	A	in	S.	aureus,	is	upregulated	in	the	exponential	growth	phase	of	the	
bacteria	and	the	expression	could	be	regulated	via	various	factors	25.	In	our	
experiments,	the	use	of	IMDM	over	TSB	is	preferred,	since	we	work	with	
neutrophils,	and,	most	importantly,	because	the	composition	of	culture	media	
for	mammalian	cells,	such	as	IMDM,	is	more	closely	resembling	the	
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composition	of	human	conditions.	S.	aureus	behaves	differently	In	IMDM	than	
when		cultured	in	TSB	medium	26,	which	is	an	interesting	and	important	
observation.		
	
Protein	A	is	one	of	the	important	virulence	factors	that	S.	aureus	uses	to	evade	
the	immune	system.	By	Protein	A	binding	to	the	Fcγ	region	of	immunoglobulin	
IgG,	bacteria	can	avoid	being	opsonized	and	phagocytosed	by	neutrophils	and	
other	immune	cells,	as	it	inhibits	binding	to	the	neutrophils	Fc	receptor	27.	In	
previous	experiments	we	already	reported	that	dead	bacteria	are	
phagocytosed	by	neutrophils	and	do	not	induce	NETosis	24.	We	now	observed	
that	phagocytosis	was	inhibited	when	Protein	A	was	added	to	dead	bacteria,	
although	in	our	experiment,	to	our	knowledge,	no	IgG	was	present.	Protein	A	
has	also	been	described	to	bind	to	the	TNFR1	of	immune	cells,	causing	
production	of	pro-inflammatory	cytokines	such	as	IL-6	and	TNF-α	28.	Both	of	
these	cytokines	have	been	described	as	inducers	of	NETosis	29,30.	Additionally,	
Protein	A	can	activate	NADHP	oxidase	31,	on	which	NETosis	depends	32.	
Collectively,	this	would	indicate	that	Protein	A	alone	could	activate	NETosis	by	
binding	to	TNFR1.	However,	in	our	experiments	no	NETosis	was	observed	
when	Protein	A	was	added	to	the	neutrophils	without	bacteria,	indicating	that	
another	stimulus,	for	example	a	different	cofactor	secreted	by	living	S.	aureus,	
is	needed	in	addition	to	Protein	A.		
	
The	observations	in	our	study	that	Protein	A	is	both	a	determinant	of	NETs	
formation	and	can	inhibit	phagocytosis	without	IgG	are	interesting	additions	
to	previous	studies,	where	living	S.	aureus	bacteria	were	reported	to	degrade	
the	NETs	16,33.	These	studies	speculated	that	the	ability	of	NETosis	induction	
by	bacteria	might	be	a	function	of	bacteria	to	kill	human	neutrophils,	due	to	
the	high	survival	of	bacteria	that	were	able	to	escape	the	NETs.	Our	findings	
contribute	to	this	hypothesis,	and	suggests	that	S.	aureus	is	not	only	able	to	
evade	phagocytosis	by	secreting	Protein	A,	but	also	to	destroy	the	neutrophils	
by	evoking	NETosis,	from	which	they	can	escape	by	producing	nucleases.		
	
In	this	study,	we	used	the	double	knockout	strain	S.	aureus	Newman	for	SpA	
and	Sbi.	The	NETosis	inducing	capacity	of	this	strain	also	might	have	been	
affected	by	Sbi.	Sbi	has	a	similar	function	and	structure	as	Protein	A,	and	it	can	
interact	with	complement	protein	C3,	thereby	inhibiting	opsonisation	and	
therefore	phagocytosis	33,34.	However,	in	our	experiments	we	were	able	to	
fully	rescue	NETosis	induction	by	only	adding	purified	Protein	A,	indicating	
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that	Protein	A	is	the	important	determinant	of	NETosis	in	this	experimental	
setting.				
	
In	chronic	wound	infections	such	as	osteomyelitis	and	ulcers,	S.	aureus	is	one	
of	the	most	frequently	isolated	bacteria3,35.	By	understanding	more	about	
direct	interaction	between	the	human	immune	system,	in	this	case	
neutrophils,	and	S.	aureus,	we	may	find	more	ways	to	efficiently	target	the	
bacteria	by	interfering	with	the	bacterial	products	that	influence	and	inhibit	
our	immune	system.	In	conclusion,	the	amount	of	Protein	A	present	is	an	
important	determinant	of	NETosis	induction	by	S.	aureus,	and	NETosis	
inducing	capacities	of	strains	with	little	to	no	Protein	A	present	can	be	
enhanced	by	addition	of	commercial	Protein	A.		
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Chapter	4	
	
The	Role	of	Nuclease	during	the	Early	stages	of	Biofilm	
formation	
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Abstract	
The	chronic	character	of	Staphylococcus	aureus	infections,	like	osteomyelitis	
and	foot	ulcers,	is	often	associated	with	biofilm	formation.	eDNA	is	thought	to	
play	a	crucial	role	in	the	structural	stability	of	biofilms	but	it	also	induces	host	
immune	responses.	Studying	the	bacterial	products	made	during	biofilm	
formation,	we	observed	that	S.	aureus	already	during	the	early	stages	
produces	nuclease	1	when	grown	in	IMDM.	As	eDNA	is	supposed	to	play	an	
important	role	during	biofilm	formation,	we	studied	the	implications	of	
Nuclase1	production	on	biofilm	accumulation	in	both	TSB	and	IMDM.	In	TSB,	
nuclease	production	is	delayed	compared	to	IMDM	grown	bacteria.	
Furthermore,	biofilms	grown	in	TSB	showed	accumulation	of	dead	cells	eDNA	
while	IMDM	grown	biofilms	produced	vast	amounts	of	PIA.	Illustrating	that	
biofilms	developing	in	IMDM	do	not	need	eDNA	for	structural	stability.	Based	
on	these	results,	we	investigated	the	effect	of	nuclease	Nuc1	production	on	
NETosis	and	ROS	production	by	PMNs	using	IMDM	medium	and	could	show	
that	nuclease	can	degraded	the	biofilm-induced	NETs.	Interestingly,	ROS	
production	by	PMNs	was	decreased	when	biofilm	was	present	but	was	not	
affected	by	nuclease	production.	Our	findings	suggest	that	S.	aureus	produces	
nuclease	in	both	early	and	late	biofilm,	and	that	nuclease	contributes	to	
immune	evasion	of	biofilms.	
	
Introduction	
Staphylococcus	aureus	(S.	aureus)	is	a	well-known	human	pathogen	that	can	
cause	infections	from	mild	subcutaneous	to	life	threatening	invasive	
infections.	When	infections	caused	by	S.	aureus	become	chronic,	biofilm	
formation	can	often	be	observed.	The	non-cellular	component	of	the	bacterial	
extracellular	matrix	(ECM),	that	encloses	a	biofilm,	is	a	complex	matrix	that	
consists	of	polysaccharides,	glycolipids,	proteins	and	extracellular	DNA	
(eDNA)	1.	eDNA	formation	in	S.	aureus	biofilms	is	facilitated	by	an	autolysis	
process	that	mimics	apoptosis	of	eukaryotic	cells	1	and	is	thought	to	play	a	
crucial	role	in	the	structural	stability	of	biofilms	2.		
	
	In	a	previous	study	from	our	group	(Sultan,	et	al.,	unpublished	data)	we	
observed	that,	during	the	early	stages	of	biofilm	formation,	S.	aureus	produces	
immune	modulators	like	SCIN,	CHIPS	and	FLIPR,	facilitating	the	defense	of	the	
developing	biofilms	against	host	early	immune	responses.	Furthermore,	we	
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observed	the	production	of	nuclease	during	the	early	stages	of	biofilm	
formation	when	S.	aureus	was	grown	in	Iscove’s	Modified	Dulbecco’s	Medium	
(IMDM).	S.	aureus	can	produce	two	types	of	nucleases:	Nuc1	and	Nuc2	3.	The	
major	type	of	nuclease	produced	by	S.	aureus	is	Nuc14.	Nuc1	production	is	
particularly	conserved	across	all	strains	of	S.	aureus	and	it	has	been	used	as	
one	of	the	specific	markers	to	identify	S.	aureus	5,6.	It	is	known	that	in	vitro	
transcription	and	production	of	Nuc1	by	S.	aureus	can	be	regulated	by	the	2-
component	system	SaeRS	7.	Nuclease	production	is	associated	with	prevention	
of	bacterial	cell	attachment	and	biofilm	formation	1,2,8.		
	
Whilst	eDNA	stabilizes	the	biofilm	structure,	it	also	induces	host	immune	
responses.	For	example,	unmethylated	CpG	motifs	of	bacterial	eDNA	can	be	
recognized	by	TLR9	9,10,	causing	further	host	immune	activation	via	sequential	
recruitment	of	sequential	recruitment	of	MyD88	and	TRAF-6	9,10.	In	biofilm,	
nuclease	Nuc1	is	an	enzyme	that	can	dissolve	and	degrades	eDNA	that	
interconnects	between	bacterial	cells	within	biofilm	8.	Furthermore,	in	a	study	
with	planktonic	S.	aureus,	nuclease	was	described	to	be	associated	with	
evasion	of	neutrophil	extracellular	traps	(NETs),	a	mechanism	of	cell	death	of	
the	polymorphonuclear	cells	(PMN),	that	trap	and	kill	bacteria	11,12.	
Additionally,	Berends	et	al	11	demonstrated	in	a	murine	respiratory	tract	
infection	model	that	S.	aureus	nuclease	also	plays	a	role	in	immune	avoidance	
against	NETs	in	vivo.	Taken	together,	nuclease	production	seems	to	be	an	
important	strategy	for	S.	aureus	to	modulate	the	innate	host	response,	
allowing	a	biofilm	to	develop.	On	the	other	hand,	nuclease	formation	is	
thought	to	destabilize	biofilms	as	well.	
	
To	approach	this	controversy,	we	aimed	to	study,	in	the	context	of	a	
developing	biofilm,	the	consequences	of	nuclease	production	on	a)	biofilm	
accumulation	and	b)	defense	against	the	innate	host	immune	response.	
Therefore,	we	first	determined	biofilm	accumulation,	composition	and	
nuclease	production	in	the	mammalian	cell	culture	medium	IMDM	and	as	
comparison	in	the	classical	medium,	tryptic	soy	broth	(TSB).	Furthermore,	we	
studied	the	NETosis	inducing	abilities	of	early	biofilms	and	the	effect	of	
nuclease	on	NETs	degradation	and	ROS	production.			
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Materials	and	Methods	
Bacterial	strains	and	growth	condition		
The	S.	aureus	strains	used	in	this	study	are	listed	in	Table	1.	The	strains	were	
plated	on	TrypticaseTM	Soy	Agar	(TSA)	with	5%	sheep	blood	overnight	at	37	°C	
(Becton	Dickinson,	Breda,	The	Netherlands).		
	
Table	1:	Strains	of	S.	aureus	that	are	used	on	this	study.	
Strain	
Genetic	
Background	
Description	
Source	
Newman	 ST8	 Laboratory	strain	 	
8325-4	 ST8	 Laboratory	strain	 A.	Cheung	
M82	 ST20	 Clinical	isolate	from	a	patient	
with	an	osteomyelitis	
infection	in	Indonesia	
Sultan,	et	al.		
M116	 	ST239,	ST8	 Clinical	isolate	from	a	patient	
with	an	osteomyelitis	
infection	in	Indonesia	
Sultan,	et	al.		
RWW50	 ST8,	USA300	 Clinical	isolate	from	the	
collection	of	MMIZ	Erasmus	
MC,	The	Netherlands	
W.	van	
Leeuwen	
MW2	 ST1,	USA400	 Clinical	isolate	 	
Mu50	 ST5	 Clinical	isolate	 	
	 	 	 	
	
Bacterial	growth	and	biofilm	assessment		
Biofilm	formation	was	assessed	in	vitro	using	a	dynamic,	microtiter	plate,	
biofilm	formation	assay	as	previously	described	13-16	with	slight	modifications.	
S.	aureus	bacteria	cultured	overnight	on	TSA	were	suspended	in	4	ml	of	0.9%	
NaCl	to	reach	OD660nm	of	2.0	(±	0.2).	One	microliter	of	this	suspension	was	
added	to	199	μl	Iscove’s	Modified	Dulbecco’s	Medium	(IMDM)	(Gibco,	
Bleiswijk,	the	Netherlands)	in	separate	wells	of	a	sterile	flat-bottom	96-well	
polystyrene	tissue	culture	plate	(CELLSTAR®	Greiner	Bio-One,	Alphen	aan	de	
Rijn,	the	Netherlands)	16.	Plates	were	incubated	for	1,	2,	4	and	24	hours	under	
150	rpm	orbital	shaking	at	37	°C.	At	these	times	points,	the	formed	biofilms	
were	washed	once	with	200	μl	sterile	water,	air	dried	for	30	minutes	at	room	
temperature	and	stained	for	2	minutes	with	50	μL	of	1%	crystal	violet	(Sigma	
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Aldrich,	Zwijndrecht,	the	Netherlands).	Excess	of	crystal	violet	was	removed	
by	washing	the	plates	five	times	with	200	µL	of	sterile	water.	The	biofilms	
were	dissolved	in	200	µL	extraction	solution	consisting	of	50%	dH2O	40%	
ethanol	(Sigma	Aldrich)	and	10%	acetic	acid	(Sigma	Aldrich).	Lastly,	to	
determine	the	biofilm	mass,	the	absorbance	of	crystal	violet	was	measured	at	
OD490nm	in	a	microplate	reader	(Epoch	2	Microplate	reader,	BioTek	
Instruments,	Inc.,	Winooski,	VT,	USA).	
	
Determination	of	nuc	presence	
Presence	of	nuc	gene	was	performed	according	to	a	PCR	protocol	as	described	
previously	17.	
	
Production	of	immune	modulators	during	S.	aureus	biofilm	formation		
	S.	aureus	Newman,	clinical	strains	M82	(ST20),	M116	(ST239)	and	also	
RWW50	(USA300)	were	cultured	as	described	above.	We	cultured	the	biofilm	
for	either	1,	3	or	23	hours.	At	these	time	points	we	discarded	the	supernatant	
to	remove	all	non-attached	or	planktonic	bacteria,	washed	the	biofilm	with	
200	µL	IMDM	once	and	added	200	µl	of	fresh	IMDM	medium	and	proceeded	
incubation	for	1	hour	at	the	conditions	described	above.	Subsequently,	we	
collected	the	supernatants,	and	labelled	them	as	the	2nd,	4th,	and	the	24th	hour	
biofilm	supernatants.	All	individual	supernatants	from	all	time	points	and	all	
different	strains	were	filtered	through	a	0.2	µm	sterile	filter	(Whatman®	GE	
Healthcare	Life	Sciences,	Little	Chalfont,	UK)	and	stored	at	-20	°C	until	further	
usage.	The	supernatant	collected	after	1	hour	of	biofilm	formation	served	as	
negative	control.	
	
Quantification	of	nuclease	production	with	competitive	Luminex	assay		
Nuclease	production	during	biofilm	formation	was	quantified	using	a	
multiplex	competitive	luminex	assay	13,18.	Nuclease	production	was	measured	
in	the	biofilm	supernatant	of	the	1st,		2nd,	4th		and	the	24th	hour	of	biofilm	
formation.	Briefly,	the	diluted	biofilm-derived	supernatants	were	incubated	
separately	with	1/200	diluted	human	pooled	serum	(HPS)	at	22	°C	for	35	
minutes.	This	mixture	was	used	for	the	simultaneous	semi-quantification	of	
the	non-captured	IgG’s	specific	for	S.	aureus	biofilm	derived	immune	
modulators	using	Luminex	bead	based	flow	cytometry	(Luminex	Corporation,	
Austin,	Tx,	USA).	Nuclease	antigen	was	coupled	to	MagPlex	beads	(Luminex	
Corporation)	according	to	the	manufacturer’s	protocol	The	Luminex	assay,	
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analyzed	using	a	Luminex	BioPlex	200	System	using	Bio-Plex®	Manager	
software	version	6.1	(Bio-Rad	Laboratories,	Inc.,	USA)	was	performed	as	
described	previously	19	with	one	modification;	that	is,	we	measured	50	beads	
per	region	20.	Negative	control	beads	(beads	to	which	no	antigen	was	added	
during	coupling)	were	included	in	all	assays.		All	data	are	based	on	three	
separate	experiments.	The	mean	fluorescence	intensity	(MFI)	values	of	these	
triplicates	were	averaged	if	the	CV	value	was	lower	than	25%;	and	the	
standard	error	of	the	mean	(SEM)	was	calculated.	For	each	sample,	and	each	
individual	antigen	we	calculated	the	proportion	(in	%)	of	uncaptured	IgG	
specific	for	nuclease.	This	was	achieved	using	a	semi-quantitative	
measurement	of	the	antigen	specific	antibody	absorption	from	HPS	by	biofilm	
supernatant,	which	indirectly	reflects	the	presence	of	the	immune	modulators	
in	the	biofilm	supernatant	21	and	subtracting	this	percentage	from	100%.	
Statistical	differences	of	nuclease	production	between	the	time	points	of	
measurements	were	calculated	by	comparing	the	percentage	of	uncaptured	
anti-nuclease	IgG	from	the	2nd,	4th	and	the	24th	hour	time	points	with	the	1st	
hour	as	reference	control.		
	
Identification	of	the	immune	modulators	by	mass	spectrometry		
One	hundred	microliter	of	supernatants	derived	from	the	4th	hour	during	
biofilm	formation	of	the	RWW50	(USA300)	and	Newman	strains	were	
precipitated	at	1:10	v/v	with	ice-cold	acetone	and	centrifuged	for	10	minutes	
at	18407x	g	at	4	°C.	Subsequently,	pellets	were	washed	twice	with	50	µl	of	cold	
acetone.	Then,	pellets	were	air	dried	for	30	minutes	and	dissolved	in	10	µl	of	
50	mM	NH4HCO3.	Solution	digestion	was	performed	according	to	an	adjusted	
protocol	as	described	by	Dekker,	et	al	22.	Ten	microliters	of	0.2%	Rapigest	
(Waters	Corporation,	Milford,	MA,	USA),	which	was	previously	diluted	in	50	
mM	NH4HCO3,	was	added	into	10	μL	sample.	This	mixture	then	was	reduced	
with	5	mM	dithiothreitol	(DTT)	(Thermo	Fisher	Scientific,	Waltham,	MA,	USA)	
at	60	°C,	450	rpm	for	30	minutes.	After	cooling	down	to	room	temperature,	
this	mixture	was	alkylated	in	the	dark	with	15	mM	iodoacetamide	(Thermo	
Fisher	Scientific)	at	ambient	temperature	for	30	min,	and	digested	overnight	
with	1:100	(w/w)	trypsin	(Promega	Corporation,	Fitchburg,	WI,	USA)	at	37	°C	
and	450	rpm.	Five	percent	trifluoroacetic	acid	was	added	to	obtain	a	final	
concentration	of	0.5%	trifluoroacetic	acid	(pH<2).	After	45	minutes	of	
incubation	at	37	°C	and	450	rpm,	the	samples	were	centrifuged	at	13,000	x	g	
for	10	minutes	and	the	supernatant	was	used	for	liquid	chromatography–mass	
spectrometry	(LC-MS).	Mass	spectrometry	and	data	analyses	were	performed	
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as	described	elsewhere	22.	Database	search	was	performed	against	the	
uniprot_sprot_v151112	database	(selected	for	Bacteria,	332280	entries).	
Quantification	of	nuclease	activity	with	FRET-based	assay		
We	quantified	the	nuclease	activity	using	a	previously	described	fluorescence	
resonance	energy	transfer	(FRET)-based	assay	23.	The	FRET	substrate	was	
purchased	from	Eurogentec	(Maastricht,	the	Netherlands)	24.	The	FRET	
substrate	was	diluted	to	2	µM	in	tris	Buffer	(20	mM	Tris,	pH	8.0,	and	10	mM	
CaCl2)	23,24.	To	measure	the	activity	of	biofilm	associated	nuclease	of	each	
strain,	biofilms	were	grown	in	a	flat-bottom	96-well	black	polystyrene	tissue	
culture	plate	(Costar,	Corning	incorporated,	NY,	USA)	at	37	°C	with	continuous	
150	rpm	agitation.	After	incubation	for	3	hours,	biofilms	were	washed	once	
with	IMDM	or	TSB.	Twenty-five	microliter	of	new	IMDM	or	TSB	(with	or	
without	tested	compounds)	and	25	µL	diluted	FRET	substrate	was	added	into	
the	biofilms.	The	biofilms	were	then	incubated	in	a	FLUOstar	Optima	
microplate	fluorescence	reader	(BMG	lab	technologies)	at	30	°C	with	150	rpm	
periodic	rotational	shaking	for	2	hours.	The	accumulation	of	fluorescence	
during	these	2	hours,	used	as	a	measurement	for	nuclease	activity,	was	
determined	automatically	every	5	minutes	(excitation	552	nm/emission	580	
nm/Gain	800).	Results	are	reported	as	fluorescence	units.	Mean	Fluorescence	
Intensity	(MFI)	of	three	separate	experiments	were	calculated.	
Live/Dead	-	WGA	staining	for	biofilm	
Biofilms	were	stained	with	LIVE/DEAD®	BacLight	Bacterial	Viability	Kit	
(Thermo	Fisher	Scientific,	Bleiswijk,	The	Netherlands)	and	Wheat	Germ	
Agglutinin	(WGA)	-	Alexa	Fluor®	350	conjugate	(Invitrogen	BV,	Breda	(The	
Netherlands),	according	to	the	manufacturer’s	protocol	with	slight	
modification.	Four	hours	old	biofilms	were	washed	once	with	200	µL	of	PBS.	
The	biofilms	were	then	incubated	with	50	µL	of	PBS,	50	μl	of	15	μM	propidium	
iodide	(PI),	50	μl	of	2.5	μM	SYTO9	and	0.5	μl	of	1	mg/mL	WGA-Alexa	fluor®	
350	conjugate	on	each	well.	The	plate	was	incubated	at	22	°C	on	an	orbital	
shaker	(300	rpm)	in	the	dark	for	35	minutes.	The	Biofilms	were	imaged	using	
a	Olympus	IX51	fluorescence	microscope	(Olympus	Nederland	B.V.,	
Zoeterwoude,	The	Netherlands)	with	40x	magnification.		
	
NETosis	assay	
Human	neutrophils	were	isolated	as	described	previously	25	and	stained	with	
Hoechst	34580	(1:10	000,	Life	Technologies,	Landsmeer,	The	Netherlands)	
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and	Propidium	iodide	(PI,	1:400,	Sigma	Aldrich,	Zwijndrecht,	The	
Netherlands).	One	hundred	microliters	of	107/mL	neutrophils	were	added	to	
a	three	hours	old	biofilm	formed	by	Newman	or	RWW50		(in	presence	or	
absence	of	5	µg/mL	nuclease),	in	a	flat-bottom	96-well	polystyrene	tissue	
culture	plate	(CELLSTAR®	Greiner	Bio-One,	Alphen	aan	den	Rijn,	The	
Netherlands).	Biofilm	–	PMN	interactions	were	imaged	with	a	confocal	
microscope	(Leica	SP5	AOBS)	after	20	minutes	of	incubation	at	37	°C.	Hoechst	
and	PI	were	excited	by	405	nm	and	561	nm	lasers.	NETs	were	visible	as	PI	
positive	elongated	structures	and	were	quantified.		
	
Cellular	ROS	activation	assay	
Three	hours	old	biofilms	prepared	in	IMDM	were	washed	and	refreshed	with	
100	µL	new	IMDM	(in	presence	or	absence	of	5	µg/mL	nuclease).	One	hundred	
microliters	of	107/mL	neutrophils	then	added	to	the	biofilms.	The	biofilms	
were	then	prepared	for	the	Cellular	ROS	activation	assay	(GeneCopoeiaTM,	
Nivelles,	Belgium)	according	to	the	manufacturers	protocol.	The	kinetics	of	the	
first	145	minutes	of	ROS	activation	was	measured	in	FLUOstar	Optima	
microplate	fluorescence	reader	(excitation	552	nm/emission	580	nm/Gain	
800).	Results	were	reported	as	fluorescence	units.	Mean	Fluorescence	
Intensity	(MFI)	of	three	independent	experiments	were	calculated.	
	
Statistical	analysis	
Statistical	analysis	was	performed	by	using	the	Prism	5.0	package	(Graph	Pad	
Software,	San	Diego,	CA,	USA)	and	Microsoft	Excel	2010.We	used	unpaired	t-
test	or	one-way	ANOVA	for	data	analysis,	where	P	≤	0.05	was	considered	as	
statistically	significant.	All	experiments	were	independently	repeated	for	
three	times	and	the	mean	with	Standard	Error	of	the	Mean	(SEM).	
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Results	
Nuclease	expression	by	early	biofilms	
To	 confirm	 our	 initial	 observation	 that	 during	 early	 biofilm	 development	 in	
IMDM,	S.	aureus	generates	Nuc1,	Nuc1	production	was	studied	after	1,	2,	4	and	
24	hours	by	competitive	Luminex	assay.	Nuc1	was	found	in	the	supernatant	of	
biofilms	from	all	isolates	(Fig.	1B-F).	During	the	4th	hour	of	biofilm	formation,	
Nuc1	was	 significantly	 expressed	 by	M82	 (P	 ≤	 0.01),	M116	 (P	 ≤	 0.001)	 and	
RWW50	 (P	 ≤	 0.001)	 (Fig.	 1).	 Additionally,	 a	 positive	 correlation	 between	
nuclease	production	and	biofilm	mass	was	found	for	M82	(r=0.903;	p	=0.053),	
M116	 (r=0.813;	 p=0.187),	 8325-4	 (r=0.999;	 p=0.0002),	 RWW50	 (r=0.847;	
p=0.152)	 and	 for	 Newman	 (r=0.947;	 p=0.053)	 (Fig.	 1B-F).	 We	 further	
confirmed	 Nuc1	 production	 during	 early	 stages	 of	 biofilm	 formation	 using	
mass-spectometry	(Table	2).		
	
	
Figure	1:	Nuclease	expression	during	biofilm	formation.	The	competitive	Luminex	assay	
monitored	the	presence	of	nuclease	(A)	indirectly	in	the	supernatants	of	the	2nd,	4th	and	
the	24th	hour	during	biofilm	formation	of	S.	aureus	M82	(B),	M116	(C),	M116	(D),	RWW50	
(E)	and	Newman	strains	(F).	Presented	are	biofim	(bar)	en	Nuclease	(line).	These	figures	
have	been	generated	from	three	separate	experiments.	Error	bars	presented	are	mean	
and	SEM.		
	
	
80	
Table	2:	Mass-spectrometry	for	nuclease	from	the	4th	and	the	24	hour	of	biofilm	
formation.	
Strains	
Biofilm	
supernatant	
Unique	peptides	
detected*	
Sequence	coverage	
(%)*	
Protein	identification	
probability	(%)*	
I	 II	 III	 I	 II	 III	 I	 II	 III	
Newman	
t=4h	 5	 -		 -		 25.6	 -		 -		 100	 -		 -		
t=24h	 11	 3	 1	 40.8	 16.7	 6.58	 100	 100	 92,9	
RWW50	
(USA300)	
t=4h	 5	 5	 11	 21.1	 24.6	 46.9	 100	 100	 100	
t=24h	 16	 10	 -		 47.8	 36.8	 -		 100	 100	 -		
*Three	 separate	 experiments	 I,	 II	 and	 III.	 All	 biofilms	 had	 Protein	 Nuc	 and	 Protein	
accession	number	Q5HHM4.	
	
As	nuclease	activity	is	mostly	described	during	later	stages	biofilm	formation	
in	 conventional	 media	 and	 nuc-GFP	 transcription	 was	 noticeable	
approximately	after	10	hours	of	biofilm	incubation	in	BHI	media	24	or	while	6	
hours	 in	 TSB	 26,	 	 we	 setup	 an	 experiment	 in	 which	 we	 compared	 nuclease	
activity	in	biofilms	grown	in	both	TSB	and	IMDM.	Therefore,	we	
quantified	 nuclease	 activity	 for	 two	 hours	 in	 3	 hours	 old	 biofilms	 using	 a	
FRET-based	 assay.	 Here,	 we	 saw	 that	 nuclease	 activity	 of	 strains	 8325-4,	
M116,	Newman	and	MW2,	was	higher	when	grown	in	IMDM,	compared	to	the	
Nuclease	 activity	 of	 these	 strains	 in	 TSB	 (P	 ≤	 0.001)	 (Fig.	 2).	 Interestingly,	
strain	RWW50,	which	belongs	to	the	USA300	family,	and	strain	Mu50	show	no	
significant	 different	 in	 nuclease	 activity	 between	 these	 two	 growth	 media	
(p=0.05).	
	Figure	2:	Nuclease	production	by	biofilm	of	different	S.	aureus	strains	in	TSB	and	IMDM.	
FRET-based	 measurement	 of	 Nuclease	 production	 during	 the	 4th	 and	 the	 5th	 hour	 of	
biofilm	formation	of	S.	aureus	8325-4,	Newman,	M116,	RWW50,	MW2	and	Mu50	in	TSB	
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(A)	and	IMDM	(B).		Figures	have	been	generated	from	three	separate	experiments.	Error	
bars	represent	SEM.	
	
Contribution	of	eDNA	to	biofilm	mass	in	the	early	stages	of	biofilm	formation	
If	eDNA	is	an	important	factor	in	the	accumulation	of	bacterial	cells	during	
biofilm	formation,	how	is	it	possible	that	biofilm	formation	in	IMDM	does	not	
seem	to	be	hampered	during	the	early	stages?	We	therefore	studied	the	
biofilm	content	of	4	and	24	hour	biofilms	grown	in	TSB	and	IMDM.	The	
composition	of	biofilm	after	4	hours	of	biofilm	formation	showed	that	dead	
cells	or	eDNA	were	minimally	present	in	both	TSB	and	IMDM,	but	after	24	
hours	of	biofilm	formation,	eDNA	was	observed,	particularly	in	biofilm	formed	
in	TSB	medium	(Fig.	3).	Interestingly,	in	biofilms	grown	in	IMDM,	the	
polysaccharide	intercellular	adhesin	(PIA)	was	visible	after	4	hours	of	biofilm	
formation	and	abundantly	present	after	24	hours	(Fig.	3).	
	
	
Figure	3:	Extracellular	DNA	formation	in	biofilm.	Four	and	twenty-four	hours	biofilms	of	
S.	aureus	Newman	(A)	and	RWW50	(B)	in	TSB	and	IMDM	were	stained	with	Syto9	(DNA,	
Green)	and	PI	(extracellular	DNA,	Red)	staining	in	combination	with	WGA	(Blue)	staining	
and	visualized	by	fluorescence	microscopy.	Figures	are	a	representative	result	of	3	
separate	experiments.	
	
Biofilm	activates	ROS-independent	NETs	formation			
In	the	experiments	described	above,	we	observed	that	biofilm	formation,	
when	grown	in	IMDM,	is	facilitated	in	particular	by	PIA,	and	we	did	not	find	
reasonable	amounts	of	eDNA.	It	could	be	that	Nuc1	is	playing	a	role	in	the	
defense	against	the	immune	system	by	prevention	of	eDNA	accumulation	
during	biofilm	formation	in	IMDM.	Furthermore,	previously,	it	was	described	
in	a	planktonic	setting	that	nuclease	can	degrade	NETs	to	ensure	the	survival	
of	S.	aureus11,12.	In	order	to	investigate	if	this	is	also	happening	in	a	biofilm	
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setting,	we	added	freshly	isolated	PMNs	to	3	hours	old	washed	biofilm.	Here,	
we	saw	massive	NETosis	induction	by	both	S.	aureus	Newman	and	by	RWW50	
biofilms.	When	5	µg/mL	of	nuclease	was	added	to	the	biofilm	before	
incubation	with	PMN,	almost	no	NETs	were	observed	(Fig.	4).	Furthermore,	
during	the	co-incubation	of	PMN	with	3	hours	old	biofilm	of	Newman	or	
RWW50,	we	saw	that	reactive	oxygen	species	(ROS)	levels	of	PMN	were	not	
significantly	different	with	spontaneous	ROS	production	by	PMN	itself		(Fig.	
5).	This	findings	indicate	that	S.	aureus	biofilm-induce	NETs	formation	is	ROS-
independent.	Meanwhile,	the	addition	of	nuclease	alone	had	no	effect	on	ROS	
activation	(Fig.	5).		
	
	
Figure	4:	NETs	activation	by	early	biofilm.	Exogenous	nuclease	inhibited	the	formation	of	
NETs	(red)	during	the	4th	hour	of	biofilm	formation	of	Newman	(A-B)	and	RWW50	(C-D)	
in	presence	of	human	PMN	cells.	Figures	are	a	representative	result	of	3	separate	
experiments.	
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Figure	5:	Biofilm	inhibits	PMN	ROS	activation.	When	PMN	and	3	hours	old	biofilm	were	
co-incubated	for	2	hours,	ROS	activation	by	PMN	was	decreased	compared	to	PMN	
without	biofilm	or	to	the	positive	control	tert-butyl	hydroperoxide	(TBHP),	which	is	a	
common	ROS	inducer.	Nuclease	had	no	effect	on	this	ROS	inhibition.	MFI:	mean	
fluorescence	intensity.	
	
Discussion	
During	the	early	stages	of	biofilm	formation	of	S.	aureus	in	the	eukaryotic	
growth	medium	IMDM,	we	observed	the	production	of	nuclease	Nuc1	using	
three	different	methods.	Furthermore,	this	nuclease	production	was	higher	in	
IMDM	compared	to	TSB	in	most	of	the	tested	strains.		
	
Currently,	it	is	expected	that	one	of	the	roles	of	nuclease	is	to	release	the	
bacteria	from	the	eDNA	containing	biofilm	matrix	and	destabilization	of	
biofilm	23.	However,	most	of	the	experiments	leading	to	this	assumption	were	
performed	in	TSB.	When	we	grew	biofilms	in	IMDM,	we	observed	biofilm	
accumulation	even	though	the	concentration	of	nuclease	activity	increased	as	
well.	This	indicates	that	in	IMDM,	biofilm	formation	is	independent	of	eDNA.	
Analysis	of	biofilm	composition	formed	in	IMDM	and	TSB	revealed	that	indeed	
after	4	hours	of	growth,	all	biofilms	contained	almost	no	eDNA,	but	biofilms	
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formed	in	IMDM	did	contain	PIA.	After	24	hours	of	growth	in	TSB,	dead	
cell/eDNA	was	observed,	but	was	minimally	present	in	IMDM	grown	biofilms.	
In	addition	after	24	hours,	PIA	was	abundantly	present	in	the	IMDM	cultured	
biofilms,	but	was	not	observed	in	the	TSB	cultured	biofilms.	This	might	be	due	
to	the	activity	of	the	SaeRS	system	7.	SaeRS	systems,	which	regulate	nuc	
transcription,	may	be	activated	differently	between	these	two	growth	media.	
In	mammalian	cell	culture	medium	that	contains	plasma,	the	Sae	system	is	
required	for	biofilm	formation,	while	in	TSB,	the	Sae	system	is	dispensable	27.	
The	SaeRS	gene	can	be	activated	by	limited	or	absence	of	Fe	in	medium,	such	
as	in	IMDM	27,	and	may	stimulate	the	production	of	both	PIA	and	Nuclease	28-
30.	This	could,	therefore,	also	explain	why	biofilms	grown	in	IMDM	produce	
more	nuclease.	Because	nucleases	break	down	DNA,	it	has	been	described	to	
be	produced	by	biofilm	to	regulate	biofilm	mass	8,24.	This	would	indeed	be	the	
case	in	biofilm	grown	in	TSB,	as	it	consists	of	eDNA	that	and	can	be	regulated	
in	this	manner.	However,	when	grown	in	IMDM,	the	early	and	robust	
production	of	nuclease	might	have	broken	down	most	eDNA	in	these	biofilms,	
leaving	only	PIA.	Since	deacetylated	PIA	is	positively	charged	31,32,	PIA	can	act	
as	an	extra	protection	for	bacteria	within	the	biofilm	against	many	
antimicrobial	factors	produced	by,	for	example,	innate	immune	cells	33.	
	
In	our	study,	we	found	that	early	biofilms	are	inducers	of	NETosis,	and	that	
nuclease	Nuc1	can	degrade	these	NETs.	PMN	are	the	first	immune	cells	to	
respond	to	an	injury,	and	one	of	their	host	defense	responses	is	the	formation	
of	NETs	34.	When	we	incubated	3	hours	old	biofilm	with	PMN,	we	observed	the	
formation	of	NETs,	whereas	no	NETs	were	found	when	the	biofilm	was	
incubated	with	nuclease	beforehand.	Previously,	nucleases,	secreted	by	
planktonic	S.	aureus,	have	been	described	to	break	down	NETs	12.	NETs	have	
been	described	as	an	immune	response	against	pathogens	34	and	can	be	
induced	by	bacteria	25,35,	fungi	36	and	bacterial	products	such	as	LPS	37.	S.	
aureus	is	a	very	strong	inducer	of	NETosis	35,38,	the	process	of	NETs	formation	
in	which	neutrophils	excrete	their	DNA,	histones	and	antimicrobial	proteins	
into	the	ECM,	which	is	activated	in	a	ROS	independent	manner	11.	When	
present,	bacteria	are	trapped	in	the	NETs,	thus	bacterial	spreading	is	limited.	
Recently,	NETs	have	also	been	detected	in	biofilm	39.	However,	other	studies	
observe	phagocytosis	by	PMN	that	invade	biofilm	formed	by	S.	aureus	40.	Our	
results	support	that	biofilms	are	also	inducers	of	NETosis,	but	these	NETs	can	
be	degraded	by	nuclease.	Furthermore,	it	has	been	described	that	S.	aureus	
biofilm	can	produce	SasH	(AdsA),	which	can	convert	the	degraded	DNA	
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products	into	deoxyadenosine	(dAdo),	an	important	immune	modulator	41,42.	
In	this	study,	we	present	the	first	step	in	understanding	the	interaction	
between	S.	aureus	biofilm	and	NETosis	in	the	immune	system.	Future	studies	
need	to	further	elucidate	how	the	balance	between	the	parallel	induction	and	
inhibition	of	NETosis	by	biofilms	is	regulated	and	how	it	affects	the	role	of	
NETosis	in	the	pathophysiology	of	biofilm.		
	
Finally,	we	did	not	observe	ROS	production	of	PMN	in	our	biofilm	
experiments.	PMN	typically	have	three	different	antimicrobial	mechanisms:	
(1)	Phagocytosis:	pathogens	are	engulfed	into	a	phagosome	and	destroyed	by	
NADPH-dependent	mechanisms	(ROS	production)	or	antimicrobial	proteins.	
(2)	Degranulation:	pathogens	are	killed	by	ROS	and	antimicrobial	proteins,	
that	are	released	into	the	ECM	by	PMN	and	(3)	NETosis	43.	NETosis	can	be	
induced	by	both	ROS-dependent	and	ROS-independent	pathways	44.		ROS	
production,	therefore,	is	essential	in	all	PMN	host	defense	mechanisms.	In	our	
biofilm	experiments,	we	saw	a	ROS-independent	formation	of	NETs,	indicating	
as	NETs	are	formed	while	at	the	same	time	ROS	was	inhibited	by	biofilm.	This	
is	in	line	with	previous	literature	in	planktonic	S.	aureus	35	and	Leishmania	45.		
	
Since	there	are	indications	that	nuclease	does	not	act	alone	to	modulate	early	
host	innate	responses	41,42,	other	immune	modulators	that	are	present	during	
the	early	stage	of	biofilm	formation	should	be	explored.	Investigation	of	the	
role	of	other	SaeRS-related	immune	modulators	such	as	Eap	(map)	46	and	sasH	
(AdsA)	in	immune	modulation	should	be	prioritized,	since	the	role	of	these	
immune	modulators	in	host	immune	evasion	related	to	nuclease	has	already	
been	described	elegantly	in	planktonic	S.	aureus	studies	41,42,47-49,	but	not	yet	in	
biofilm.					
	
Many	studies	on	biofilm	are	currently	using	classic	growth	medium	such	as	
TSB	for	biofilm	experiments.	On	the	contrary,	IMDM	seems	to	be	a	more	
reasonable	choice	as	it	better	mimics	the	human	environment.	We	have	now	
demonstrated	that	biofilms	grow	and	respond	differently	in	IMDM	compared	
to	TSB.	Iron-limited	or	free	medium	like	IMDM	or	RPMI	would	be	more	
suitable	for	ex	vivo	studies	with	biofilm,	since	these	media	could	support	both	
S.	aureus	biofilm	and	human	cells,	enabling	co-incubation	experiments.	
Therefore,	the	use	of	IMDM	in	biofilm	related	studies	might	be	a	better	way	to	
support	ex	vivo	investigation	of	biofilm-related	infections.							
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Abstract	
Background:	Children	with	meningococcal	sepsis	are	highly	at	risk	for	
fulminant	disease,	multi-organ	failure	and	death.	Recently,	neutrophil	
extracellular	traps	(NETs)	levels	have	been	indicated	as	a	marker	for	severity	
in	different	kinds	of	sepsis.	Our	aim	was	to	study	the	role	of	NETosis	in	
meninogococcal	sepsis	in	children.		
Methods:	We	measured	MPO-DNA,	a	marker	for	NETs,	in	serum	of	
meningococcal	sepsis	patients	upon	admission	to	PICU,	at	24	hours,	and	at	1	
month	and	studied	the	association	with	clinical	outcome.	Subsequently,	we	
tested	whether	N.	meningitidis,	isolated	from	children	with	meningococcal	
sepsis,	were	able	to	induce	NETosis,	using	confocal	microscopy	live	imaging.	
Results:	MPO-DNA	levels	at	admission	(n=35,	median	0.21	AU/mL,	IQR	0.12-
0.27)	and	at	24	hours	(n=39,	median	0.14	U/mL,	IQR	0.09-0.25)	were	
significantly	higher	than	the	MPO-DNA	levels	after	1	month	(controls,	n=36,	
median	0.07	AU/mL,	IQR	0.05-0.09,	p<0.001).	We	did	not	observe	a	
correlation	between	MPO-DNA	levels	and	mortality,	cell-free	DNA	or	other	
inflammatory	markers.	In	addition,	N.	meningitidis	are	fast	and	strong	
inducers	of	NETosis.	
Conclusion:	Children	admitted	to	PICU	for	meningococcal	sepsis	have	higher	
NETs	levels	at	admission	and	after	24	hours	than	controls.	NETs	levels	were	
not	associated	with	outcome,	cell-free	DNA	or	other	inflammatory	markers.	
These	NETs	may	be	induced	by	N.	meningitidis,	since	these	are	strong	NETosis	
inducers.	
	
Introduction	
Meningococcal	sepsis	is	notorious	for	its	rapid	progression	to	fulminant	
disease,	multi-organ	failure	and	death	1,2.	Complex	interplays	between	host,	
pathogen,	and	environmental	factors,	including	immune	evasion	mechanisms,	
determine	the	severity	of	Neisseria	meningitidis	infections,	ranging	from	
harmless	colonization	to	lethal	disease	3-5.	
	
A	recently	identified	mechanism	that	may	play	a	role	in	the	pathology	of	
meningococcal	sepsis	is	NETosis.	The	release	of	neutrophil	extracellular	traps	
(NETs)	is	an	important	part	of	innate	immune	defense	6,7.	NETs	are	an
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extracellular	DNA	matrix,	containing	also	granule	proteins	and	histones,	
released	by	neutrophils	to	degrade	virulence	factors	and	to	kill	bacteria	8.	
NETs	are	primarily	considered	as	a	protective	mechanism	against	a	broad	
range	of	microorganisms,	including	gram-negative	and	gram-positive	bacteria,	
because	they	prevent	bacteria	from	spreading	and	contain	toxic	histones	8,9.	
Several	inducers	of	NETosis	are	known,	including	bacterial	species	such	as	
Staphylococcus	aureus	10.	Multiple	studies	describe	a	negative	influence	on	
outcome	in	mice	and	humans	11,12,	since	the	tissue	damage	caused	by	NETs	
may	contribute	to	disease	severity	13,14.	Also	cell	free	DNA	(cfDNA),	the	
backbone	of	a	NET,	has	been	described	to	contribute	to	disease	via	the	
formation	of	microthrombi	and	to	inhibit	fibrinolysis	15.	
	
Studies	on	the	relationship	between	NETs	and	Neisseria	meningitidis	in	sepsis	
are	lacking.	Our	objective	was	to	study	the	role	of	NETs	in	children	with	
meningococcal	sepsis.	We	measured	levels	of	NETs,	cell-free	DNA	and	other	
inflammatory	markers	in	serum	from	children	with	meningococcal	sepsis	and	
studied	the	association	with	severity	of	disease.	We	also	investigated	whether	
N.	meningitidis	isolates	from	patients	are	able	to	induce	NETosis.	
	
Material	and	methods	
Patients	and	samples	
From	1988	to	2005,	children	with	meningococcal	sepsis	presenting	to	the	
pediatric	intensive	care	unit	(PICU)	of	Erasmus	MC-Sophia	Children’s	Hospital	
(Rotterdam,	The	Netherlands)	were	prospectively	enrolled	in	meningococcal	
studies	16-19.	These	studies	were	conducted	in	accordance	with	the	Declaration	
of	Helsinki	and	Good	Clinical	Practice	guidelines.	All	individual	meningococcal	
studies	as	well	as	the	current	laboratory	study	(MEC-2015-497)	were	
approved	by	the	ethical	committee	of	Erasmus	MC,	and	written	informed	
consent	was	obtained	from	parents	or	legal	guardians.	All	patients	fulfilled	
internationally	agreed	criteria	for	sepsis	20.	Blood	samples	were	taken	on	
admission	to	PICU,	at	24	hours	after	PICU	admission,	and	at	1	month	after	
PICU	admission.	Since	all	children	were	healthy	at	1	month,	the	1	month	
convalescence	samples	were	used	as	controls.	Samples	were	processed	on	ice	
and	serum	was	stored	at	-80°C	until	analysis.	This	is	a	retrospective	
laboratory	study	in	remaining	samples	of	prospectively	collected	samples.	
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Clinical	data	collection	
Clinical	data	were	collected	prospectively.	Disease	severity	was	indicated	by	
Pediatric	Risk	of	Mortality	(PRISM)	21,	predicted	death	based	on	the	
Rotterdam	score	17,	disseminated	intravascular	coagulation	(DIC)	score	22,	and	
the	base	excess	and	platelet	count	at	presentation	(BEP)	score	23.	Patients	
were	classified	as	death	if	death	occurred	during	PICU-stay.	PICU-free	days	in	
patients	who	died	were	considered	zero.		
	
NETosis	measurements		
Our	MPO-DNA	ELISA	assay	was	performed	as	reported	earlier	24.	For	detection	
of	NETs	in	serum,	we	adjusted	the	commercial	human	ELISA	kit	that	measures	
cell	death	(Cell	death	detection	ELISAPLUS,	Cat.	No	11920685001,	Roche	
Diagnostics	Nederland	B.V.,	Almere,	the	Netherlands)	25.	Briefly,	ELISA	plates	
were	coated	with	a	mouse-anti-human	myeloperoxidase	(MPO)	monoclonal	
antibody	(AbD	Serotec,	Oxford,	UK),	a	NETs	marker,	overnight	at	4	°C.	The	
plates	were	then	washed	with	Phosphate	Buffered	Saline	(PBS)	containing	
0,05	%	v/v	Tween®-20	and	incubated	with	blocking	solution	(1%	BSA/PBS)	
overnight	at	4	°C.	Next,	samples	were	added	to	the	plate	and	incubated	with	
MPO-DNA	immunoreagens	for	2	hours	at	300	rpm	at	RT,	washed	and	
incubated	with	2,2'-azino-bis(3-ethylbenzothiazoline-6-sulphonic	acid)	
(ABTS)	reagens	for	30	min	at	250	rpm	at	RT.	The	reaction	was	stopped	with	
stop	solution	from	the	kit	and	plates	were	measured	using	a	Biotek	reader	
(FLX	800,	Austria)	at	405	nm	with	a	490	nm	reference	filter.	The	NETs	
reference	curve	was	created	from	neutrophils	that	were	transferred	to	FBS	
serum	and	stimulated	with	phorbol-myristate-acetate	(PMA)	for	4	hours.	
Samples	were	serially	diluted	and	stored	at	-80°C.	Values	are	expressed	as	
arbitrary	units	(AU/mL).		
Inflammatory	markers	CRP,	fibrinogen,	soluble	TNFr,	IL-1B,	IL-6,	and	IL-8	and	
cell-free	DNA	(nucleosomes)	were	measured	in	previous	studies	from	our	
research	group	16-19,26.	
Neutrophil	isolation	
Neutrophils	were	isolated	as	previously	described	10.	Briefly,	red	blood	cells	
and	granulocytes	were	isolated	from	blood	from	adult	healthy	donors,	as	
approved	by	the	Medical	Ethics	Committee	of	the	Erasmus	MC,	using	
LymphoprepTM	(Stem	cell	Technologies,	Grenoble,	France).	Granulocytes	were	
further	purified	by	lysing	the	erythrocytes	with	erythrolysis	buffer	(3.1M	
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NH4Cl,	0.2M	KHCO3,	0.02M	EDTA,	pH	7.4)	and	washing	the	neutrophil	rich	
pellet	twice	with	HEPES	(0.115M	NaCl,	0.012mM	CaCl2,	1.51mM	MgCl2,	4mM	
KCl,	0.01M	HEPES,	pH	7.4)	buffer.		
In	vitro	NETosis		
For	experiments	with	meningococcal	bacteria,	neutrophils	were	transferred	to	
Dulbecco’s	Modified	Eagle	Medium	(DMEM)	culture	medium	without	any	
additions	(Biowhittaker,	Lonza,	Walkersville,	USA)	in	a	confocal	ring.	
Propidium	Iodide	(PI,	1:400,	Sigma	Aldrich,	Zwijndrecht,	The	Netherlands)	
was	added	to	visualize	extracellular	DNA	during	live	imaging.				
To	visualize	extracellular	DNA	(NETs),	neutrophils	were	stained	for	DNA	with	
Hoechst	34580	(1:	10000,	Life	Technologies,	Landsmeer,	The	Netherlands)	
and	PI	(1:400,	Sigma	Aldrich,	Zwijndrecht,	The	Netherlands)	prior	to	contact	
with	N.	meningitidis	as	described	previously	by	our	group	27.	Clinical	isolates	
of	N.	meningitidis	bacteria	were	cultured	as	described	previously	28.	After	4	
hours	of	culturing,	100	µl	1x108/ml	bacteria	were	added	to	500	µl	2x106/ml	
neutrophils.	NETs	were	visualized	using	confocal	microscopy	(Leica	SP5	
AOBS).	Excitation	of	Hoechst	with	a	405	laser	and	a	BP	420-500	emission	filer,	
and	excitation	of	PI	with	a	561	141	and	BP	580-620	emission	filter.	Elongated	
PI	positive	structures	larger	than	10	µm	(the	average	diameter	of	a	
neutrophil)	were	defined	as	NETs.	Round	PI	positive	structures	equal	or	
smaller	than	10	µm	were	defined	as	necrotic	neutrophils.						
	
Statistical	analysis	
Patient	characteristics	and	MPO	levels	are	presented	as	numbers	and	
proportions	(means	and	percentages)	or	medians	and	interquartile	ranges.	To	
compare	MPO-DNA	levels	between	the	three	time	points,	we	used	the	Kruskal-
Wallis	test,	including	the	post-hoc	Mann-Whitney	rank-sum	test.	To	compare	
MPO-DNA	level	between	survivors	and	non-survivors,	we	used	the	Mann-
Whitney	rank-sum	test.	Correlations	were	assessed	using	Spearman’s	rank	
correlation.	Linear	regression	analyses	were	performed	on	logarithmically	
transformed	data.	Graphs	were	created	with	GraphPad	Prism	7.00.	All	
statistical	analyses	were	performed	using	Statistical	Package	for	the	Social	
Sciences	(SPSS,	IBM,	version	21).	Two-sided	p-values	<0.05	were	considered	
to	indicate	statistical	significance.	
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Results	
NETs	levels	in	meningococcal	sepsis	
In	this	study	we	included	60	children	with	meningococcal	sepsis	(58%	male,	
median	age	2	years	and	10	months	[IQR	21	months-9	years]),	of	whom	35,	39,	
and	36	serum	samples	were	available	originating	from	admission	to	PICU,	
after	24	hours,	and	at	1	month,	respectively.	Patient	characteristics	are	
presented	in	Table	1.	
	
Table	1:	Patient	characteristics	at	admission	to	PICU	(n=60).	Characteristics	for	2	
patients	are	unknown.		
	 Total	group	
(n=60)	
Non-survivors	
(n=11)	
Survivors	
(n=49)	
P-value	
Male	gender	(%)	 36	(58%)	 7	(64%)	 29	(59%)	 ns	
Age	(years)	 2.9	(1.8-9.6)	 2.2	(0.8-2.8)	 3.5	(1.9-10)	 0.08	
PRISM	score	 17	(10-25)	 25	(21-34)	 17	(12-24)	 0.003	
P	(death	Rotterdam)*		 12	(2–	72)	 98	(83–99)	 5	(1–25)	 <0.001	
Presence	of	DIC$	(%)	
DIC	score#	
P	(death	BEP)~		
26	(52%)	
6	(4-7)	
6	(3-19)	
10	(100%)	
7	(6-7)	
30	(20-59)	
16	(40%)	
5	(4-6)	
5	(3-12)	
<0.001	
ns	
<0.001	
*	Data	are	available	for	49	patients;	11-non-survivors	and	38	survivors.	$	Data	are	
available	for	50	patients;	10	non-survivors	and	40	survivors.	These	data	represent	the	
values	collected	at	t=0.	#	Data	are	available	for	36	patients;	6	non-survivors	and	30	
survivors.	~	Data	are	available	for	53	patients;	11	non-survivors	and	42	survivors.	
Categorical	variables	are	presented	as	percentages,	continuous	variables	are	presented	
as	median	(IQR).	Abbreviations:	PRISM	=	pediatric	risk	of	mortality21,	P	(death	
Rotterdam)	=	predicted	death	rate	based	on	the	Rotterdam	score17,	DIC=Disseminated	
intravascular	coagulation22,	P	(death	BEP)	=	predicted	death	rate	based	on	the	BEP	score	
23.	
	
MPO-DNA	levels	at	admission	(n=35,	median	0.21	AU/mL,	IQR	0.12-0.27)	and	
at	24	hours	(n=39,	median	0.14	AU/mL,	IQR	0.09-0.25)	were	significantly	
higher	than	the	convalescent	MPO-DNA	levels	in	the	control	group	of	
survivors	after	1	month	(n=36,	median	0.07	AU/mL,	IQR	0.05-0.09,	p<0.001)	
(Figure	1A).	The	MPO-DNA	level	in	children	who	eventually	died	did	not	differ	
significantly	from	survivors	at	admission	to	PICU	(non-survivors:	n=11,	
median	0.23	AU/mL,	IQR	0.12-0.47;	survivors:	n=23,	median	0.16	AU/mL,	IQR	
0.12-0.25,	p=0.14)	and	after	24	hours	(non-survivors:	n=3,	median	0.14	
AU/mL;	survivors:	n=34,	median	0.15	AU/mL,	IQR	0.09-0.26,	p=0.48)	(Figure	
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1B).	
	
	
Figure	1:	MPO-DNA	levels	measured	at	different	time	points	(A)	and	in	relation	to	
survival	(B).		
NETs	and	inflammatory	markers	in	sepsis		
Since	NETs	can	be	induced	by	inflammatory	markers,	and	NETs	in	turn	can	
lead	to	an	increased	inflammatory	response,	we	explored	the	correlations	
between	inflammatory	markers	(neutrophil	count,	and	serum	C-reactive	
protein	(CRP),	fibrinogen,	soluble	Tumor	Necrosis	Factor	(TNFr),	Interleukine	
(IL)-1B,	IL-6	and	IL-8	levels)	and	MPO-DNA	levels	in	our	samples.	We	did	not	
observe	any	significant	correlation	of	NETs	levels	with	any	of	these	markers	
(Table	2).		
Table	2:	Correlation	of	MPO-DNA	levels	with	pro-inflammatory	factors.		
Laboratory	parameter	 R-Spearman	
T=0		
	
P-value	
R-Spearman	
T=24	
	
P-value	
Neutrophils	
CRP	
0.043	(23)	
0.105	(28)	
0.85	
0.60	
0.211	(27)	
-0.114	(29)	
0.29	
0.86	
Fibrinogen	 0.035	(29)	 0.86	 0.037	(36)	 0.82	
Soluble	TNFr	 0.238	(17)	 0.36	 -	 -	
IL-1B	 0.391	(17)	 0.12	 -	 -	
IL-6	 0.326	(17)	 0.20	 -0.068	(20)	 0.78	
IL-8		 0.35	(17)	 0.17	 -0.291	(20)	 0.21	
Number	of	patients	are	indicated	between	brackets.	
NETs	and	cell-free	DNA	
Because	nucleosome	levels	in	serum	reflect	cell-free	DNA,	we	tested	how	
serum	levels	of	nucleosomes	were	correlated	to	serum	levels	of	NETs.	We	did	
not	find	a	significant	correlation	between	nucleosomes	and	MPO-DNA	at	any	
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of	the	time	points	(t=0:	r=0.162,	p=	0.54;	t=24:	r=0.044,	p=0.86;	t=1m:	
r=0.025,	p=0.93).	
In	vitro	formation	of	NETs	in	the	presence	of	Neisseria	meningitidis	
In	our	pilot	experiment,	we	saw	that	clinical	isolates	from	N.	meningitidis	
induce	NETs	in	vitro	in	adult	neutrophils.	NETs	were	visible	after	15	minutes	
of	incubation	of	neutrophils	with	the	bacteria	(Fig.	2).	
In	the	control	experiment	with	unstimulated	neutrophils	without	bacteria,	no	
NETs	were	seen.	
	
	
Figure	2:	Unstimulated	neutrophils	(A)	vs	NETs	(see	arrows)	formed	by	N.	meningitidis	
(B).	Blue:	Hoechst	staining	for	DNA.	Red:	PI	staining	for	extracellular	DNA	(NETs)	and	
dead	cells.		
Since	neutrophils	started	dying	approximately	30-40	minutes	after	contact	
with	N.	meningitidis,	we	only	observed	NETs	within	this	time	frame.		
	
Discussion		
This	is	the	first	study	to	describe	NETs	in	children	with	meningococcal	sepsis,	
describing	both	in	vitro	and	in	vivo	data.	The	main	findings	of	our	study	are	
that	NETs	levels	in	these	children	are	higher	at	admission	to	PICU	and	after	24	
hours	compared	to	levels	after	one	month.	We	also	found	that	NETs	levels	
were	not	associated	with	clinical	outcome	in	our	cohort.	Lastly,	in	a	pilot	
experiment	we	found	that	N.	meningitidis,	isolated	from	children	with	
meningococcal	sepsis,	are	strong	NETs	inducers	in	adult	neutrophils.	
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In	our	study	the	NETs	levels,	measured	by	MPO-DNA	levels,	in	children	with	
meningococcal	sepsis	are	higher	in	the	acute	phase	of	disease,	i.e.	at	admission	
to	PICU	and	at	24	hours	after	admission,	compared	to	1	month.	Similar	results	
were	previously	observed	in	adult	studies,	reporting	increased	NETs	levels	
during	the	acute	phase	of	sepsis	11,13,29.	
	
Multiple	animal	and	patient	studies	associated	NETs	levels	with	sepsis	
severity	and	outcome	13,14.	This	effect	of	NETs	in	sepsis	likely	results	from	the	
interplay	between	NETs,	platelets	and	thrombin,	which	activates	coagulation	
and	inhibits	fibrinolysis,	leading	to	more	severe	DIC	13,14,30.	In	our	study,	we	
did	not	find	an	association	between	NETs,	severity	parameters,	and	outcome.	
Our	study	group	was	relatively	small,	and	may	have	been	underpowered	to	
detect	these	effect.	Alternatively,	the	positive	and	negative	effects	of	NETosis,	
respectively	containing	meningococcal	infection	and	inducing	tissue	damage	
and	deregulate	coagulation	might	be	balanced	in	meningococcal	sepsis	in	
children.		
	
Previously,	Zeerleder	et	al	(2013)	31	measured	nucleosomes	in	this	cohort	and	
reported	that	nucleosomes	are	correlated	with	several	factors,	such	as	organ	
dysfunction,	several	cytokines	and	patient	outcome.	In	some	studies,	
nucleosomes	are	used	as	marker	for	NETosis	32.	We	did	not	observe	a	
correlation	between	MPO-DNA	and	nucleosome	levels	in	this	study,	indicating	
that	the	nucleosomes	in	these	patients	are	probably	cell-free	DNA	originating	
of	other	cell	death	mechanisms	than	neutrophils	in	NETosis.	In	sepsis	patients,	
severe	tissue	and	organ	damage	are	the	main	cause	of	death.	Cell-free	DNA	is	
therefore	very	likely	originating	from	these	damaged	cells.		
	
We	have	shown	in	a	pilot	experiment	that	N.	meningitidis	isolated	from	sepsis	
patients,	are	able	to	induce	NETosis	in	neutrophils	in	vitro.	This	is	in	line	with	
a	previous	study	on	NETs	formation	by	N.	meningitidis	28.	This	article	
describes	that	N.	meningitidis	is	also	able	to	evade	NETs	different	from	S.	
aureus,	which	excretes	nucleases	to	break	down	the	NETs	33.	N.	meningitidis	
secretes	small	outer	membrane	vesicles	(SOMVs)	that	bind	to	the	NETs,	
blocking	the	binding	of	the	bacteria	themselves.	In	our	experiments,	we	
observed	that	after	30-40	minutes,	neutrophils	underwent	necrosis	next	to	
NETosis,	as	expected	since	the	bacteria	are	known	to	be	toxic.	Altogether,	our	
results	indicate	that	N.	meningitidis	has	developed	multiple	mechanisms	to	
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avoid	and	destroy	neutrophils,	which	might	contribute	to	the	severe	
pathogenesis	of	these	bacteria	in	sepsis.		
	
This	is	the	largest	prospective	cohort	of	children	with	severe	meningococcal	
disease	of	which	detailed	clinical	and	extensive	laboratory	data	are	available.	
Although	a	total	number	of	60	patients	might	be	relatively	small	compared	to	
adult	sepsis	cohorts,	the	advantage	from	our	study	is	that	these	children	are	
all	affected	by	the	same	bacterium,	N.	meningitidis.	The	detailed	assays	
performed	and	measurements	of	several	factors	over	time	allowed	us	to	study	
correlations	with	markers	assessed	in	both	the	current	and	previous	studies	
26,31.	Also,	we	were	able	to	follow	these	patients	over	time	and	collect	data	on	
many	variables,	including	NETs	and	inflammatory	markers.	
	
We	have	shown	that	N.	meningitidis	is	capable	of	inducing	NETosis	in	
neutrophils	isolated	from	healthy	adult	donors	in	vitro.	Unfortunately	age	
matched	donors	were	not	available,	as	volumes	obtained	for	diagnostic	tests	
are	limited	in	children.	Therefore	we	cannot	exclude	that	neutrophils	of	
children	might	react	differently	34.	However,	as	NETs	were	present	in	our	
patient	serum	samples,	such	a	difference	in	vitro	is	not	expected.	
	
Conclusions	
N.	meningitidis	are	strong	NETs	inducers.	Children	admitted	to	PICU	for	
meningococcal	sepsis	have	higher	NETs	levels	at	admission	and	after	24	hours	
than	controls.	NETs	levels	were	not	associated	with	positive	or	negative	
outcome	or	other	inflammatory	markers,	indicating	that	the	beneficial	and	
detrimental	effects	of	NETosis	in	meningococcal	sepsis	might	be	balanced.	We	
also	did	not	find	a	correlation	between	MPO-DNA	and	nucleosomes,	indicating	
that	nucleosomes	are	not	only	NETs	but	all	cell	free	DNA.		
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Abstract		
Complement	factor	H	(FH)	has	been	shown	to	bind	to	VWF	and	to	influence	its	
cleavage	by	ADAMTS13	in	vitro.	No	data	on	this	interaction	in	humans	is	
available.	
We	aimed	to	study	whether	FH	influences	the	relationship	between	VWF	and	
ADAMTS13	and	the	risk	of	arterial	thrombosis.		
We	determined	plasma	FH	antigen	levels	in	350	young	patients	with	a	first	
event	of	arterial	thrombosis	and	293	healthy	controls	from	the	ATTAC	study	
cohort,	and	studied	the	effect	of	FH	on	the	known	relationship	of	VWF	antigen	
(VWF:Ag)	and	ADAMTS13	activity	(ADAMTS13:Act)	with	the	risk	of	arterial	
thrombosis.	Moreover,	we	specifically	determined	the	relationship	between	
FH	and	the	VWF	collagen	binding	activity	(VWF:CB)	over	VWF:Ag	ratio	as	a	
surrogate	marker	for	VWF	multimer	length.	Finally,	we	determined	
correlations	of	FH	with	classic	risk	factors	for	arterial	thrombosis.	
FH	levels	were	higher	in	cases	compared	to	controls,	and	negatively	correlated	
with	VWF:CB/VWF:Ag	ratio.	In	our	population,	we	found	no	effect	of	high	FH	
on	the	association	of	VWF:Ag	and	ADAMTS13:Act	with	arterial	thrombosis	
risk.	FH	levels	were	linked	to	markers	of	the	metabolic	syndrome	including	
body	mass	index	(BMI),	HbA1c,	age	and	cholesterol	and	also	C-reactive	
protein,	which	suggests	a	possible	role	of	FH	in	the	turnover	of	oxidized	lipids.		
In	conclusion,	FH	does	not	seem	to	affect	the	interaction	between	VWF,	
ADAMTS13	and	arterial	thrombosis	risk.	
	
Introduction	
Inflammation	plays	a	central	role	in	the	pathophysiology	of	arterial	
thrombosis.	Endothelial	cells	respond	to	inflammatory	stimuli	by	expressing	a	
range	of	different	proteins,	such	as	adhesion	receptors	for	interactions	with	
platelets	and	leukocytes	and	secreted	proteins,	including	the	large	
glycoprotein	von	Willebrand	factor	(VWF).	VWF	forms	large	multimer	strands	
and	may	form	the	largest	protein	in	the	bloodstream	in	terms	of	its	length.	
These	long	VWF	strands	are	highly	reactive	towards	platelets	and	mediate	the	
initial	adhesion	of	platelets	to	the	vessel	wall	under	high	shear	stresses	such	
as	encountered	in	the	arteries.	VWF	multimer	size	is	regulated	by	the	plasma	
protease	ADAMTS13,	which	cleaves	VWF	into	smaller,	less	platelet-reactive,	
multimers	of	average	length.	The	involvement	of	both	VWF	and	ADAMTS13	in	
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arterial	thrombosis	has	previously	been	found,	as	reviewed	by	us	and	others	1-
3.	We	have	previously	observed	that	VWF	levels	were	increased	in	patients	
with	arterial	thrombosis	compared	to	healthy	controls,	whilst	low	ADAMTS13	
level	formed	an	independent	risk	factor	4-6.	
During	inflammation,	the	complement	pathways	also	become	activated	and	
further	contribute	to	thrombosis	7.	Recent	in	vitro	studies	have	suggested	that	
complement	factor	H	(FH),	an	important	regulator	of	the	alternative	
complement	pathway,	interacts	with	VWF	and	may	affect	its	proteolysis	by	
ADAMTS13.	Factor	H	is	best	known	for	its	role	in	atypical	hemolytic	uremic	
syndrome	(aHUS),	a	disease	characterized	by	thrombotic	microangiopathy,	
although	the	underlying	mechanism	between	FH	and	thrombotic	
microangiopathy	is	still	largely	unclear	8.	Turner	and	Moake	were	the	first	to	
describe	that	FH	binds	to	ultra-large	VWF	strings	anchored	to	endothelial	cells	
in	vitro	9.	In	further	in	vitro	studies	it	was	shown	that	FH	may	act	as	a	
reductase	of	VWF,	thus	reducing	VWF	multimer	length	10.Thereafter,	FH	has	
been	shown	to	co-precipitate	with	VWF	from	serum	and	that	FH	enhanced	the	
proteolysis	of	the	VWF	A2	domain	by		making	VWF	more	susceptible	for	
cleavage	by	ADAMTS13	and	the	cleavage	of	VWF-platelet	strings	on	cultured	
endothelial	cells	under	flow	11.	However,	in	a	different	study	it	was	found	that	
FH	inhibited	the	proteolysis	of	VWF	by	ADAMTS13	in	a	static	assay	and	that	
FH	led	to	an	increased	VWF	mediated	platelet	aggregation	in	a	ristocetin	
cofactor	assay	12.		
Together,	these	in	vitro	studies	suggest	that	the	interaction	of	FH	with	VWF,	
either	positively	or	negatively,	impacts	on	ADAMTS13	mediated	regulation	of	
VWF	multimer	length	and	thus	its	platelet	binding	properties.		
In	this	study	we	determined	levels	of	the	complement	regulator	FH	in	young	
patients	with	arterial	thrombosis	to	evaluate	whether	FH	influences	the	risk	of	
thrombosis	development.	In	addition,	we	assessed	the	relation	of	FH	level	to	
VWF	antigen	(VWF:Ag),	ADAMTS13	activity	and	the	collagen	binding	activity	
(CB)	of	VWF	as	ratio	of	VWF	antigen	(VWF:CB/VWF:Ag)	as	surrogate	marker	
for	VWF	multimer	size,	as	it	is	directly	related	to	the	number	of	collagen	
binding	domains.	Moreover,	we	determined	possible	associations	of	FH	with	
inflammatory	markers,	including	the	acute	phase	C-reactive	protein	(CRP)	and	
the	levels	of	extracellular	nucleosomes	as	marker	for	cell	death.	Finally,	we	
assessed	the	relation	of	FH	antigen	level	to	classic	markers	of	thrombosis,	
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including	markers	of	the	metabolic	syndrome	and	hypertension.	
	
Material	and	methods	
Patients	
We	performed	a	case	control	study	of	350	young	patients	with	a	first	event	of	
arterial	thrombosis	and	293	healthy	controls,	part	of	the	previously	reported	
ATTAC	study	cohort	13,14.	Measurements	were	performed	on	currently	
available	plasma	from	patients	included	before	April	2005,	in	which	
ADAMTS13	activity	was	previously	determined.		Males	were	younger	than	45	
and	females	younger	than	55	years.	The	cohort	consisted	of	three	subgroups:	
a	coronary	heart	disease	(CHD)	group	containing	patients	with	acute	
myocardial	infarction	and	unstable	angina	pectoris,	an	ischemic	stroke	(IS)	
group	also	containing	patients	with	a	transient	ischemic	attack,	and	a	
peripheral	arterial	disease	(PAD)	group.	Definitions	have	previously	been	
described	13,14.	Population	based	controls	were	neighbours	or	friends	of	the	
patient	without	a	history	of	cardiovascular	disease	and	fulfilling	the	same	age	
criteria.	Medical	ethical	committee	approval	was	obtained	from	Erasmus	MC,	
Rotterdam,	the	Netherlands.	All	patients	and	controls	gave	informed	consent	
for	inclusion	in	the	study.	Citrate	plasma	was	collected	1-3	months	after	the	
thrombotic	event,	to	prevent	influence	of	the	acute	phase	reaction.	
ELISA	and	bioassays	
The	antigen	levels	of	complement	factor	H	were	determined	in	citrate	plasma	
using	a	previously	established	ELISA	15.	In	brief,	1	µg/mL	monoclonal	anti-
FH.16	directed	against	complementary	repeats	16-17	was	coated	on	Maxisorp	
plates	(Nunc),	samples	were	diluted	in	high	performance	ELISA	buffer	(HPE,	
Sanquin),	and	after	washing	detected	using	0.25	µg/mL	horse-radish	
peroxidise	labelled	polyclonal	goat	anti-human	FH	antibody	(Quidel)	and	TMB	
as	a	substrate.	A	pool	of	sera	from	400	donors	containing	288	µg/mL	FH	was	
used	as	a	standard.	VWF:Ag,	VWF:CB,	and	ADAMTS13:Act	levels	were	
previously	determined	13.		
Levels	of	extracellular	nucleosomes	were	determined	as	previously	described	
16.	In	summary,	Maxisorp	plates	(Nunc)	were	coated	with	5	µg/mL	anti-
histone	H3	monoclonal	antibody,	samples	diluted	in	HPE	and	after	washing	
detection	was	performed	using	0.5	µg/mL	biotin	labelled	F(ab’)2	fragment	of	a	
monoclonal	antibody	against	the	histone	H2A/H2B/DNA	complex,	followed	by	
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a	streptavidin-HRP	step	and	detection	using	TMB	substrate.	One	arbitrary	unit	
is	the	amount	of	nucleosomes	released	by	≈100	Jurkat	cells,	which	
corresponds	roughly	to	~1	ng	histone	based	on	total	protein	quantitation.	
Other	values	(CRP,	cholesterol,	HbA1c)	were	determined	using	commercial	
assays	as	part	of	earlier	studies	of	the	ATTAC	cohort.	
Statistical	analyses	
The	medians	with	95%	confidence	intervals	are	presented	as	not	all	values	
were	normally	distributed.	Mann-Whitney	U	test	was	performed	to	compare	
cases	and	controls.	Correlations	of	FH	with	VWF	and	ADAMTS13	parameters,	
markers	of	inflammation	and	other	markers	associated	with	thrombosis	were	
determined	using	Spearman	rank	correlation	analysis.	Comparison	between	
subgroups	of	arterial	thrombosis	was	performed	using	Kruskall	Wallis	
statistics.	For	logistic	regression	analysis,	levels	were	divided	into	quartiles	
based	on	the	distribution	in	the	control	group.	The	lowest	quartile	was	used	as	
the	reference	group,	except	for	ADAMTS13	activity	where	the	highest	quartile	
was	used	as	reference.	For	extracellular	nucleosomes	2	groups	were	formed	
based	on	the	lower	detection	limit	of	the	assay	of	5	U/ml,	since	most	levels	
were	below	this	detection	limit.	Using	logistic	regression	analysis,	odds	ratio	
(OR)	and	95%	confidence	interval	(95%	CI)	were	calculated.	We	adjusted	for	
age	and	gender,	or	performed	extensive	adjustments	for	cardiovascular	risk	
factors	(age,	gender,	smoking,	diabetes	mellitus,	and	hyperlipidemia).		A	p-
value	of	<0.05	was	considered	statistically	significant	to	reject	the	null	
hypothesis.	All	statistical	analyses	were	performed	using	the	SPSS	software	
package	version	21	(IBM	SPSS	Statistics,	release	21.0.0.1)	
Results	
FH	in	patients	with	arterial	thrombosis	
The	levels	of	FH	were	determined	in	350	patients	with	arterial	thrombosis	
and	293	healthy	controls.	As	expected	in	thrombotic	patients,	Body	Mass	
Index	(BMI),	and	the	incidence	of	smoking	and	diabetes	were	higher	in	cases	
(Table	1).	Median	FH	levels	were	higher	in	cases	compared	to	controls,	343	
(interquartile	range,	288-410)	µg/mL	versus	318	(95%	CI	268-378)	µg/mL	
(p=0.006).	From	previously	determined	VWF:Ag	and	VWF:CB	values	we	
calculated	the	VWF:CB/VWF:Ag	ratio,	as	a	surrogate	marker	for	VWF	
multimer	size.	In	contrast	to	our	expectations,	VWF:CB/VWF:Ag	was	slightly	
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lower	with	a	median	ratio	of	1.10	(IQR	0.92-1.29)	in	cases	and	a	ratio	of	1.12	
(IQR	0.99-1.30)	in	controls	(p=0.07),	whilst	ADAMTS13	activity	levels	were	
lower	in	cases	at	144%	(IQR	103-167)	compared	to	163%	(IQR	138-184)	in	
controls	(p<0.001).	To	determine	the	contribution	of	inflammation	to	FH	
levels	we	analysed	the	correlation	with	CRP,	the	general	marker	of	
inflammation,	and	extracellular	nucleosomes.	CRP	levels	were	higher	in	cases,	
median	0.81	mg/L	(IQR	0.30-2.43)	compared	to	0.61	mg/L	(IQR	0.26-1.67)	in	
controls	(p=0.02).	It	is	unclear	whether	nucleosome	levels	were	different,	as	
these	were	below	the	5	U/mL	detection	limit	in	~70%	of	cases	and	controls.		
	
Table	1.	Baseline	characteristics	
	 	
Controls	 Cases	
	 	
n=293	 n=350	
Age	in	y,	median	(IQR)		 39	(28-50)	 43	(35-51)	
Male	(%)		
	
36%	 43%	
BMI	in	kg/m2,	median
	
(IQR)		
24.4	(19.4-
29.4)	
26.3	(20-32.6)	
Smoking	(%)		 52%	 81%	
Diabetes	(%)		 1%	 9%	
Use	of	statins	(%)		 1%	 89%	
Medians	with	interquartile	range	(IQR)	are	given	for	age	and	BMI,	other	data	are	counts	
(yes	or	no)	with	percentage	calculated.	Smoking	includes	both	past	and	present	smoking.	
Diabetes	and	hyperlipidemia,	which	was	defined	as	cholesterol	level	>5	mmol/l	or	
receiving	lipid	lowering	treatment,	were	based	on	clinical	diagnosis.		
	
The	correlation	of	FH	antigen	level	with	VWF,	ADAMTS13,	and	other	markers	
The	relationship	between	FH	on	the	one	hand	and	VWF:Ag,	VWF:CB,	
VWF:CB/VWF:Ag,	ADAMTS13:Act,	CRP	and	nucleosomes	on	the	other	hand	
was	performed	using	Spearman	Rank	correlation	analysis	as	several	
parameters	were	not	normally	distributed	(Table	2).	FH	levels	were	
significantly	correlated	with	CRP	in	both	controls	and	cases,	RS=0.29	
(p<0.001)	and	RS=0.15	(p=0.006),	respectively,	whilst	FH	levels	correlated	to	
levels	of	VWF:Ag,	VWF:CB/VWF:Ag,	and	also	nucleosomes	in	the	cases	only,	
with	RS=0.12	(p=0.02),		
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RS=-0.15	(p=0.004)	and	RS=0.13	(p=0.018)	respectively.	No	association	of	FH	
antigen	level	with	VWF:CB	and	ADAMTS13:Act	was	found	in	the	cases	and	
controls	of	this	study	population.	
Table	2.	Correlation	of	FH	with	VWF	and	ADAMTS13	parameters	and	markers	of	
inflammation	and	known	risk	factors	of	thrombosis.	
	 	
Controls	 Cases	
	 	
n=293	 n=350	
	 	 Rs	 P	 Rs	 P	
VWF:Ag	 0.05	 0.38	 0.12*	 0.02	
VWF:CB		
	
0.05	 0.38	 0.03	 0.55	
VWF:CB/VWF:Ag		 -0.03	 0.65	 -0.15**	 0.004	
ADAMTS13	activity#		 0.01	 0.89	 -0.06	 0.36	
CRP		 0.29**	 <0.001	 0.15**	 0.006	
Nucleosomes		 0.11	 0.07	 0.13*	 0.02	
Age	 0.09	 0.12	 0.14**	 0.008	
BMI	 0.25**	 <0.001	 0.36**	 <0.001	
SBP	 0.06	 0.32	 0.03	 0.56	
DBP	 0.04	 0.55	 0.02	 0.78	
Cholesterol†	 0.20**	 0.001	 N.A.#	 N.A.#	
HbA1c†	 0.10	 0.12	 0.24**	 <0.001	
Spearman	rank	correlation	test.	Rs:	Spearman	rank	correlation	coefficient,	CRP:	C-
reactive	protein,	BMI:	body-mass	index,	SBP:	systolic	blood	pressure,	DBP:	diastolic	
blood	pressure,	HbA1c:	hemoglobin	A1c.	
#ADAMTS13	activity	was	determined	in	222	controls	and	261	cases.	†Cholesterol	levels	
were	determined	in	270	controls	and	350	cases,	‡HbA1c	levels	were	determined	in	268	
controls	and	344	cases.	#	Not	determined	since	89%	of	cases	use	statins.		
Next,	we	determined	the	association	of	FH	antigen	levels	with	other	known	
risk	factors	of	arterial	thrombosis,	including	age,	BMI,	systolic	and	diastolic	
blood	pressure,	cholesterol	level	and	the	level	of	glycated	hemoglobin	
(HbA1c),	a	marker	used	in	diabetes	control	(Table	2).	FH	antigen	levels	
strongly	correlated	with	BMI	in	both	controls	and	cases,	RS=0.25	(p<0.001)	
and	RS=0.36	(p<0.001)	respectively.	Moreover,	FH	antigen	level	correlated	to	
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age	and	HbA1c	in	patients,	RS=0.14	(p=0.008)	and	RS=0.24	(p<0.001),	and	with	
cholesterol	level	in	controls,	RS=0.20	(p=0.001).	
Logistic	regression	and	subgroup	analysis	
We	then	performed	logistic	regression	analysis	to	determine	the	risk	of	
arterial	thrombosis	(Table	3).	No	relation	was	found	between	FH	levels	and	
risk	of	thrombosis	between	the	highest	quartile	(odds	ratio	(OR)	1.37	with	
95%CI	0.86-2.19)	compared	to	the	lowest	quartile,	after	adjustment	for	age	
and	gender.	The	non-significant	increase	of	40%	was	largely	lost	upon	
extended	adjustment	for	smoking,	diabetes	and	hyperlipidemia,	(OR	0.90,	
95%CI	0.53-1.54).	Upon	performing	a	similar	analysis	for	the	
VWF:CB/VWF:Ag	ratio,	we	also	found	no	differences	in	thrombosis	risk	with	
OR	0.81	(95%CI	0.51-1.26)	in	the	highest	quartile	(Q4)	when	compared	to	the	
lowest	quartile	(Q1),	after	adjustment	for	age	and	gender,	which	remained	the	
same	after	extended	adjustment	OR	0.77	(95%CI	0.47-1.26).	The	influence	of	
ADAMTS13	activity	on	arterial	thrombosis	risk	was	most	pronounced;	with	an	
OR	of	thrombosis	in	quartile	Q1	of	4.47	(95%CI	2.49-8.01)	or	3.73	(95%CI	
1.96-7.09)	after	extended	adjustment,	when	compared	to	quartile	Q4.	
Although	increased,	no	significant	differences	were	found	in	risk	of	
thrombosis	correlated	to	CRP	levels:	OR	1.28	(95%CI	0.80-2.04).	After	
adjustment,	the	OR	was	only	1.01	(95%CI	0.61-1.68).	
	
Table	3.	FH,	VWF:CB/VWF:Ag	ratio,	ADAMTS13,	CRP,	and	nucleosomes	and	the	risk	of	
arterial	thrombosis	
	
Complement	factor	H	(ug/ml)	
adjustment	
age/gender	
extended	
adjustments		
		 boundaries	
n,	
controls	 n,	cases	 OR	 95%CI	 OR	 95%CI	
Q1	 <268	 73	 65	 1	(ref)	 		 1	(ref)	 		
Q2	 296-318	 74	 65	 0.88	
0.53-
1.44	 0.67	
0.38-
1.17	
Q3	 319-378	 73	 100	 1.24	
0.77-
1.99	 0.87	
0.51-
1.49	
Q4	 >379	 73	 116	 1.37	
0.86-
2.19	 0.90	
0.53-
1.54	
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VWF:CB/VWF:Ag	ratio	
Q1	 <0.99	 73	 121	 1	(ref)	 		 1	(ref)	 		
Q2	 1.00-1.24	 73	 66	
0.56	
0.36-
0.89	 0.58	
0.34-
0.96	
Q3	 1.25-1.30	 73	 78	
0.68	
0.43-
1.07	 0.76	
0.46-
1.27	
Q4	 >1.31	 73	 85	
0.81	
0.51-
1.26	 0.77	
0.47-
1.26	
ADAMTS13	activity	(%)		
	 	 	 	 	
Q1	 <137	 55	 117	 4.47	
2.49-
8.01	 3.73	
1.96-
7.09	
Q2	 138-163	 56	 64	 2.14	
1.17-
3.91	 1.80	
0.93-
3.48	
Q3	 164-184	 56	 51	 1.84	
0.99-
3.43	 1.83	
0.91-
3.64	
Q4	 >185	 55	 29	 1	(ref)	 		 1	(ref)	 		
CRP	(mg/ml)		
	 	 	 	 	 	
Q1	 <0.26	 73	 76	 1	(ref)	 		 1	(ref)	 		
Q2	 0.27-0.61	 77	 70	 0.78	
0.48-
1.26	 0.95	
0.56-
1.60	
Q3	 0.62-1.67	 71	 87	 1.06	
0.66-
1.70	 1.31	
0.78-
2.22	
Q4	 >1.68	 69	 112	 1.28	
0.80-
2.04	 1.01	
0.61-
1.68	
Nucleosomes	(U/ml)		
	 	 	 	
D1	 <5	 207	 240	 1	(ref)	 		 1	(ref)	 		
D2	 >5.01	 86	 110	 0.95	
0.66-
1.35	 1.05	
0.70-
1.56	
Levels	were	divided	in	quartiles	based	on	the	distribution	in	the	control	group.	The	
lowest	quartile	was	used	as	the	reference,	except	for	ADAMTS13	activity	where	the	
highest	quartile	was	used	as	reference.	For	extracellular	nucleosomes	2	groups	were	
formed	based	on	the	lower	detection	limit	of	the	assay	of	5	U/ml.	Odds	ratio	(OR)	and	
95%	confidence	interval	(95%	CI)	were	calculated	using	logistic	regression.	We	adjusted	
for	age	and	gender,	or	performed	extensive	adjustments	for	cardiovascular	risk	factors	
(age,	gender,	smoking,	diabetes,	and	hyperlipidemia).	
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Addition	of	the	VWF	ratio	to	the	model	with	FH,	age	and	gender	did	not	
change	the	risk	estimates	of	arterial	thrombosis	(-2	log	likelihood	of	the	model	
are	613	and	605,	respectively,	P[χ2(4)]=n.s.).	Further	addition	of	ADAMTS13	
to	the	model	strongly	improved	the	risk	prediction	(-2	log	likelihood	of	the	
model	becomes	569,	P	[χ2(4)]<0.001).	In	our	analyses,	ADAMTS13	activity	
forms	the	main	parameter	that	determines	the	risk	of	arterial	thrombosis	and	
no	significant	contribution	of	FH	or	VWF	to	the	model	is	seen	in	this	young	
arterial	thrombosis	patient	group.	
Finally,	we	performed	a	subgroup	analysis	of	FH	levels	in	CHD,	IS	and	PAD	(n	
of	206,	98	and	46	cases	respectively).	The	FH	levels	were	statistically	
significant	different	between	the	different	patient	subgroups	with	the	Kruskal-
Wallis	test	(χ2(2)	=	12.41,	p	=	0.002),	with	a	median	(range)	of	356	(IQR	299-
418)	µg/mL	for	CHD,	317	(IQR	262-371)	µg/mL	for	IS	and	343	(IQR	307-413)	
µg/mL	for	PAD	(p=0.002	Kruskal	Wallis,	p<0.001	between	CHD	and	IS).		
	
	
Discussion	
In	patients	with	arterial	thrombosis,	FH	levels	were	associated	with	the	
VWF:CB/VWF:Ag	ratio.	No	association	was	found	between	FH	levels	and	
ADAMTS13	activity.	In	the	cases,	FH	levels	were	higher	than	in	healthy	
controls,	but	no	association	with	risk	of	thrombosis	was	observed.		
We	found	a	negative	correlation	between	FH	levels	and	the	VWF:CB/VWF:Ag	
ratio.	In	vitro	studies	have	shown	that	FH	binds	to	ultra	large	VWF	multimeric	
strings	and	makes	VWF	more	susceptible	to	cleavage	by	ADAMTS13	10,11.	FH	
was	found	to	bind	to	the	A2	domain	of	VWF	11,	which	also	contains	the	
ADAMTS13	cleavage	site.	Addition	of	FH	enhanced	the	proteolysis	of	platelet	
decorated	VWF	strings	at	the	surface	of	cultured	endothelial	cells	10.	We	used	
the	VWF:CB/VWF:Ag	ratio	as	a	surrogate	marker	for	VWF	multimer	length	to	
determine	a	possible	effect	of	FH	on	the	cleavage	of	VWF	by	ADAMTS13.	The	
collagen	binding	activity	of	VWF	is	directly	related	to	the	number	of	collagen	
binding	VWF	A3	(and	A1)	domains	of	VWF.	The	observed	negative	correlation	
between	FH	level	and	VWF:CB/VWF:Ag	ratio	is	compatible	with	a	mechanism	
where	FH	binding	to	VWF	catalyzes	its	proteolysis	by	ADAMTS13.	
	
Upon	analysis	of	the	relationship	of	the	VWF:CB/VWF:Ag	ratio	with	the	risk	of	
thrombosis,	we	found	that	this	ratio	was	lower	in	patients	with	arterial	
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thrombosis	compared	to	controls	in	Q2	and	Q3	compared	to	Q1,	which	was	in	
contrast	to	our	expectations.	No	differences	were	found	between	Q1	and	Q4.	
However,	both	VWF:CB	and	VWF:Ag	were	significantly	higher	in	patients	with	
arterial	thrombosis,	as	expected.	Hence,	these	levels	are	likely	to	have	risen	as	
a	consequence	of	endothelial	activation	that	results	in	the	release	of	large	
VWF	multimers.	It	is	possible	that	some	of	the	largest	VWF	multimers	remain	
sequestered	to	the	endothelial	cell	surface	and	would	therefore	not	show	up	in	
the	circulation.		
	
It	 has	 been	 suggested	 that	 FH	 and	 VWF	 are	 both	 inflammatory	 factors	 17,18.	
Indeed,	we	found	a	positive	association	between	FH	and	VWF:Ag	levels,	which	
also	forms	a	marker	of	endothelial	activation	and	inflammation.	We	also	found	
that	FH	levels	correlated	with	CRP	levels,	both	in	patients	and	controls.	It	has	
been	 suggested	 that	 both	 FH	 and	 CRP	 interact	 with	 oxidized	 phospholipids	
that	 arise	 during	 inflammation,	 which	 form	 damage-associated	 molecular	
patterns	 (DAMP)	 that	 activate	 the	 innate	 immune	 system	 19.	 The	 authors	 of	
that	 study	 speculate	 that	 this	 recognition	 may	 enable	 the	 innate	 immune	
system	to	mediate	important	physiological	housekeeping	functions,	including	
the	 removal	of	dying	 cells.	 Indeed,	FH	was	also	 correlated	with	extracellular	
nucleosome	 levels,	 a	 marker	 of	 cell	 death,	 in	 our	 patients.	 Extracellular	
nucleosomes	 in	 the	 blood	 may	 potentially	 also	 be	 derived	 from	 neutrophil	
extracellular	 traps	 (NETs)	 that	 are	 released	 in	 inflammation	 and	 which	 are	
known	contributors	to	both	venous	and	arterial	thrombosis20.	Of	interest,	FH	
has	 been	 implicated	 in	 the	 regulation	 of	 NETs	 formation,	 although	 no	 such	
effect	was	observed	with	soluble	rather	than	immobilized	FH	21.	However,	the	
extracellular	 nucleosome	 levels	 in	 our	 study	 population	were	 low	 and	 often	
even	 below	 the	 detection	 limit,	 probably	 because	 plasma	 samples	 were	
obtained	 1-3	months	 after	 the	 acute	 thrombotic	 event,	 this	 in	 contrast	 to	 a	
previous	study	where	extracellular	nucleosomes	associated	with	the	presence	
of	deep	vein	thrombosis	at	the	time	of	occurrence	22.	
	
We	found	correlations	between	FH	with	classic	risk	factors	for	thrombosis,	e.g.	
BMI,	HbA1c,	age	and	cholesterol	levels.	These	factors	are	all	part	of	the	
metabolic	syndrome,	which	is	linked	to	obesity	and	the	development	of	
diabetes.	Our	results	are	consistent	with	previously	reported	associations	
between	FH	and	circulating	lipids	and	indices	of	body	fat,	including	BMI,	body	
fat,	triglycerides,	cholesterol	and	also	HbA1c	and	insulin	in	a	population	of	
healthy	individuals	23.	As	virtually	no	information	on	the	regulation	of	FH	
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antigen	levels	and	its	clearance	exists,	further	research	into	the	mechanisms	
that	contribute	to	the	observed	association	with	the	metabolic	syndrome	are	
needed.		
Since	our	data	render	it	plausible	that	FH	modulates	the	effect	of	ADAMTS13,	
we	studied	the	association	between	FH	and	the	risk	of	arterial	thrombosis.	
Indeed,	FH	levels	were	higher	in	cases	than	in	controls.	In	our	subgroup	
analysis	on	the	type	of	arterial	thrombosis,	we	saw	that	FH	levels	were	higher	
in	CVD	patients	than	in	IS	patients.	However,	in	our	logistic	regression	models	
we	did	not	identify	FH	as	a	predictor	of	thrombosis	risk,	neither	on	its	own	
nor	by	interaction	with	VWF	and	ADAMTS13	in	a	combined	model.	In	this	
population,	ADAMTS13	was	the	major	determinant	of	the	risk	of	thrombosis.	
We	previously	published	this	relationship	between	ADAMTS13	and	risk	of	
CVD	in	the	ATTAC	population	13	and	also	in	prospective	studies	for	both	
ischemic	stroke	and	coronary	heart	disease	4-6.	Our	data	suggest	that	the	effect	
of	FH	on	ADAMTS13	cleavage	of	VWF	is	present,	but	that	other	mechanisms	
are	more	important	in	determining	the	risk	of	arterial	thrombosis.		
	
In	conclusion,	we	found	high	FH,	high	VWF:Ag	and	low	ADAMTS13:Act	in	
patients	with		arterial	thrombosis.	FH	antigen	levels	in	arterial	thrombosis	are	
linked	to	markers	of	the	metabolic	syndrome	and	suggest	a	possible	role	in	the	
turnover	of	oxidized	lipids.		
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Abstract	
The	fibrin	matrix	of	the	thrombus	that	is	formed	directly	after	wounding,	is	an	
important	determinant	of	the	success	of	the	early	phase	of	wound	healing.	
This	phase	is	often	impaired	in	patients	with	diabetes.	A	promising	approach	
to	improve	skin	wound	healing	is	the	application	of	a	pro-angiogenic	fibrin	
matrix	onto	the	wound.	We	studied	this	in	59	female	WAG/RijCrl	diabetic	rats,	
in	which	we	created	two	dorsal	full-thickness	wounds	of	which	one	was	
treated	with	a	human	physiological	fibrin	matrix	(2	mg/ml)	and	one	with	PBS	
as	control.	Wound	healing	parameters	were	determined	at	different	time	
points.	The	wound	closure	was	significantly	improved	in	fibrin-treated	
wounds	on	day	3	and	7.	Also,	fibrin-treated	wounds	showed	a	significantly	
higher	perfusion	on	day	28	and	35	compared	to	control	wounds	(p<0.05).	
CD68	staining	revealed	that	human	fibrin	did	not	induce	an	immune	response.	
In	conclusion:	the	application	of	a	fibrin	matrix	on	a	diabetic	wound	showed	
improved	perfusion	and	an	increased	early	closure	rate	of	the	wound	area.		
	
Introduction	
An	important	first	step	in	wound	healing	is	the	formation	of	a	fibrin	clot.	
Fibrin	is	formed	from	the	soluble	plasma	protein	fibrinogen,	a	molecule	of	340	
kDa	that	is	generated	in	the	liver	and	circulates	in	blood	with	a	concentration	
of	approximately	2	mg/ml.	It	consists	of	six	polypeptide	chains	connected	by	
disulfide	bonds;	two	Aα,	two	Bβ	and	γ	chains	(1-3).	Fibrin	is	the	end	product	
of	the	coagulation	cascade,	formed	by	the	cleavage	of	fibrinopeptides	A	and	B	
from	fibrinogen	by	thrombin	(3-5).	The	primary	function	of	the	fibrin	matrix	is	
to	stop	bleeding.	In	addition	to	its	role	in	hemostasis,	the	fibrin	matrix	also	
stimulates	the	attraction,	migration,	adhesion	and	proliferation	of	a	variety	of	
cells	that	are	important	in	wound	healing,	such	as	inflammatory	cells,	
fibroblasts	(6)	and	endothelial	cells	(1,	7).		
	
Patients	with	Diabetes	mellitus	(DM)	often	have	disturbed	wound	healing,	
which	is	a	growing	clinical	problem	since	the	prevalence	of	DM	is	increasing	in	
Western	societies.	Worldwide,	about	9%	of	all	adults	suffer	from	DM	and	
every	year	about	1.5	million	people	die	from	the	effects	of	DM	(8).	These	
numbers	show	a	dramatic	increase	over	the	last	30	years	(9).	One	of	the	major	
limitations	in	the	healing	of	wounds	in	DM	patients	is	circulatory	insufficiency	
due	to,	among	others,	stiffening	of	the	microvessels.	When	blood	circulation	is	
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improved,	the	delivery	of	nutrients	and	oxygen	to	the	wound	area	will	be	
enhanced.	Since	oxygen	is	one	of	the	most	important	molecules	in	
angiogenesis,	increased	circulation	and	oxygenation	will	improve	wound	
healing	(10).	
Fibrin	has	been	used	in	studies	on	wound	healing,	However,	these	studies	
used	fibrin	glue	consisting	of	fibrinogen	with	a	high	concentration	of	20-40	
mg/ml	with	a	high	concentration	of	4	U/mL	thrombin	is	used	as	a	delivery	
tool	of	growth	factors	in	wound	healing	(11-13).	Fibrin	matrices	from	this	
high-concentration	fibrinogen	have	a	very	tight	matrix	structure	that	allows	
none	to	only	very	limited	angiogenesis	and	fibrinolysis.	In	our	previous	
research	we	have	already	shown	that	using	an	optimized	fibrin	matrix	in	a	
wound,	based	on	a	concentration	of	fibrinogen	of	2	mg/ml,	creates	a	fibrin	
matrix	with	the	highest	capacity	of	endothelial	cell	ingrowth	in	vitro	and	in	
vivo	in	a	normal	rat	wound	healing	model	(14).	As	patients	with	DM	often	have	
circulatory	insufficiency,	we	now	hypothesize	that	a	fibrin	matrix	can	also	
improve	angiogenesis	in	delayed	diabetic	wound	healing.		
We	studied	the	effect	of	a	physiological	fibrin	matrix	on	delayed	wound	
healing	in	a	diabetic	delayed	wound	healing	rat	model.	
	
Material	and	methods	
Animals	
Sixty	five	female	WAG/RijCrl	rats		(6-8	weeks	old),	purchased	from	Charles	
River	(l’Arbresle,	France),	were	housed	in	pairs	under	standard	12	hour	
light/dark	cycles.	Food	and	water	were	available	ad	libitum.	The	rats	were	
allowed	to	acclimatize	to	their	environment	for	one	week	prior	to	diabetes	
induction.	The	experimental	protocol	was	approved	by	the	Animal	
Experiments	Committee	under	the	Dutch	national	Experiments	on	Animals	
Act	and	adhered	to	the	rules	laid	down	in	this	national	law	that	serves	the	
implementation	of	“Guidelines	on	the	protection	of	experimental	animals”	by	
the	Council	of	Europe	(1986),	Directive	86/609/EC.	All	surgery	was	
performed	under	isoflurane	anesthesia	and	the	animals	received	Temgesic	
two	days	after	surgery	to	minimize	suffering.		
	
Diabetes	induction	
Animals	(weight	>120	grams,	8-10	weeks	of	age)	were	fasted	overnight	and	
received	an	intraperitoneal	injection	of	60	mg/kg	Streptozotocin	(STZ,	Sigma-
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Aldrich,	St.	Louis,	MO)	in	0.05	mol/L	sodium	citrate	buffer	(pH=4.5).	The	
diabetic	condition	was	carefully	monitored	for	at	least	5	weeks	before	the	
start	of	the	experiment.	The	diabetic	state	of	the	animals	was	monitored	via	
physiological	changes	(e.g.	elevated	blood	glucose	levels	and	urine	production,	
thinner	skin	and	weight	loss).	
	
Full-thickness	ulcer	wound	model	and	treatment	
After	a	stable	diabetic	period	of	at	least	5	weeks,	the	rats	received	two	dorsal	
full-thickness	wounds.	The	left	wound	was	covered	with	300	µl	PBS	pH	7.4	
and	served	as	a	control.	The	right	wound	was	covered	with	300	µl	fibrin	
matrix,	consisting	of	human	fibrinogen	(2	mg/ml	in	PBS	pH	7.4,	Enzyme	
Research	Laboratories,	South	Bend	IN,	USA),	containing	0.43	U/ml	FXIII	
(determined	photometrically	with	Berichrom	Factor	XIII,	Siemens	Healthcare	
diagnostics,	Deerland,	IL),	depleted	of	plasminogen,	von	Willebrand	Factor	
and	fibronectin	mixed	with	human	thrombin	(1U/ml,	Siemens	Healthcare	
Diagnostics,	Breda,	the	Netherlands)	immediately	before	application	to	the	
wound.	Before	surgery,	animals	were	anesthetized	with	a	mixture	of	
isoflurane	and	oxygen.	After	removal	of	the	dorsal	hair,	two	full-thickness	
wounds	with	a	diameter	of	15	mm	(3	cm	apart,	4	cm	caudal	from	the	scapulae)	
were	created	with	surgical	scissors	as	previously	described	by	Tong	et	al	(15).	
Initial	wound	sizes	in	control	and	fibrin-treated	wounds	were	similar.	After	
application	of	the	fibrin	matrix,	the	animals	were	left	in	a	dorsolateral	position	
for	15	minutes	to	allow	the	fibrin	matrix	to	form.		All	animals	received	
Temgesic	(0,05	mg/kg,	Rekitt	Benckiser	Healthcare,	Ltd.,	Hull,	East	Yorkshire,	
UK)	i.m.	before	surgery	and	twice	a	day	for	two	days	after	surgery.	Animals	
were	followed	for	either	3	(n=6),	7	(n=20),		21	(n=20)	or	42	(n=19)	days,	
randomly	assigned,	and	sacrificed	for	wound	histology	and	gene/protein	
expression	assays.		
	
Perfusion	measurements	
Perfusion	in	the	wounded	area	and	the	normal	(unwounded)	skin	was	
measured	weekly	from	14	days	after	surgery	onwards	using	O2C	(LEA	
Medizintechnik,	Giessen,	Germany).	Measurements	were	performed	according	
to	manufacturer’s	recommendations.	Four	perfusion	parameters	were	
measured:	oxygen	saturation	(SO2),	relative	hemoglobin	(rHb),	blood	flow	in	
the	microcapillary	network	and	blood	flow	velocity.	SO2	and	rHb	levels	were	
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measured	using	a	white	light	probe.	Blood	flow	and	flow	velocity	were	
measured	by	using	changes	in	laser	light	frequency	within	vessels	(16).		
	
Vessel	capacity	measurements	
Vessel	capacity	in	the	wounded	area	was	measured	weekly	from	14	days	after	
wound	induction	onwards	with	a	Laser	Doppler	monitor	(LDPM,	Perimed	
Periflux	System	5000,	Perimed	AB).	A	pre-heated	33	⁰C	probe	was	placed	onto	
the	wound	for	approximately	3	minutes	for	baseline	measurements.	
Subsequently,	the	probe	was	heated	to	44	⁰C	and	measurements	were	
continued	for	another	3	minutes.	Vessel	capacity	was	calculated	relative	to	
baseline	measurements	at	33	⁰C	as	the	%	increase	and	expressed	in	perfusion	
units	(PU)	(15).	Only	wounds	without	crust	were	measured.			
	
Macroscopic	wound	area	measurements	
Each	week,	the	wounds	were	photographed	and	area	measurements	were	
performed	(3,	7,	14	and	21	days)	using	ImageJ	1.49q	(Wayne	Rasband,	
National	Institutes	of	Health,	USA).	Each	wound	area	was	measured	after	
selecting	the	wounded	area	with	a	tracing	tool.	On	t=0,	the	wound	surface	was	
considered	100%	and	calculated	wound	areas	revealed	the	%	of	wound	
closure	per	time	point.		
	
Immunohistochemistry	
Collected	wound	tissue	specimens	were	fixed	in	4%	formalin	for	24	hours.	
Immunohistochemistry	was	performed	on	paraffin	sections	(5	µm).	Slides	
were	rehydrated	and	treated	with	0.05%	trypsin	with	0.1%	calcium	chloride	
in	distilled	water	for	antigen	retrieval.	To	inhibit	endogenous	peroxidase,	
slides	were	washed	with	3%	H2O2	in	PBS	pH	7.4.	After	blocking	with	5%	skim	
milk,	slides	were	incubated	overnight	at	4	⁰C	with	primary	antibodies	
polyclonal	goat	anti-rat	CD34	(dilution	1:200,	R&D	systems,	cat.	nr.	AF4117,	
lot	ZDP0107081	)	or	monoclonal	mouse	anti-rat	CD68	(dilution	1:100,	
Serotec,	cat.	nr.	NLA59-MCA3	41R,	batch	060509)	diluted	in	1%	BSA/PBS	pH	
7.4.	Biotinylated	secondary	antibodies	rabbit	anti	goat	(1:200,	DAKO)	or	goat	
anti	mouse	(dilution	1:200,	DAKO)	were	applied	after	washing,	respectively.	
All	antibodies	were	validated	by	using	a	positive	and	negative	control	
according	to	the	manufacturer’s	recommendations	in	each	staining.	For	
visualization,	slides	were	incubated	with	streptavidin-HRP	(dilution	1:300,	
Biotech)	and	DAB	(3,3’	Diaminobenzidine,	Sigma	Aldrich)	and	counterstained	
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with	haematoxylin.	In	CD68	slides,	the	positive-signal	density	was	classified	
by	three	independent,	blinded	observers	as	absent	(1),	low	(2),	medium	(3),	
high	(4)	and	very	high	(5).	In	CD34	slides,	vessels	per	mm2	were	counted.	
Here,	only	day	7	was	included	for	analysis	due	to	aspecific	binding	of	the	
antibody	to	mature	collagen	on	later	time	points.	The	thickness	of	the	
epidermis	was	evaluated	on		haematoxylin	and	eosin	(H&E)	stained	slides.		
	
Statistical	analysis	
Data	are	presented	as	mean	±	standard	error	of	the	mean	(SEM).	Group	
differences	were	analyzed	by	univariate	ANOVA	with	Statistical	Package	for	
the	Social	Sciences	(SPSS,	IBM,	version	21).	Results	were	considered	
significant	if	p<0.05.		
Results	
Diabetic	state	of	the	animals	
After	diabetes	induction,	65	rats	had	an	average	glucose	level	of	29.1	±	0.5	
mmol/L.	Weights	in	the	different	groups	were	similar.	5	animals	recovered	
from	their	diabetic	state	and	were,	therefore,	not	included	in	this	study.	No	
animals	died	during	the	experimental	procedure.			
	
Fibrin	matrix	improves	wound	healing	
Fibrin-treatment	of	the	diabetic	wound	significantly	increased	the	wound	
closure	rate	in	the	first	days	after	wounding,	both	on	day	3	(14.9	±	5.4	%	
closure	in	controls	vs	34.6	±	3.2	%	closure	in	fibrin-treated	wounds,	p=0.02)	
and	on	day	7	(64.0	±	1.8	%	closure	in	controls	vs	71.5	±	1.9	%	closure	in	fibrin-
treated	wounds,	p=0.006)	(Fig.	1	and	Table	1).	On	day	21	the	wound	closure	
was	nearly	complete	in	both	groups	(93.9	±	0.4	%	in	controls	vs	94.6	±	0.6	%	
in	fibrin-treated	wounds,	p=0.29).	No	difference	was	seen	in	epidermal	
thickness.	Similar	numbers	of	CD68	positive	cells	were	seen	in	the	wound	area	
of	fibrin-treated	and	control	wounds,	indicating	that	the	human	fibrin	did	not	
trigger	an	enhanced	immune	response	in	the	rats.		
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Figure	1:	Improved	wound	closure	rate	(A	and	B)	on	day	3	and	7	of	fibrin-treated	wounds	
compared	to	control	wounds.	Scale	bars	are	5	mm.	*p<0.05,	**p<0.01.	
	
Table	1:	Wound	healing	in	the	diabetic	rat	model.			
	 Control	 Fibrin-treated	 P-value	
SO2	(%)	
o Day	14	
o Day	21	
o Day	28	
o Day	35	
o Day	42	
	
		87.9	±	1.6	
		90.8	±	1.2	
		80.3	±	2.6***	
		85.9	±	2.7**	
		69.7	±	3.9	
	
		92.2	±	3.3	
		90.0	±	1.8	
		94.7	±	1.3***	
		94.6	±	0.8**	
		76.7	±	2.2	
	
0.27	
0.73	
0.00002	
0.004	
0.13	
rHb	(AU)	
o Day	14	
o Day	21	
o Day	28	
o Day	35	
o Day	42	
	
		61.8	±	3.4	
		30.0	±	3.1	
		31.4	±	2.6**	
		32.4	±	1.7***	
		32.3	±	2.5	
	
		63.5	±	3.2	
		35.7	±	4.5	
		44.1	±	3.3**	
		43.4	±	1.8***	
		38.0	±	2.0	
	
0.71	
0.30	
0.005	
0.00009	
0.08	
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Blood	flow	(AU)	
o Day	14	
o Day	21	
o Day	28	
o Day	35	
o Day	42	
	
308.8	±	33.5	
136.3	±	14.1	
175.1	±	17.9*	
234.1	±	15.7*	
228.1	±	12.7	
	
330.0	±	42.0	
187.7	±	24.7	
242.1	±	22.2*	
319.8	±	31.4*	
199.4	±	26.0	
	
0.70	
0.08	
0.03	
0.02	
0.33	
Blood	flow	velocity	(AU)	
o Day	14	
o Day	21	
o Day	28	
o Day	35	
o Day	42	
	
		40.8	±	2.2	
		26.7	±	1.4*	
		29.8	±	1.3**	
		33.9	±	1.3**	
		33.7	±	1.1	
	
		41.3	±	2.6	
		32.2	±	2.0*	
		36.3	±	2.0**	
		40.8	±	2.2**	
		31.2	±	1.9	
	
0.86	
0.03	
0.009	
0.01	
0.28	
Vessel	capacity	
o Day	14	
o Day	21	
o Day	28	
o Day	35	
o Day	42	
	
		25.8	±	6.2	
		20.0	±	3.7	
		33.9	±	5.3	
		26.8	±	4.1	
		29.8	±	5.2	
	
		19.4	±	4.2	
		25.2	±	5.3	
		34.2	±	3.6	
		32.9	±	4.9	
	35.4	±	8.6	
	
0.39	
0.43	
0.96	
0.35	
0.58	
Data	are	given	as	mean	±	SEM.	Oxygen	saturation	(SO2)	are	percentages,	relative	
hemoglobin	levels	(rHb),	blood	flow	and	blood	flow	velocity	are	artificial	units.	Vessel	
capacity	is	expressed	relative	to	baseline	measurements	at	33	⁰C	as	the	%	of	increase.		
				*p	<	0.05.		
		**p	<	0.01.		
***p	<	0.001.		
	
The	fibrin	matrix	promotes	perfusion	
In	the	early	phase	of	wound	healing,	the	wound	closure	was	faster	in	the	
fibrin-treated	wounds.	On	day	21	and	day	28,	wound	perfusion	was	
significantly	higher	in	the	fibrin-treated	wounds	compared	to	the	control	
wounds,	as	indicated	on	day	21	by	blood	flow	velocity	(32.2	±	2.0	AU	fibrin-
treated	vs	26.7	±	1.4	AU	control,	p=0.03)	(Fig.	2)	and	on	day	28	by	oxygen	
saturation	(94.7	±	1.3	%	fibrin-treated	vs	80.3	±	2.6	%	control,	p<0.0001),	
relative	hemoglobin	(44.1	±	3.3	AU	fibrin-treated	vs	31.4	±	2.6	AU	control,	
p=0.005),	blood	flow	(242.1	AU	±	22.2	fibrin-treated	vs	175.1	±	17.9	AU	
control,	p=0.025)	and	blood	flow	velocity	(36.3	±	2.0	AU	fibrin-treated	vs	29.8	
±	1.3	AU	control,	p=0.009).	Similar	effects	were	observed	on	day	35	(Table	1).	
Both	SO2	and	rHb	showed	significant	higher	values	in	fibrin-treated	wounds	
(p<0.0001)	and	blood	flow	velocity	showed	a	positive	trend	(p=0.069)	over	
time.	Vessel	capacity	measurements	by	Laser	Doppler	(Table	1)	and	CD34	
counts	were	similar	in	both	groups.		
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Figure	2:	Improved	O2C	values	on	time	points	21d,	28d	and	35d	after	wounding.	A:	%	of	
the	oxygen	saturation.	B:	Relative	values	of	the	relative	hemoglobin	levels.	C:	Relative	
values	of	the	blood	flow.	D:	Relative	values	of	the	blood	flow	velocity.	*p<0.05.	**p<0.01.	
***p<0.001.		
	
Discussion	
The	most	important	finding	from	our	study	was	that	fibrin	improves	wound	
perfusion	and	wound	closure	in	delayed-healing	skin	wounds	in	diabetic	rats.	
This	study	is	the	first	to	apply	a	fibrin	matrix	with	a	physiological	
concentration	(2	mg/ml)		in	a	diabetic	delayed	wound	healing	model.	Our	
results	show	an	improved	wound	healing	rate	and	an	increased	blood	flow,	
representing	the	extensiveness	of	the	microcapillary	network.	In	our	previous	
studies,	both	our	in	vitro	data	and	our	healthy	rat	model	also	showed	
improved	angiogenesis	with	a	fibrin	matrix	(1,	14).	Previous	studies	have	
been	performed	with	fibrin	in	wound	healing,	but	these	used	fibrin	as	a	
growth	factor	delivery	tool,	and	were	made	from	fibrinogen	with	very	high	
concentrations	of	20-40	mg/ml.	These	concentrations	form	a	dense	fibrin	
sealant	or	film	rather	than	a	matrix	in	which	endothelial	cells	can	invade	for	
angiogenesis,	in	which	the	structure	of	the	fibrin	matrix	is	crucial	(17).	Thus	
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there	is	an	essential	difference	in	the	physiological	fibrin	matrix	that	we	used	
in	this	study.			
	
In	this	study,	control	wounds	were	treated	with	PBS,	in	which	the	fibrinogen	
was	also	diluted.	With	this	model	we	aimed	to	simulate	the	clinical	situation	in	
which	wounds	are	not	directly	covered	by	a	matrix.	The	observed	effect	of	
fibrin	on	wound	healing	could	be	due	to	different	mechanisms,	including	the	
effect	of	a	protective	film	onto	the	wound	or,	as	previously	suggested,	
angiogenesis.	Based	on	previous	literature	describing	fibrin	as	an	
angiogenesis	promoting	protein,	we	suggest	that	the	angiogenic	properties	of	
the	fibrin	matrix	has	the	strongest	effect	on	wound	healing.				
	
In	addition	to	the	importance	of	the	physiological	fibrinogen	concentration	we	
used	for	our	fibrin	matrix,	also	FXIII	may	affect	the	results.	FXIII	stabilized	the	
fibrin	matrix	by	cross-linking	the	fibrin	fibers,	and	the	importance	of	this	
process	is	illustrated	by	the	bleeding	complications	that	are	seen	in	patients	
suffering	from	FXIII	deficiency	(18).	Additionally,	low	FXIIII	levels	increases	
pore	size	of	the	fibrin	fibers,	fiber	thickness	and	increases	the	fibrinolysis	rate	
of	the	matrix	(19).	In	our	fibrinogen	preparation,	FXIII	is	present	at	a	
concentration	of	0.43	U/ml,	which	is	well	above	the	level	of	FXIII	that	gives	
clinical	complications	(1-3%).	Furthermore,	we	used	fibrinogen	that	is	
depleted	from	plasminogen,	which	has	an	important	role	in	fibrinolysis	and	
angiogenesis.	In	this	study	and	in	our	previous	experiments	(14),	we	have	
shown	that	the	plasminogen	that	is	needed	for	the	wound	healing	in	our	
model	is	provided	by	the	animals	themselves.				
	
Despite	the	improved	perfusion,	vessel	capacity	did	not	differ	significantly	
between	treated	and	non-treated	wounds.	From	day	21,	the	mean	values	of	
the	fibrin-treated	wounds	were	slightly	higher	than	the	mean	values	of	the	
non-treated	wounds,	however	did	not	reach	significance.	This	pattern	is	
consistent	with	the	positive	trend	found	in	O2C	measurements.		
	
	
The	number	of	monocytes	and	macrophages	in	the	wound	area	did	not	differ	
between	treated	and	non-treated	wounds,	indicating	that	the	addition	of	a	
human	fibrin	matrix	does	not	increase	the	immune	response	in	the	early	
phase	of	wound	healing.	This	suggests	that	treatment	of	human	diabetic	ulcers	
with	fibrin	will	be	well	tolerated.	
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Our	diabetic	rat	model	shows	the	characteristics	of	diabetes	(e.g.	weight	
loss/hampered	weight	increase,	thinner	skin,	high	glucose	levels	and	elevated	
urine	production)	and	delayed	wound	healing	(20),	as	previously	described	in	
other	diabetic	rat	models	(16,	21,	22).	The	difference	between	rats	and	
humans	is	that	rats	have	a	muscle	layer	under	their	skin,	causing	wound	
contraction.	By	using	an	internal	control,	it	is	expected	that	the	difference	
observed	in	wound	size	between	fibrin-treated	and	control	wounds	are	due	to	
treatment	and	not	wound	contraction.			
	
Disturbed	wound	healing	is	a	problem	in	patients	with	DM.	Of	all	patients,	
approximately	15%	will	develop	delayed	healing	wounds,	of	which	24%	
ultimately	result	in	lower	limb	amputation	(23).	After	amputation,	morbidity	
and	mortality	is	reported		50-60%	on	a	2-year	survival	rate	(24).	Given	the	
high	number	of	diabetic	delayed	healing	wounds,	it	is	of	clinical	importance	to	
provide	a	treatment	that	is	well	accepted,	affordable	and	time	efficient.	Fibrin	
is	already	a	known	substance	in	the	clinic,	as	high	concentration	fibrinogen	is	
applied	as	fibrin	glue.	However,	these	fibrin	matrices	do	not	promote	cell	
migration	due	to	the	high	density	of	the	fibrin	network	(25).	With	our	model,	
we	show	that	the	addition	of	a	healthy	human	fibrin	matrix	with	a	
physiological	concentration	may	be	a	promising	and	safe	treatment	for	
improving	diabetic	wound	healing	by	improving	perfusion.	Furthermore,	the	
addition	of	a	fibrin	matrix	can	be	easily	translated	and	applied	in	the	clinic	on	
diabetic	delayed	healing	wounds.			
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Chapter	8	
General	discussion
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NETs	as	a	common	thread	(or	threat?)	in	several	diseases	
NETs	play	a	key	role	in	chronic	wound	healing,	which	is	the	scope	of	this	
thesis,	but	also	in	diseases	such	as	sepsis	and	thrombosis.	In	the	consecutive	
chapters	of	this	thesis,	we	have	investigated	how	NETs	are	formed	(chapters	
2,3	and	4)	and	what	their	role	is	in	various	diseases	(chapters	5	and	6).	As	an	
intertwining	thread,	the	importance	of	fibrin	in	chronic	wounds	was	also	
explored	(chapter	7).	Whereas	it	is	clear	that	a	physiological	concentration	of	
fibrin	improves	wound	healing,	the	effect	of	NETs	in	wound	healing	is	less	
clear.	NETs,	like	other	immune	cells,	can	act	as	a	double-edged	sword:	
favorable	to	wound	healing	is	that	they	can	trap	and	destroy	pathogens,	but	
detrimental	is	that	they	can	also	cause	collateral	damage	to	the	surrounding	
tissue.	In	thrombi,	NETs	have	been	described	to	strengthen	the	clot,	therefore	
the	clots	become	more	resistant	to	lysis,	which	may	worsen	patient	outcome	
1,2.	Furthermore,	some	bacteria	like	S.	aureus	have	developed	strategies	to	
evade	the	immune	system,	for	example	by	breaking	down	the	NET3	or	
blocking	phagocytosis4.			
In	sepsis,	NETs	have	previously	been	described	as	a	predictor	of	patient	
outcome5.	We	explored	in	chapter	5	the	correlation	between	patient	outcome	
and	plasma	levels	of	NETs,	measured	in	the	serum	of	children	with	severe	
meningococcal	sepsis.	In	a	previous	study	from	our	group	in	this	population,	a	
significant	correlation	between	nucleosomes	(a	marker	for	extracellular	DNA)	
and	patient	outcome	was	found6.	Therefore,	the	obvious	hypothesis	was	that	
NETs	levels	are	also	correlated	to	patient	outcome.	However,	in	contrast	to	
our	expectations	and	the	literature,	we	did	not	see	a	clear	effect	of	NETs	on	
patient	survival.	Also,	no	correlation	was	found	between	nucleosomes	and	
NETs,	which	we	quantified	using	an	MPO-DNA	ELISA,	indicating	that	the	
nucleosomes	marker	alone	measures	not	the	same	as	the	NETs	levels.	Other	
studies	found	a	correlation	between	nucleosomes	and	neutrophil	elastase	
(NE)	levels,	another	marker	for	NETs7.	However,	NE	is	a	common	marker	for	
neutrophil	levels,	and	like	we	used	MPO-DNA	complex	levels	in	our	study,	also	
NE	complexed	to	DNA	should	be	investigated.	Then,	in	future	studies,	the	
correlation	between	MPO-DNA	and	NE-DNA	could	be	explored.	It	should	be	
noted	that	our	patient	group	was	relatively	small.	Nevertheless,	as	we	did	not	
find	any	indication	of	an	association	between	patient	survival	and	NETs,	we	do	
not	expect	to	find	significant	results	in	a	larger	cohort.	In	our	studies,	in	
chapters	2	and	3,	we	observed	that	the	type	of	bacteria	is	important	in	the	
amount	of	NETs	formed.	This	has	also	been	reported	in	earlier	studies8.	This	
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could	indicate	that	different	types	of	bacterial	species	are	responsible	for	
inducing	a	different	amount	of	NETs,	and	that	these	NETs	only	become	a	
problem	when	extensively	present.	This	might	be	the	case	in	other	forms	of	
sepsis,	but	in	our	meningococcal	sepsis	patient	group,	this	was	not	observed.		
The	hypothesis	that	different	intensities	of	NETosis	play	a	role	in	different	
types	of	sepsis	is	very	obvious,	considering	the	enormous	variation	in	NETosis	
induction	rate	between	and	even	within	bacterial	species8.		We	explored	this	
potency	to	induce	NETosis	in	chapter	2	with	S.	aureus	and	E.	coli,	and	in	
chapter	3	with	different	strains	of	S.	aureus.	Especially	in	the	studies	
presented	in	chapter	3,	it	became	clear	that	every	bacterial	strain	has	its	own	
unique	defense	mechanism	against	our	immune	system,	causing	variation	in	
response	by	our	neutrophils.	This	may	also	explain	the	difference	in	severity	
of	NETs	in	sepsis	caused	by	different	bacterial	species.		
In	chapter	6,	the	effect	of	FH	and	nucleosome	levels	on	VWF	cleavage	by	
ADAMTS13	was	explored	in	a	case-control	study	of	young	patients	with	
arterial	thrombosis	(ischemic	stroke	and	myocardial	infarction).	Here,	we	
observed	that	FH	was	correlated	to	nucleosome	levels,	indicating	an	
interaction	between	FH	and	the	removal	of	dead	cells.	However,	the	most	
important	finding	in	this	study	was	that	FH	levels	were	increased	in	patients,	
as	compared	to	controls,	and	that	these	levels	were	negatively	correlated	with	
VWF:CB/VWF:Ag	ratio,	which	indicates	VWF	multimer	size,	as	it	is	directly	
related	to	the	number	of	collagen	binding	domains.	FH	can	bind	to	VWF,	and	
previously	this	has	been	associated	with	higher	amounts	of	high	molecular	
weight	VWF	multimers	and	increased	VWF	mediated	platelet	aggregation9.	
Therefore,	our	hypothesis	was	that,	in	our	patient	group,	this	mechanism	
could	play	a	role	in	arterial	thrombosis.	However,	no	association	with	FH	
levels	or	nucleosome	levels	and	thrombosis	was	observed.	It	would	be	
interesting	to	measure	MPO-DNA	complex	levels	in	these	patients,	to	see	if	
there	is	a	correlation	between	NETs	levels	and	nucleosome	levels.	It	also	
would	be	interesting	to	correlate	the	NETs	levels	from	the	plasma	to	NETs	
found	in	thrombi	derived	from	these	patients.	It	should	be	taken	into	account,	
however,	that	the	plasma	from	these	patients	was	derived	when	the	acute	
inflammatory	state	was	over,	therefore,	less	NETs	could	be	expected.	
The	process	and	appearance	of	NETosis	
NETosis	can	be	induced	by	different	stimuli,	which	has	been	explored	in	
chapter	2.	One	of	our	most	interesting	findings	was	that	different	stimuli	had	
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different	effects	regarding	the	extrusion	of	the	DNA	complex	by	the	
neutrophils,	including	breaking	of	the	nuclear	membrane	and	mixture	of	the	
cellular	components.	In	experiments	with	PMA,	DNA	extrusion	could	take	up	
to	4	hours.	With	other	inducers,	like	bacteria	or	Ionomycin,	this	process	was	
much	faster:	5	minutes	and	1.5	hours,	respectively.	We	observed	that	NETosis	
by	these	inducers	clearly	differed	from	each	other.	In	the	case	of	Ionomycin,	
the	cellular	membranes	became	porous	within	15	minutes,	allowing	PI	to	bind	
to	the	DNA	whilst	still	in	the	nucleus.	Thereafter,	the	DNA	mixed	with	the	
other	cellular	components	and	extruded	from	the	neutrophil.	When	only	
looking	at	the	final	image	after	4	hours,	neutrophils	stimulated	by	PMA	and	
Ionomycin	look	similar,	which	underpins	the	importance	of	time-lapse	
imaging	to	follow	the	process	of	NETosis.	However,	in	the	case	of	bacterial	
experiments,	time-lapse	imaging	was	not	possible	due	to	the	fast	NETosis	
induction	by	bacteria.	Not	only	was	the	process	much	faster,	also	the	
morphology	of	the	NETs	differed	greatly	from	NETs	resulting	from	
neutrophils	stimulation	with	PMA	or	Ionomycin.	Whereas	in	PMA	and	
Ionomycin-stimulated	neutrophils	the	DNA	often	remained	close	to	the	
remainder	of	the	neutrophil,	DNA,	extruded	after	stimulation	with	bacteria,	
often	appeared	elongated	and	thread-like.	The	extension	of	these	NETs	
depended	largely	on	the	type	and	number	of	bacteria	added.	Some	bacterial	
strains,	as	mentioned	before	and	as	described	in	chapter	3,	induced	
significantly	less	NETosis	than	others,	for	example,	S.	aureus	Newman	
produced	much	more	NETs	than	S.	aureus	ST239-M116.	In	the	latter,	NETs	
remained	more	closely	to	the	neutrophil	remains.		
The	morphology	of	our	PMA-induced	NETs	very	much	resembles	the	NETs	
(and	NETosis	process)	as	described	previously	by	other	groups10,11.	However,	
there	also	are	reports	in	which	PMA-induced	NETs	appear	thread-like	and	
resemble	the	NETs	found	after	bacterial	induction	of	NETosis12-17.	Some	of	
these	papers	show	imaged	NETs	using	SEM,	which	is	a	more	detailed	imaging	
technique	than	our	confocal	and	SIM	images.	More	often,	NETs	structures	
were	stained	with	MPO	and	NE	after	fixation	and	immunohistochemistry	
(IHC).	It	is	possible	that	during	IHC,	the	morphology	of	the	NETs	change	
compared	to	NETs	found	in	live	imaging,	like	the	ones	we	showed	in	chapter	2.	
In	our	experience,	NETs	were	very	fragile	and	were	lost	during	the	washing	
steps	of	our	IHC	protocols.	
In	summary,	it	is	difficult	to	judge	differences	in	morphology	of	NETs	due	to	
their	fragileness	and	susceptibility	to	change.	Therefore,	it	would	be	
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interesting	to	observe	the	change	in	morphology	when	NETosis	is	induced	by,	
for	example,	PMA,	and	movement	is	induced	in	the	vicinity	of	moving	bacteria.	
In	this	way,	it	could	be	explored	if	bacterial	movement	causes	the	difference	in	
morphology,	or	if	bacteria	have	a	different	NETosis	inducing	mechanism.		
NETosis	as	a	defense	mechanism	
One	of	the	most	interesting	discussion	points	in	this	thesis	is	the	functionality	
of	the	NETs,	as	discussed	in	chapter	3.	The	earliest	research	on	NETosis	states	
that	NETs	are	a	defense	mechanism	to	trap	and	kill	bacteria	that	is	more	
efficient	than	phagocytosis13.	Later,	and	in	line	with	our	findings,	it	was	
observed	that	multiple	bacterial	species	can	escape	and	survive	the	NETs3,18,19.	
S.	aureus	generally	has	developed	multiple	ways	to	evade	the	human	immune	
system.	For	example,	S.	aureus	is	able	to	excrete	Protein	A,	which	has	been	
described	in	literature	as	a	regulator	of	phagocytosis	and	the	complement	
system4,20.	We	have	now	shown	another	function	of	Protein	A:	the	quantity	of	
NETosis	is	dependent	on	the	amount	of	Protein	A	secreted	by	S.	aureus.	This	
could	indicate	NETosis	regulation,	as	bacteria	can	excrete	Protein	A	in	
response	to	immune	cells.	From	perspective	of	the	bacteria,	neutrophil	
destruction	could	be	a	positive	act:	this	way	phagocytosis	is	prevented	and	
when	NETs	are	released,	S.	aureus	can	dismantle	these	by	secreting	nuclease,	
as	was	observed	in	chapter	4.	Additionally,	S.	aureus	can	form	biofilms,	which	
are	protecting	the	bacteria	by	secreting	nucleases	at	an	early	stage.	We	saw	
that	these	biofilms	are,	when	grown	in	IMDM	to	simulate	the	human	cell	
environment,	largely	consisting	of	PIA.	It	is	known	that	deacetylated	PIA	can	
protect	bacteria	from	innate	immune	cells	because	of	its	positive	charge	21-23.	
Also,	when	neutrophils	are	co-incubated	with	S.	aureus	biofilm,	ROS	
production	is	inhibited.	As	mentioned	previously,	ROS	production	is	a	large	
part	of	the	neutrophil’s	defense	mechanism.	Summed	up,	S.	aureus	has	
developed	a	spectrum	of	mechanisms	to	protect	itself	from	human	
neutrophils,	including	Protein	A	production	and	biofilm	formation.		
The	role	of	fibrin	in	wound	healing	
In	chapter	7,	we	explored	the	potential	of	adding	unfractionated	human	fibrin	
as	a	novel	matrix	to	wounds	in	diabetic	rats	in	order	to	improve	the	healing	
process.	In	previous	studies	by	our	group,	fibrin	has	been	shown	to	provide	a	
good	scaffold	for	angiogenesis	in	vitro,	and	it	improved	wound	healing,	
angiogenesis	and	perfusion	when	applied	onto	the	wounds	of	healthy	rats	24.	
Therefore,	we	hypothesized	that	in	diabetic	rat	wounds,	the	effects	would	be	
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even	more	prominent.	In	our	study,	we	saw	improved	wound	closure	on	day	3	
and	7	and	improved	wound	perfusion	after	21	days.	We	attempted	to	explore	
the	underlying	mechanism	and	found	a	176	times	upregulation	of	the	eNOS	
gene	in	a	qPCR,	but	our	Western	Blot	data	did	not	confirm	this	finding.	Here,	
the	eNOS	protein	was	only	1.03x	higher	in	the	fibrin-treated	wounds	
compared	to	the	controls.	Therefore,	the	mechanism	should	be	further	
explored.	However,	fibrin	effects	on	tissue	perfusion	warrant	further	
investigation	of	its	clinical	use.	We	were	able	to	conclude	that	fibrin	on	its	own	
has	potential	to	improve	wound	healing	in	a	clinical	setting.	Previously,	
platelet	rich	plasma	(PRP)25-27	and	platelet	rich	fibrin	(PRF)28	have	been	
implemented	in	clinical	trials.	Even	though	these	studies	show	promising	
results,	they	often	include	small	patient	groups,	only	report	positive	results	for	
the	beginning	of	the	trial	or	do	not	include	a	proper	control	group.		
Future	perspectives	
One	of	the	most	promising	findings	in	this	thesis	is	the	ability	of	
unfractionated	fibrin	to	improve	diabetic	wound	healing.	Because	of	its	
angiogenic	abilities,	we	hypothesized	that	fibrin	would	improve	wound	
healing	by	boosting	perfusion	in	rats,	which	we	indeed	found.	The	next	step	is	
to	test	human	fibrin,	in	a	physiological	concentration	(2	mg/ml),	in	human	
wounds.	At	the	moment,	fibrin	is	already	used	in	the	clinic	as	tissue	glue,	
which	has	very	high	fibrinogen	and	thrombin	concentrations	(60-80	mg/ml	
and	800	U/ml,	respectively).	When	applied	to	wounds,	normal	fibrin	will	be	an	
optimal		matrix	for	cellular	ingrowth	and	new	vessels	and	can	be	lysed	
normally,	to	be	replaced	by	myofibroblasts	and	eventually	collagen.			
The	relation	between	NETs	and	wound	healing	needs	to	be	further	explored.	
Are	NETs	advantageous	in	wound	healing?	The	function	of	NETs	seems	the	
most	efficient	in	wound	healing,	as	many	bacteria	are	present	and	NETs	
strengthen	the	fibrin	matrix29.	A	paper	by	Wong	and	colleagues,	however,	
suggests	that	in	wound	healing	in	diabetic	mice,	NETs	may	be	
disadvantageous	as	wound	healing	improved	when	the	NETs	are	depleted	
with	DNase30.	They	point	out	that	NETs	contain	toxic	components	that	destroy	
the	ECM,	therefore	delaying	wound	healing.	In	addition,	NETs,	induced	by	
PMA,	have	been	described	to	hamper	fibrinolysis29	in	normal	plasma	clots,	
which	would	also	hamper	wound	healing.	As	diabetic	wound	healing	is	often	
hampered,	it	would	be	interesting	to	compare	the	effect	of	normal	and	
diabetic	NETs,	induced	by	bacteria,	on	the	fibrinolysis	of	normal	and	diabetic	
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human	plasma	clots.	Furthermore,	biopsies	of	non-healing	diabetic	wounds	
should	be	investigated.	A	biobank	with	chronic	wound	biopsies	could	be	set	
up	to	explore	NETs	in	these	tissues,	for	example	by	immunofluorescent	
staining	or	ELISA.	In	both	cases,	levels	of	MPO-DNA	complexes	can	be	
measured,	similar	to	our	methods	in	chapter	5,	giving	an	indication	of	the	
amount	of	NETs	compared	to	control	tissue.	Normal	skin	could	be	taken	as	a	
control.			
S.	aureus	is	a	key	player	in	chronic	infection	and	thus	inflammation	in	wounds.	
One	of	our	main	findings	in	this	thesis	was	that	S.	aureus	Protein	A	is	a	
determinant	of	NETosis.	We	found	that	if	more	Protein	A	was	present,	more	
NETosis	could	be	observed.	Furthermore,	when	Protein	A	was	added	to	a	
Protein	A	knockout	strain	of	S.	aureus,	NETosis	could	be	rescued.	However,	no	
NETosis	was	observed	when	Protein	A	alone	was	added	to	neutrophils,	
indicating	that	Protein	A	by	itself	is	not	enough	to	induce	NETosis.	We	
speculated	that	bacteria	needed	to	be	present	to	induce	NETosis,	however,	
when	Protein	A	was	added	to	dead	S.	aureus,	no	NETosis	was	observed.	
Therefore,	we	expect	that	a	co-factor,	secreted	by	living	S.	aureus,	must	be	
present	in	order	to	induce	NETosis.	To	fully	understand	the	mechanism	
behind	NETosis	induction	by	S.	aureus	via	Protein	A,	this	co-factor	must	be	
found.			
In	conclusion,	NETs	have	been	described	in	many	different	diseases,	such	as	
chronic	wound	healing,	sepsis	and	thrombosis.	However,	in	our	studies,	the	
effect	of	NETs	was	often	much	less	clear	than	described	previously.	Fibrin,	on	
the	other	hand,	seems	to	have	more	potential	in	improving	diabetic	wound	
healing.			
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Summary	
The	aim	of	this	thesis	was	to	investigate	the	effect	of	fibrin,	NETs	and	the	
induction	of	NETosis,	in	wound	healing.	To	achieve	this,	we	created	in	vitro	
models	to	study	the	formation	of	NETs	by	several	inducers,	such	as	PMA,	LPS,	
S.	aureus,	E.	coli	and	N.	meningitidis.		Furthermore,	we	studied	the	role	of	NETs	
and	extracellular	DNA	in	sepsis	and	thrombosis.	A	diabetic	rat	model	was	used	
to	study	the	effect	of	fibrin	on	wound	healing.		
In	chapter	2	we	created	a	systematic	review	in	order	to	obtain	more	insight	in	
the	different	inducers	of	NETosis	used	in	literature.	Here,	we	found	a	wide	
variation	in	reported	effectiveness	of	these	inducers.	Therefore,	we	
investigated	a	subset	of	these	inducers	(PMA,	S.	aureus	(alive	and	dead),	E.	coli	
(alive	and	dead),	LPS,	LPS	+	platelets,	LPS	+	activated	platelets,	activated	
platelets	and	ionomycin),	in	our	own	standardized	time-lapse	model.	We	
found	that	PMA,	living	bacteria	and	ionomycin	were	all	robust	inducers	of	
NETosis.	All	other	inducers	were	less	potent.	Furthermore,	using	time-lapse	
microscopy,	we	observed	a	difference	in	the	NETosis	induction	process	
between	PMA	and	ionomycin,	indicating	the	importance	of	this	technology.	
In	chapter	3,	we	investigated	the	role	of	Protein	A,	an	important	immune	
modulator	produced	by	S.	aureus,	in	NETosis	induction.	We	used	four	different	
S.	aureus	strains	to	induce	NETosis	and	determined	their	Protein	A	
production.	We	saw	a	positive	correlation	between	the	amount	of	NETs	and	
the	amount	of	Protein	A	present.	Significantly	less	NETosis	was	measured	
using	a	Protein	A	knockout	strain	to	induce	NETosis,	which	elevated	to	normal	
levels	when	commercial	Protein	A	was	added.	When	Protein	A	was	added	to	
dead	S.	aureus,	no	NETosis	was	observed.	This	indicates	that	Protein	A	plays	
an	important	role	in	the	induction	of	NETosis	by	living	S.	aureus.			
In	chapter	4,	the	role	of	nuclease,	as	produced	by	S.	aureus	biofilm,	was	
explored	to	obtain	more	insight	in	biofilm	growth	and	defence	against	the	
innate	immune	system.	Nuclease	production	by	biofilm	was	studied	using	two	
different	culture	media:	TSB,	which	is	most	commonly	used	in	literature,	and	
IMDM,	a	mammalian	cell	culture	medium	which	more	closely	represents	
human	cell	environment.	We	observed	that	significantly	more	nuclease	was	
produced	when	biofilm	was	grown	in	IMDM.	Furthermore,	mature	biofilm	
grown	in	IMDM	consisted	mostly	of	PIA,	whereas	mature	biofilm	grown	in	TSB	
consisted	mostly	of	eDNA.	Additionally,	biofilms	were	able	to	induce	NETosis,	
and	NETs	could	be	degraded	using	nucleases.	These	nucleases,	however,	did	
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not	have	an	effect	on	ROS	production	by	neutrophils,	which	was	lower	when	
neutrophils	were	incubated	with	biofilm.	Taken	together,	nuclease	production	
by	biofilms	can	regulate	biofilm	composition	and	protect	the	biofilm	from	the	
innate	immune	system	by	breaking	down	NETs.		
In	chapter	5,	the	contribution	of	NETosis	on	the	severity	of	meningococcal	
sepsis	in	children	was	explored.	Serum	samples	from	these	patients	were	used	
to	measure	MPO-DNA	levels,	a	marker	for	NETosis.	We	aimed	to	study	
correlations	between	these	levels	and	patient	outcome	and	other	
inflammatory	markers,	such	as	CRP,	IL6	and	IL8.	Whilst	MPO-DNA	levels	were	
higher	on	admission	and	after	24	hours	compared	to	controls,	no	associations	
were	found	between	MPO-DNA	levels	and	patient	outcome	or	any	other	
inflammatory	markers.	This	indicates	that	in	our	study	in	children	with	
meningitis,	NETs	might	not	be	as	important	in	severity	of	sepsis	compared	to	
previous	sepsis	studies.	
In	chapter	6,	the	role	of	Factor	H	and	extracellular	DNA	(nucleosomes)	on	the	
cleavage	of	VWF	by	ADAMTS13	was	studied	in	young	patients	with	arterial	
thrombosis.	FH	levels	in	these	patients	were	elevated,	but	had	no	direct	
association	with	thrombosis.	A	correlation	between	FH	levels	and	nucleosome	
levels	was	found,	which	may	indicate	a	role	of	FH	on	the	activation	of	the	
immune	system	to	clear	dead	cells.	Furthermore,	a	negative	correlation	
between	FH	and	VWF:CBS/VWF:Ag	ratio	was	found,	which	may	indicate	that	
the	presence	of	FH	in	these	patients	gives	increased	amounts	of	high	
molecular	weight	VWF	multimers	and	more	VWF	mediated	platelet	
aggregation,	leading	to	arterial	thrombosis.		
In	chapter	7,	the	wound	healing	potential	of	human	fibrin	on	diabetic	wound	
healing	was	explored.	Dorsal	wounds	were	created	in	a	diabetic	rat	model,	of	
which	one	was	treated	with	a	placebo	and	one	was	treated	with	a	fibrin	
matrix.	Wound	area	and	tissue	perfusion	were	measured	on	several	time	
points	during	wound	healing.	We	found	that	fibrin	significantly	improved	
perfusion	and	early	wound	healing,	indicating	the	potential	of	fibrin	to	boost	
wound	healing	of	poorly-healing	wounds.		
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Samenvatting	
Het	doel	van	dit	proefschrift	was	het	onderzoeken	van	het	effect	van	fibrine,	
NETs	en	NETose	inductie	in	wondgenezing.	Wij	hebben	hiervoor	in	vitro	
modellen	gecreëerd,	om	zo	de	formatie	van	NETs	door	verschillende	inducers,	
zoals	PMA,	LPS,	S.	aureus,	E.	coli	en	N.	meningitidis	te	bestuderen.	Ook	hebben	
we	de	rol	van	NETs	en	extracellulair	DNA	onderzocht	in	sepsis	en	trombose.	
Om	het	effect	van	fibrin	in	chronische	wonden	te	bestuderen,	hebben	wij	
gebruik	gemaakt	van	een	diabeet	ratmodel.		
In	hoofdstuk	2	hebben	we	een	systematic	review	verricht	om	zo	meer	inzicht	
te	krijgen	in	verschillende	inducers	van	NETose,	die	gebruikt	waren	in	de	
literatuur.	We	vonden	dat	er	veel	discrepanties	waren	in	de	effectiviteit	van	
deze	inducers.	Daarom	hebben	we	een	aantal	van	deze	inducers	(PMA,	S.	
aureus	(levend	en	dood),	E.	coli	(levend	en	dood),	LPS,	LPS	+	plaatjes,	LPS	+	
geactiveerde	plaatjes,	geactiveerde	plaatjes	en	ionomycin)	getest	in	ons	eigen	
gestandardiseerde	time-lapse	model.	We	vonden	dat	PMA,	levende	bacteriën	
en	ionomycin	sterke	inducers	van	NETose	waren.	Andere	induceres	waren	
minder	robuust.	Ook	zagen	wij	verschillen	in	het	NETose	inductie	proces	
tussen	PMA	en	ionomycin,	wat	benadrukt	hoe	belangrijk	time-lapse	
technologie	kan	zijn.		
In	hoofdstuk	3	keken	we	naar	de	rol	van	S.	aureus	Protein	A,	een	belangrijke	
immuun	modulator	geproduceerd	door	S.	aureus,	in	NETose	inductie.	We	
gebruikten	vier	verschillende	S.	aureus	stammen	om	NETose	te	induceren	en	
bepaalden	van	iedere	stam	de	Protein	A	levels.	We	vonden	een	positieve	
correlatie	tussen	de	hoeveelheid	Protein	A	en	de	hoeveelheid	NETs.	Significant	
minder	NETs	werden	gemeten	als	NETose	was	geïnduceerd	met	een	S.	aureus	
Protein	A	knockout	stam.	NETose	kon	worden	hersteld	tot	normale	levels	
door	commerciële	Protein	A	toe	te	voegen.	Als	Protein	A	werd	toegevoegd	aan	
dode	bacteriën,	zagen	wij	geen	NETose.	Dit	impliceert	dat	Protein	A	een	
belangrijke	rol	spelt	in	de	inductie	van	NETose	door	levende	S.	aureus.		
In	hoofdstuk	4	bestudeerden	we	de	rol	van	nuclease,	geproduceerd	door	S.	
aureus	biofilm,	om	meer	inzicht	te	krijgen	in	biofilm	groei	en	diens	
verdediging	tegen	het	innate	immuun	systeem.	Hiervoor	hebben	wij	de	
nuclease	productie	door	biofilms	bekeken	door	gebruik	te	maken	van	twee	
verschillende	cell	culture	media:	TSB,	wat	in	de	literatuur	het	meest	gebruikt	
wordt,	en	IMDM,	een	van	zoogdieren	afkomstig	cultuur	medium	dat	meer	lijkt	
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op	de	humane	omgeving	van	cellen.	We	zagen	een	verhoogde	nuclease	
productie	in	biofilms	die	groeiden	in	IMDM.	Ook	bestonden	volgroeide	
biofilms	in	IMDM	vooral	uit	PIA,	terwijl	volgroeide	biofilms	in	TSB	vooral	
bestonden	uit	eDNA.	Biofilms	konden	NETose	induceren,	en	nucleases	braken	
de	NETs	af.	Deze	nucleases	hadden	echter	geen	invloed	op	de	ROS	productie	
door	neutrofielen,	terwijl	de	ROS	productie	verlaagd	was	wanneer	
neutrofielen	in	de	aanwezigheid	waren	van	biofilm.	Samengevat	kan	nuclease	
de	compositie	van	biofilms	reguleren	en	beschermt	het	de	biofilm	tegen	het	
innate	immuun	systeem	door	NETs	af	te	breken.		
In	hoofdstuk	5	bekeken	we	het	effect	van	NETose	op	de	ernst	van	
meningococcen	sepsis	in	kinderen.	MPO-DNA	levels,	een	marker	voor	NETs,	
was	gemeten	in	serum	van	deze	patiënten.	We	onderzochten	hiermee	de	
correlatie	tussen	MPO-DNA	levels	en	uitkomst	en	andere	inflammatoire	
markers,	zoals	CRP,	IL6	en	IL8.	MPO-DNA	levels	waren	hoger	in	patiënten	die	
net	waren	opgenomen	en	na	24	uur	vergeleken	met	controles,	maar	geen	
associaties	waren	gevonden	tussen	MPO-DNA	levels	en	uitkomst	of	de	
inflammatoire	markers.	Dit	wijst	erop	dat	in	deze	groep,	NETs	waarschijnlijk	
niet	zo	belangrijk	zijn	voor	de	ernst	van	sepsis	vergeleken	met	voorgaande	
sepsis	studies.		
In	hoofdstuk	6	bestudeerden	we	de	rol	van	Factor	H	en	extracellulair	DNA	
(nucleosomen)	op	het	knippen	van	VWF	door	ADAMTS13	in	jonge	patiënten	
met	arteriële	trombose.	FH	levels	in	deze	patiënten	waren	verhoogd,	maar	dit	
had	geen	directe	associatie	met	trombose.	We	vonden	een	correlatie	tussen	
FH	levels	en	nucleosomen,	wat	mogelijk	een	rol	impliceert	van	FH	op	de	
activatie	van	het	immuunsysteem	om	dode	cellen	op	te	ruimen.	Ook	vonden	
we	een	negatieve	correlatie	tussen	FH	en	VWF:CB/VWF:Ag	ratio,	wat	erop	kan	
wijzen	dat	de	aanwezigheid	van	FH	in	deze	patiënten	zorgt	voor	meer	high	
molecular	weight	VWF	multimeren	en	meer	door	VWF	gemedieerde	plaatjes	
aggregatie,	wat	leidt	tot	trombose.				
In	hoofdstuk	7	onderzochten	wij	de	wondgenezende	potentie	van	humaan	
fibrine	in	diabete	wonden.	Dorsale	wonden	in	een	ratmodel	waren	behandeld	
met	een	placebo	of	een	fibrinematrix.	Wondoppervlak	en	perfusie	werden	
gemeten	op	verschillende	tijdstippen.	We	vonden	dat	fibrine	de	perfusie	en	
vroege	wondgenezing	significant	verbeterde,	wat	de	potentie	van	fibrine	om	
wondgenezing	in	niet-genezende	wonden	te	bevorderen,	benadrukt.					
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Abbreviations	
	
ADAMTS13	 A	Disintegrin-like	And	Metalloprotease	with	Thrombo	Spondin	
motifs	13	
aHUS	 	 atypical	hemolytic	uremic	syndrome	
ANOVA		 Analysis	of	Variances	
ATTAC		 Arterial	Thrombosis	TAFI	and	other	Coagulation	factors	
AU	 	 Arbitrary	Units	
BEP	 	 Base	Excess	and	Platelet	count	at	presentation	
Ca2+	 	 Calcium	
CHD	 	 Coronary	Heart	Disease	
CRP	 	 C-Reactive	Protein	
DIC	 	 Disseminated	Intravascular	Coagulation	
DM	 	 Diabetes	Mellitus	
DMEM	 	 Dulbecco’s	Modified	Eagle	Medium	
ECs	 	 Endothelial	Cells	
ECM	 	 Extracellular	Matrix	
eDNA	 	 extracellular	DNA	
ELISA	 	 Enzyme-Linked	Immunosobent	Assay	
F	 	 Factor	
FH	 	 Factor	H	
FCS	 	 Fetal	Calf	Serum	
IFN-ƴ	 	 Interferon	ƴ	
IL	 	 Interleukine		
IMDM	 	 Iscove's	Modified	Dulbecco's	Medium	
IS	 	 Ischemic	Stroke	
IQR	 	 Inter	Quartile	Range	
LPS	 	 Lipopolysaccharide	
LTA	 	 Lipoteichoic	Acid	
MI	 	 Myocardial	Infarction	
MPO	 	 Myeloperoxidase	
MRSA	 	 Methicillin-resistant	Staphylococcus	aureus	
MSU	 	 Monosodium	Urate	
NADPH	 Nicotinamide	Adenine	Dinucleotide	Phosphate	
NE	 	 Neutrophil	Elastase	
NETs	 	 Neutrophil	Extracellular	Traps	
NETosis	 The	process	of	NETs	formation	
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Nuc	 	 Nuclease	
OD	 	 Optical	Density	
PAD	 	 Peripheral	Arterial	Disease	
PBS	 	 Phosphate	Buffered	Saline	
PDGF	 	 Platelet-Derived	Growth	Factor	
PI	 	 Propidium	Iodide	
PIA	 	 Polysaccharide	Intercellular	Adhesin	
PICU	 	 Pediatric	Intensive	Care	Unit	
PKC	 	 Protein	Kinase	C	
PMA	 	 Phorbol-12-Myristate-13-Acetate	
PMN	 	 polymorphonuclear	cells	
PRISM	 	 Pediatric	Risk	of	Mortality	
PRISMA	 Preferred	Reporting	Items	for	Systematic	Reviews	and	Meta-
Analyses	
RNS	 	 Reactive	Nitrogen	Species	
ROS	 	 Reactive	Oxygen	Species	
RT	 	 Room	Temperature	
saeRS	 	 staphylococcus	aureus	exoprotein,	2-component	system	
Sbi	 	 Staphylococcal	Binding	Immunoglobulin	protein	 	
SpA	 	 Staphylococcus	aureus	Protein	A	
TAFI		 	 Thrombin-Activatable	Fibrinolysis	Inhibitor	
TF	 	 Tissue	Factor	
TGF-β	 	 Transforming	Growth	Factor	β	
TLR		 	 Toll-like	Receptor	
TNF-α	 	 Tumor	Necrosis	Factor	α	
tPA	 	 tissue	Plasminogen	Activator	
TSA	 	 TrypticaseTM	Soy	Agar	
TSB	 	 Tryptic	Soy	Broth	
VEGF	 	 Vascular	Endothelial	Growth	Factor	
VWF	 	 Von	Willebrand	Factor	
VWF:Ag	 Von	Willebrand	Factor	antigen	
VWF:CB	 Von	Willebrand	Factor	Collagen	Binding	activity
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researchers	I	know,	and	I	look	up	to	you	(not	just	literally).	Thank	you,	you	
taught	me	to	be	the	person	I’m	meant	to	be6.	Rofyan,	we	had	so	much	fun	doing	
all	these	experiments	together,	we	laughed	so	much	and	I	love	how	you’re	not	
afraid	to	make	dirty	jokes	in	front	of	me	(I	still	remember	how	shocked	you	
were	the	first	time	I	made	one,	in	front	of	the	confocal	with	the	you-know-
what	pic	haha).	Good	luck	with	your	final	year	as	a	PhD	student	and	with	your	
future	career	as	a	doctor.	I	will	miss	you	so	much,	backdoorboy!	Going	in	the	
backdoor7	will	never	be	the	same	(although	at	least	the	Hemostasis	lab	will	not	
suspect	us	anymore	of	dealing	drugs	there).					
The	very	first	paper	where	I	had	to	deal	with	statistics	and	databases	was	the	
Meningococcal	sepsis	paper,	and	for	all	the	help	writing	and	re-writing	this	
paper	I	would	like	to	thank	Gert-Jan	(Dr.	G.J.A.	Driessen)	and	Navin!	Navin,	
working	with	someone	has	barely	been	as	easy	as	working	with	you.	From	the	
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first	moment	I	thought	you	were	one	of	the	nicest	people	I’ve	met	here,	and	
my	opinion	hasn’t	changed	since	then.	We	finished	our	paper	incredibly	fast	
and	every	meeting	was	so	good.	You	will	be	an	amazing	doctor:	Go	go	go	go	
go!8				
I	had	the	pleasure	to	be	a	part	of	the	incredible	Hematology	group.	As	I	spent	
more	time	with	you	in	my	final	year,	I	totally	regretted	not	doing	so	from	the	
beginning.	You’re	like	family.	So	from	the	8th	floor:	Iris,	Lisette,	Johan,	Caroline,	
Shiraaz,	Carolien,	Jessica,	Michelle,	Carina,	Joyce,	Shirley,	Dick,	Simone,	
Maurice,	Rezin,	Samantha	and	Angelique.	Thanks	for	making	me	feel	like	I	was	
part	of	your	world9.	To	most	of	you:	thanks	for	trying	to	draw	blood	from	my	
impossible	veins.	Joyce:	I	miss	you	already	and	I’m	so	grateful	for	having	
someone	to	talk	to	about	festivals	and	bands,	but	also	other	problems.	I	would	
have	lost	it	a	long	time	ago	without	having	you	around.	You	know	what	they	
say:	you’ve	gotta	fight	for	your	right	to	party!10	Johan,	my	fellow	baker	and	still	
the	departments	pie	and	bread	baking	master,	whenever	I	see	you,	it’s	a	
wonderful	day	for	pie11	pops	into	my	head.	Keep	feeding	the	department,	and	I	
will	really	miss	you	and	your	sense	of	humor	(which	is	really	much	like	mine).	
Dick,	you	amazed	me	every	time	we	had	a	meeting,	especially	with	your	
incredible	memory.	It’s	a	shame	people	have	to	retire,	because	having	you	
around	at	the	department	was	like	having	access	to	a	walking	library	of	
knowledge.	Whenever	I	talk	to	you,	I	feel	like	I	can	climb	the	highest	mountain,	
cross	the	wildest	sea12.	Also	a	special	shout	out	to	Angelique:	you	are	so	much	
like	me,	it’s	scary.	Never	doubt	yourself,	you	are	an	amazing	researcher	and	
person	and	I’m	sure	you’ll	finish	your	PhD	with	flying	colors.	If	you	lose	
yourself	I	will	find	you13.		
Of	course	I	cannot	forget	all	the	great	people	from	the	Hemostasis	lab:	thank	
you	for	always	being	there	for	me	whenever	I	needed	help,	in	particular	Hans	
(for	the	million	times	you	got	me	blood	for	my	studies),	Debby	(for	all	the	help	
with	the	ELISAs),	Riekje	(for	all	the	answers	to	my	questions)	and	Wietse	(for	
teaching	me	everything	about	NETs	in	the	first	place).		
Finally,	from	the	13th	floor,	special	thanks	to	Onno	for	always	helping	me	find	
stuff	and	installing	Graphpad	on	my	computer	once	again,	Natalie	for	all	the	
help	with	the	qPCRs,	Keane	for	the	nice	talks	about	karaoke	(which	we	sadly	
never	did	together)	and	Jasper	(for	being	into	metal	and	Steel	Panther,	like	
me).		
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From	the	Department	of	Plastic	and	Reconstructive	Surgery,	of	which	I	was	
also	a	part,	I	would	first	of	all	like	to	thank	Prof.	Dr.	S.E.R.	Hovius.	Hearing	you	
talk	about	your	work	in	the	Plastic	and	Reconstructive	Surgery	department	
was	a	true	inspiration,	showing	how	passionate	you	are	about	your	field	of	
expertise.	If	everyone	felt	about	their	job	the	way	you	do,	the	world	would	be	
an	ever	happier	place.	Also	thanks	to	Prof.	Dr.	I.M.J.	Mathijssen,	for	stepping	up	
as	the	new	head	of	our	department,	and	for	keeping	everything	going.		
Esther,	Manja	and	Ineke,	thank	you	all	so	much	for	helping	out	with	the	animal	
work,	and	most	of	all	for	the	nice	tea	chats	we	had.	I	will	miss	you	very	much.	
Esther,	I	will	also	miss	your	chocolade	trekpudding,	one	of	the	best	things	I	
ever	ate.	Everybody	wants	a	chocolate14.	
My	fellow	PhD	students	from	Plastic	Surgery,	good	luck	with	finishing	your	
theses	and	with	becoming	doctors.	Special	thanks	to	Willem	and	Chao	for	
being	awesome	‘roommates’.			
Finally,	I	would	like	to	thank	the	Wondconsulentes	(especially	Babette	and	
Eva)	and	the	Diabetes	Voetenpoli	(especially	Iris)	for	collecting	so	much	tissue	
for	my	project.		
From	the	15th	floor,	thanks	to	Dicky,	Theo	and	Mark	for	helping	me	out	with	
multiple	experiments,	finding	antibodies	and	doing	Western	Blots.	You	are	
amazing!	
Last	but	not	least	in	the	work-related	part	of	my	acknowledgements,	thanks	to	
Brenda	from	Sanquin	for	working	together	on	the	Factor	H/VWF	story.	You	
are	such	a	good	person	and	I	wish	you	all	the	best	with	your	future	research	
projects!	
A	very	special	thank	you	to	Eldridge	Labinjo,	for	all	the	advice	and	coaching	
regarding	pitching	and	communication.	I	have	gained	so	much	from	you,	and	I	
am	so	grateful	to	have	joined	your	masterclasses.	I	truly	miss	going.	Hope	to	
see	you	again	sometime!		
Before	I	got	here	at	the	Erasmus	MC,	I	had	finished	my	Master	thesis	at	the	
LUMC.	I’m	so	happy	to	still	see	some	of	you	every	once	in	a	while	for	dinner.	
Even	everyone	I	don’t	see	that	often,	you	all	made	me	the	person	I	am	today.	
So	thank	you,	Saskia,	Daniëlle,	Lisa,	Bert,	Connie,	Robert,	Rob,	Adri	and	all	the	
others!	You’re	just	too	good	for	me	to	let	go15.	
While	applying	the	final	words	to	this	thesis,	I	have	happily	started	working	at	
the	Radboud	UMC	at	the	department	of	Genetics	with	the	amazing	group	of	
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Rob	(Dr.	R.W.J.	Collin)	and	Alex	(Dr.	A.	Garanto).	I	absolutely	love	it	so	far,	so	I	
want	to	thank	you	for	hiring	me	(and	believing	I	can	do	it),	and	thank	you,	
Lonneke,	Muriël,	Anita,	Dyah,	Julio,	Matthijs,	Tess	and	Simon	(and	of	course	
everyone	else	in	the	department!)	for	making	me	feel	at	home	from	the	
moment	I	walked	in.	It’s	always	a	good	time!16	
Of	course,	without	my	friends	I	would	have	gone	completely	nuts	while	
working	on	my	thesis.	So	here	is	a	special	shout	out	to	Jeanne,	Jolien,	Tante	
Astrid,	Astrid,	Susan,	Yara,	Marieke,	Ilse,	Leonie,	Diana,	Mary	and	everyone	
else	I	forgot!	Don’t	you	know	it’s	a	matter	of	time	we’ll	outshine	the	starlight!17			
Speaking	of	going	nuts	without	something,	music	and	partying	has	been	a	
complete	release	of	stress	over	the	past	few	years.	In	the	final	months	of	
writing	I	almost	lost	it	when	I	didn’t	go	to	as	many	parties	as	I	used	to,	so	I	
decided	that	going	by	myself	was	better	than	not	going	at	all.	And	I	felt	so	
much	better!	Concerts	were	my	ultimate	medicine	for	whenever	I	felt	horrible.	
Also,	a	very	special	band	called	Destine	made	me	the	person	I	am	today:	
without	them	I	could	never	have	done	this.	Hereby	I	would	like	to	thank	
Laurens,	Hubrecht,	Jordy,	Pim,	Huub,	Sun	and	Roger	(The	Dirty	Daddies),	
Maurice,	Lesley,	Adrian	and	Sergei	(Call	it	Off),	Robin,	Lesley,	Arthur,	Dirk-Jan	
and	Bart/Goofus	(Five	Years	Later),	Willem,	Nick,	Tom,	Harmen,	Jaap	and	
Robin	(Bottles	of	Love),	Joris	and	Thom	(Ego	Dreams),	Jen,	Zan	and	Timia	(The	
Lounge	Kittens)	and	Michael,	Satchel,	Stix	and	Lexxi	(Steel	Panther).	I	can’t	
stop	loving	you18.	In	my	darkest	days,	you’re	the	light	I	hold	on	to19.	I'll	be	there,	
till	the	stars	don't	shine,'til	the	heavens	burst	and	the	words	don't	rhyme.	I	know	
when	I	die	you'll	be	on	my	mind,	and	I'll	love	you,	always20.	
Finally	(really	this	time),	I	want	to	thank	my	amazing	family	for	always	being	
there	for	me,	even	though	you	never	had	a	clue	what	exactly	it	was	I	was	
doing.	Mom,	dad,	Yori,	grandma,	Jan,	Dineke,	Femke	and	Bart,	thanks	for	the	
support,	I	love	you.	And	Casper,	my	gorgeous	man,	thanks	for	putting	up	with	
me	and	all	my	fallouts	over	the	years.	I	can	be	a	bad	girlfriend21	sometimes,	
but	my	heart	belongs	to	you22.	
For	all	my	fellow	PhD	students	and	the	ones	to	come:	don’t	give	up,	keep	
going.	We	all	have	our	bad	days,	we	all	have	felt	that	moment	where	we	
wanted	to	throw	everything	out	of	the	window	and	stop,	but	it’s	not	worth	it.	
Your	work	will	pay	off.	And	you’ll	make	it.	This	is	worth	fighting	for,	you	know	
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we’ve	all	got	battle	scars23.	In	case	you	need	it,	here	is	a	list	of	songs	you	can	
listen	to	whenever	you’re	done	with	everything:	
- Scream	Your	Heart	Out	–	Call	it	Off	
- Break	Stuff	–	Limp	Bizkit	
- Klote	–	Want	Want	
- Ungrateful	–	Escape	the	Fate	
- Haters	Gonna	Hate	–	Chunk!	No,	Captain	Chunk!	
- Last	Resort	–	Papa	Roach	
- Growing	Pains	–	Farewell	Fighter	
Tracklist:	
1.	The	Press	and	The	President	–	“Central	Park.”	
2.	Mercy	Mercedes	–	“Lucky.”	
3.	Like	The	Stars	–	“Better	off	Believing.”	
4.	Nickelback	–	“Photograph.”	
5.	Call	it	Off	–	“Do	It	All	Again.”	
6.	Paradise	Fears	–	“Yours	Truly.”	
7.	Steel	Panther	–	“Goin’	In	The	Backdoor.”	
8.	Indevotion	–	“Go	Go	Go	Go	Go!”	
9.	The	Little	Mermaid	–	“Part	of	Your	World.”	
10.	Beastie	Boys	–“Fight	For	Your	Right.”	
11.	Family	Guy	–	“It’s	a	Wonderful	Day	For	Pie.”	
12.	John	Parr	–	“St.	Elmo’s	Fire.”	
13.	Alex	Goot	&	Against	The	Current	–	“Find	You.”	
14.	Soul	Control	–	“Chocolate.”	
15.	Five	Years	Later	–	“Too	Good	To	Let	Go.”	
16.	Owl	City	&	Carly	Rae	Jepsen	–	“Good	Time.”	
17.	Destine	–	“Anywhere	You	Wanna	Go.”	
18.	Toto	–	“Stop	Loving	You.”	
19.	The	Young	River	–	“Disappear.”	
20.	Bon	Jovi	–	“Always.”	
21.	Theory	of	a	Deadman	–	“Bad	Girlfriend.”	
22.	Steel	Panther	–	“Community	Property.”	
23.	Paradise	Fears	–	“Battle	Scars.”
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PhD	Portfolio	
	
Summary	of	PhD	training	and	teaching	activities	
Name	PhD	student:	Tamara	Hoppenbrouwers	
Erasmus	MC	department:	Hematology	and	Plastic	and	Reconstructive	Surgery		
PhD	Period:	July	2014	–	July	2017	
Promotor:	Prof.	Dr.	F.W.G.	Leebeek	
Co-promotors:	Dr.	J.W.	van	Neck	and	Dr.	M.P.M.	de	Maat	
PhD	Training	 Year	 Workload	
(ECTS)	
General	academic	skills	 	 	
• Biomedical	English	Writing	
Molmed	
Erasmus	MC	Rotterdam	
2015	 2.0	
• Biostatistical	Methods	I:	Basic	Principles	
NIHES	
Erasmus	MC	Rotterdam	
2016	 5.7	
In-depth	courses	 	 	
• Confocal	microscopy	introduction	course	
Erasmus	MC	
2014	 0.2	
• The	Microscopic	Image	Analysis:	From	Theory	to	
Practice	
Molmed	
Erasmus	MC	Rotterdam	
2015	 0.8	
• The	Translational	Imaging	Workshop	by	AMIE:	
‘From	mouse	to	man’	
Molmed	
Erasmus	MC	Rotterdam	
2015	 1.4	
• Bacteria	and	Chronic	Infections	
Coursera	
University	of	Copenhagen	
2016	 1.8	
Seminars	and	workshops	 	 	
• Seminar	COEUR	
Erasmus	MC	Rotterdam	
2014	 0.3	
• Seminar	Sanquin	
Sanquin	Amsterdam	
2016	 0.2	
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• ETRS	Summer	School	“Advancing	Wound	
Research”	
London,	UK	
2016	 1.8	
• Workshop	“Share	Your	Research	with	a	Broad	
Audience”	
LUMC	Leiden	
2016	 1.0	
• Masterclass	EC	Marie	Sklodowska-Curie	Innovative	
Training	Networks	(ITN)	Programme	for	Doctoral	
of	Joint	Doctorates	Training	
Erasmus	MC	Rotterdam	
2016	 0.7	
• Famelab	
Erasmus	MC	Rotterdam	
2017	 0.5	
• Workshop	Pitch	jezelf	(vena)	
Erasmus	MC	Rotterdam	
2017	 0.3	
International	conferences	 	 	
• 7th	Joint	Meeting	of	the	European	Tissue	Repair	
Society	(ETRS)	with	the	Wound	Healing	Society		
Oral	Presentation	
Copenhagen,	Denmark	
2015	 2.4	
Presentations	 	 	
• Department	of	Hematology		(7x)	 2014-
2017	
0.4	
• Department	of	Plastic	and	Reconstructive	Surgery	
(2x)	
2014-
2017	
0.1	
• Department	of	Pathology	(1x)	 2015	 0.1	
Teaching	activities	 	 	
Supervising	HLO	intern	
• 1	student	(20	weeks)	
2016-
2017	
2.0	
Grants		 	 	
• Trustfonds	(€175,-)	 2015	 1.0	
• Stichting	Coolsingel	(€25.000,-)	 2016	 1.0	
• mRace	Pilot	(€40.000,-)	 2016	 1.0	
	
	
